<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Drug treatment for spinal muscular atrophy types II and III - Wadman, RI - 2020 | Cochrane Library</title> <meta content="Drug treatment for spinal muscular atrophy types II and III - Wadman, RI - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006282.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Drug treatment for spinal muscular atrophy types II and III - Wadman, RI - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006282.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD006282.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Drug treatment for spinal muscular atrophy types II and III" name="citation_title"/> <meta content="Renske I Wadman" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="r.i.wadman@umcutrecht.nl" name="citation_author_email"/> <meta content="W Ludo van der Pol" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Wendy MJ Bosboom" name="citation_author"/> <meta content="Onze Lieve Vrouwe Gasthuis locatie West" name="citation_author_institution"/> <meta content="Fay‐Lynn Asselman" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Leonard H van den Berg" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Susan T Iannaccone" name="citation_author"/> <meta content="University of Texas Southwestern Medical Center" name="citation_author_institution"/> <meta content="Alexander FJE Vrancken" name="citation_author"/> <meta content="University Medical Center Utrecht, Brain Center Rudolf Magnus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD006282.pub5" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/01/06" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006282.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006282.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006282.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amines [therapeutic use]; Creatine [therapeutic use]; Cyclohexanecarboxylic Acids [therapeutic use]; gamma-Aminobutyric Acid [therapeutic use]; Hydroxyurea [therapeutic use]; Neuroprotective Agents [*therapeutic use]; Randomized Controlled Trials as Topic; Spinal Muscular Atrophies of Childhood [*drug therapy]; Thyrotropin-Releasing Hormone [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD006282.pub5&amp;doi=10.1002/14651858.CD006282.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="WbpyPs9C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD006282\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD006282\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","fr","fa","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD006282.pub5",title:"Drug treatment for spinal muscular atrophy types II and III",firstPublishedDate:"Jan 6, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006282.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006282.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD006282.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD006282.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006282.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD006282.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD006282.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD006282.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD006282.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD006282.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7746 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD006282.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0249"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0061"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0062"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0088"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-sec-0223"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/appendices#CD006282-sec-0253"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Drug treatment for spinal muscular atrophy types II and III</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Renske I Wadman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0003">W Ludo van der Pol</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0004">Wendy MJ Bosboom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0005">Fay‐Lynn Asselman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0006">Leonard H van den Berg</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0007">Susan T Iannaccone</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information#CD006282-cr-0008">Alexander FJE Vrancken</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information/en#CD006282-sec-0267">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 06 January 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD006282.pub5">https://doi.org/10.1002/14651858.CD006282.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD006282-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006282-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006282-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006282-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006282-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006282-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD006282-abs-0001" lang="en"> <section id="CD006282-sec-0001"> <h3 class="title" id="CD006282-sec-0001">Background</h3> <p>Spinal muscular atrophy (SMA) is caused by a homozygous deletion of the <i>survival motor neuron 1</i> (<i>SMN1</i> ) gene on chromosome 5, or a heterozygous deletion in combination with a (point) mutation in the second <i>SMN1</i> allele. This results in degeneration of anterior horn cells, which leads to progressive muscle weakness. Children with SMA type II do not develop the ability to walk without support and have a shortened life expectancy, whereas children with SMA type III develop the ability to walk and have a normal life expectancy. This is an update of a review first published in 2009 and previously updated in 2011. </p> </section> <section id="CD006282-sec-0002"> <h3 class="title" id="CD006282-sec-0002">Objectives</h3> <p>To evaluate if drug treatment is able to slow or arrest the disease progression of SMA types II and III, and to assess if such therapy can be given safely. </p> </section> <section id="CD006282-sec-0003"> <h3 class="title" id="CD006282-sec-0003">Search methods</h3> <p>We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and ISI Web of Science conference proceedings in October 2018. In October 2018, we also searched two trials registries to identify unpublished trials. </p> </section> <section id="CD006282-sec-0004"> <h3 class="title" id="CD006282-sec-0004">Selection criteria</h3> <p>We sought all randomised or quasi‐randomised trials that examined the efficacy of drug treatment for SMA types II and III. Participants had to fulfil the clinical criteria and have a homozygous deletion or hemizygous deletion in combination with a point mutation in the second allele of the <i>SMN1</i> gene (5q11.2‐13.2) confirmed by genetic analysis. </p> <p>The primary outcome measure was change in disability score within one year after the onset of treatment. Secondary outcome measures within one year after the onset of treatment were change in muscle strength, ability to stand or walk, change in quality of life, time from the start of treatment until death or full‐time ventilation and adverse events attributable to treatment during the trial period. </p> <p>Treatment strategies involving <i>SMN1</i>‐replacement with viral vectors are out of the scope of this review, but a summary is given in <a href="http://01" target="_blank">Appendix 1</a>. Drug treatment for SMA type I is the topic of a separate Cochrane Review. </p> </section> <section id="CD006282-sec-0005"> <h3 class="title" id="CD006282-sec-0005">Data collection and analysis</h3> <p>We followed standard Cochrane methodology.</p> </section> <section id="CD006282-sec-0006"> <h3 class="title" id="CD006282-sec-0006">Main results</h3> <p>The review authors found 10 randomised, placebo‐controlled trials of treatments for SMA types II and III for inclusion in this review, with 717 participants. We added four of the trials at this update. The trials investigated creatine (55 participants), gabapentin (84 participants), hydroxyurea (57 participants), nusinersen (126 participants), olesoxime (165 participants), phenylbutyrate (107 participants), somatotropin (20 participants), thyrotropin‐releasing hormone (TRH) (nine participants), valproic acid (33 participants), and combination therapy with valproic acid and acetyl‐L‐carnitine (ALC) (61 participants). Treatment duration was from three to 24 months. None of the studies investigated the same treatment and none was completely free of bias. All studies had adequate blinding, sequence generation and reporting of primary outcomes. </p> <p>Based on moderate‐certainty evidence, intrathecal nusinersen improved motor function (disability) in children with SMA type II, with a 3.7‐point improvement in the nusinersen group on the Hammersmith Functional Motor Scale Expanded (HFMSE; range of possible scores 0 to 66), compared to a 1.9‐point decline on the HFMSE in the sham procedure group (P &lt; 0.01; n = 126). On all motor function scales used, higher scores indicate better function. </p> <p>Based on moderate‐certainty evidence from two studies, the following interventions had no clinically important effect on motor function scores in SMA types II or III (or both) in comparison to placebo: creatine (median change 1 higher, 95% confidence interval (CI) –1 to 2; on the Gross Motor Function Measure (GMFM), scale 0 to 264; n = 40); and combination therapy with valproic acid and carnitine (mean difference (MD) 0.64, 95% CI –1.1 to 2.38; on the Modified Hammersmith Functional Motor Scale (MHFMS), scale 0 to 40; n = 61). </p> <p>Based on low‐certainty evidence from other single studies, the following interventions had no clinically important effect on motor function scores in SMA types II or III (or both) in comparison to placebo: gabapentin (median change 0 in the gabapentin group and –2 in the placebo group on the SMA Functional Rating Scale (SMAFRS), scale 0 to 50; n = 66); hydroxyurea (MD –1.88, 95% CI –3.89 to 0.13 on the GMFM, scale 0 to 264; n = 57), phenylbutyrate (MD –0.13, 95% CI –0.84 to 0.58 on the Hammersmith Functional Motor Scale (HFMS) scale 0 to 40; n = 90) and monotherapy of valproic acid (MD 0.06, 95% CI –1.32 to 1.44 on SMAFRS, scale 0 to 50; n = 31). </p> <p>Very low‐certainty evidence suggested that the following interventions had little or no effect on motor function: olesoxime (MD 2, 95% –0.25 to 4.25 on the Motor Function Measure (MFM) D1 + D2, scale 0 to 75; n = 160) and somatotropin (median change at 3 months 0.25 higher, 95% CI –1 to 2.5 on the HFMSE, scale 0 to 66; n = 19). One small TRH trial did not report effects on motor function and the certainty of evidence for other outcomes from this trial were low or very low. </p> <p>Results of nine completed trials investigating 4‐aminopyridine, acetyl‐L‐carnitine, CK‐2127107, hydroxyurea, pyridostigmine, riluzole, RO6885247/RG7800, salbutamol and valproic acid were awaited and not available for analysis at the time of writing. </p> <p>Various trials and studies investigating treatment strategies other than nusinersen (e.g. SMN2‐augmentation by small molecules), are currently ongoing. </p> </section> <section id="CD006282-sec-0007"> <h3 class="title" id="CD006282-sec-0007">Authors' conclusions</h3> <p>Nusinersen improves motor function in SMA type II, based on moderate‐certainty evidence.</p> <p>Creatine, gabapentin, hydroxyurea, phenylbutyrate, valproic acid and the combination of valproic acid and ALC probably have no clinically important effect on motor function in SMA types II or III (or both) based on low‐certainty evidence, and olesoxime and somatropin may also have little to no clinically important effect but evidence was of very low‐certainty. One trial of TRH did not measure motor function. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD006282-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD006282-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD006282-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD006282-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD006282-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD006282-abs-0013">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD006282-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD006282-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD006282-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD006282-abs-0005" lang="en"> <h3>Medicines for spinal muscular atrophy types II and III</h3> <p><b>What was the aim of this review?</b> </p> <p>This Cochrane Review aimed to look at the effects of medicines on spinal muscular atrophy (SMA) types II and III in terms of disability, muscle strength, ability to stand or walk, quality of life, and time to death or full‐time ventilation, within one year of beginning treatment. We also wanted to identify any harmful effects of the treatments during the trial period. Cochrane review authors collected relevant studies to answer this question and found 10 studies. </p> <p><b>Key messages</b> </p> <p>Nusinersen given by intrathecal (into the spine) injection probably improves disability in SMA. </p> <p>Creatine, phenylbutyrate, gabapentin, hydroxyurea, valproic acid and combination therapy with valproic acid and acetyl‐L‐carnitine probably have no clinically important effect on motor function (movements and actions of the muscles) in SMA types II and III, based on evidence from single completed, published trials. </p> <p>Olesoxime and subcutaneous somatotropin may have little or no effect on motor function in SMA, but the reliability of the evidence was very low. One trial of intravenous (into a vein) thyrotropin‐releasing hormone (TRH) did not measure motor function and the reliability of the evidence was very low. All the studies had limitations in design or performance that could have affected the results. </p> <p><b>What was studied in the review?</b> </p> <p>This review is of medicines for SMA types II and III. Symptoms of SMA first appear in childhood and adolescence. The main feature is increasing muscle weakness. Children with SMA type II will never be able to walk without support; they usually live into adolescence or longer, but with a shortened life expectancy. The age of onset of SMA type II is between six and 18 months. Children with SMA type III will walk independently but may lose the ability to walk at some time and they have a normal life expectancy. The age of onset of SMA type III is after 18 months. </p> <p><b>What were the main results of the review?</b> </p> <p>We identified 10 trials, which included 717 participants. All trials compared a medicine with an inactive substance (placebo) or sham (pretend) procedure. The trials studied oral (by mouth) creatine (55 participants), oral gabapentin (84 participants), oral phenylbutyrate (107 participants), oral hydroxyurea (57 participants), intrathecal nusinersen (126 participants), oral olesoxime (165 participants), subcutaneous (under the skin) somatotropin (20 participants), intravenous TRH (nine participants), oral valproic acid (33 participants) or combination therapy with oral valproic acid and acetyl‐L‐carnitine (ALC) (61 participants). Treatment duration was from three to 24 months. </p> <p>Nusinersen had a beneficial effect on motor function in people with SMA type II, when compared to a sham procedure. There were probably no beneficial effects on motor function in SMA types II/III for creatine, gabapentin, hydroxyurea, phenylbutyrate, valproic acid or combination therapy with valproic acid and ALC. Olesoxime and somatotropin may have no effect on motor function. The small TRH trial did not assess motor function and did not provide evidence of any reliability on other outcomes. We found all the studies to have limitations in design or performance that could have affected the results. Eight studies were (partially) funded by pharmaceutical companies, either by supplying the study drug or by giving financial support otherwise. In two studies investigating nusinersen and olesoxime, the pharmaceutical companies were involved in data analysis and reporting. </p> <p>We are awaiting the results of nine completed trials investigating 4‐aminopyridine, ALC, CK‐2121707 hydroxyurea, pyridostigmine, riluzole, RO6885247/RG7800, salbutamol and valproic acid which were not available at the time of writing. </p> <p><b>How up to date is this review?</b> </p> <p>The evidence is up to date to October 2018.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD006282-sec-0249" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD006282-sec-0249"></div> <h3 class="title" id="CD006282-sec-0250">Implications for practice</h3> <section id="CD006282-sec-0250"> <p>Nusinersen probably improves motor function in spinal muscular atrophy (SMA) type II (moderate‐certainty evidence). </p> <p>Creatine, gabapentin, hydroxyurea, phenylbutyrate, thyrotrophin releasing hormone, valproic acid and the combination of valproic acid and acetyl‐L‐carnitine probably have no clinically important effect on motor function in SMA II/III (low‐ to moderate‐certainty evidence). Olesoxime and somatotropin may have no effect on motor function (low‐ to very low‐certainty evidence). We are uncertain about the effect of thyrotropin‐releasing hormone as the evidence is very low certainty. </p> </section> <h3 class="title" id="CD006282-sec-0251">Implications for research</h3> <section id="CD006282-sec-0251"> <p>Nusinersen is the only drug therapy for SMA for which there is moderate‐certainty evidence of benefit. New therapies or treatment strategies should preferably either be compared to nusinersen or be evaluated as an add‐on therapy to nusinersen. </p> <p>Most trials investigating new therapies are focused on the early phases of the disease, since motor improvement or lack of decline is the easiest way to establish drug efficacy. However, therapies for those who already have a prolonged disease duration should also be sought to prevent disease progression, conserve motor function and improve quality of life. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD006282-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD006282-sec-0036"></div> <div class="table" id="CD006282-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral creatine compared to placebo for children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral creatine compared to placebo for children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral creatine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral creatine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: GMFM<br/> Scale: 0–264<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in disability score was –1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Median change 1 higher</b><br/> (1 lower to 2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in total muscle strength</b> (total muscle strength)<br/> assessed with: quantitative muscle testing (in pounds)<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in total muscle strength was 2.42 pounds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.25 pounds lower</b><br/> (10.1 lower to 7.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only participants aged ≥ 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: Parent Questionnaire for the PedsQL Neuromuscular Module<br/> Scale: 0–100<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in quality of life was 2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Median change 7 lower</b><br/> (11 lower to 3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate better quality of life.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.83 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.56 % predicted higher</b><br/> (10.8 lower to 11.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only participants aged ≥ 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the placebo group in 28 participants (36 per 1000)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 deaths occurred in the treatment group among 27 participants (0 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000 (291 to 800)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.84</b> (0.51 to 1.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 43 events in 16/28 participants in placebo group and 55 events in 13/27 participants treated with creatine. Adverse events were systematically, prospectively collected at every study visit. Adverse events included mainly respiratory infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>GMFM:</b> Gross Motor Function Measure; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>MMT:</b> Manual Muscle Testing; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>b</sup> Downgraded one level due to inconsistency. Unknown cohort representation (outcome reported for 22 of the randomised participants).<br/> <sup>c</sup> Downgraded one level because of imprecision. Small sample size, inadequately for optimal information size (OIS). Cut off for OIS was the calculated sample size of the trial.<br/> <sup>d</sup> Downgraded one level for risk of bias. No information on type of adverse events included.<br/> <sup>e</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral gabapentin compared to placebo for adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral gabapentin compared to placebo for adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral gabapentin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: SMAFRS<br/> Scale: 0–50<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The median change in the SMAFRS score was 0 in the gabapentin group (37 participants) and –2 in the placebo group (34 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the SMAFRS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed as: % change in total muscle strength from baseline<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –2.2%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.3% higher</b><br/> (6.9 lower to 14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring ability to walk</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/35 participants in the placebo group developed the ability to walk at 9 or 12 months' follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/38 participants treated with oral gabapentin developed the ability to walk at 9 or 12 months' follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: change (%) from baseline in mini‐SIP<br/> Scale: 0–19<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was –0.26%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.36% higher</b><br/> (0.29 lower to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the mini‐SIP indicate poorer health status.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –2.9 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.1 % predicted lower</b><br/> (4.1 lower to 1.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from analysis of participants who completed ≥ 2 visits.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment to death or full‐time ventilation</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0 reported deaths and 0 participants required full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events were reported to be infrequent and not statistically different between treatment groups. Numerical data on adverse events were not available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were systematically, prospectively collected at every study visit.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>mini‐SIP:</b> mini‐Sickness Impact Profile; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy; <b>SMAFRS:</b> Spinal Muscular Atrophy Functional Rating Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because the small sample size.<br/> <sup>b</sup> Downgraded one level for risk of bias. Incomplete data at 12‐month follow‐up and it was unclear why cases dropped out. Three cases (two treated, one placebo) were excluded from analysis because of extreme outcomes (greater than three standard deviations).<br/> <sup>c</sup> Downgraded one level because of imprecision; small sample size, inadequate for optimal information size (OIS).<br/> <sup>d</sup> Downgraded one level because no data on adverse events were available.<br/> <sup>e</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral hydroxyurea<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral hydroxyurea</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: GMFM<br/> Scale: 0–264<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 2.02</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.88 lower</b><br/> (3.89 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the GMFM indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MHFMS<br/> Scale: 0–40<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.04</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.02 lower</b><br/> (0.12 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in non‐ambulatory participants.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MMT<br/> Scale: 16–80<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –0.03</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.55 lower</b><br/> (2.65 lower to 1.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in litres)<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.22 L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.01 L higher</b><br/> (0.25 lower to 0.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 participant died in the treatment group after 5 visits (after 8 months of treatment), due to respiratory complications. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also reported as the 1 serious adverse event.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All participants experienced adverse events. 129 events occurred in the 20 participants in the placebo group. 224 events occurred in the 37 participants in the hydroxyurea group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were systematically, prospectively collected using a questionnaire at every study visit. Adverse events: laboratory disturbances (e.g. neutropenia, thrombocytopenia, high transaminases), respiratory complaint, gastrointestinal complaints, rash, neurological symptoms, unspecified. 1 participant died in the treatment group due to respiratory complications.<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>GMFM:</b> Gross Motor Function Measure; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision. CIs were very wide.<br/> <sup>b</sup> Downgraded one level for imprecision because of small sample size (inadequate for optimal information size (OIS)). Cut‐off for OIS was the calculated sample size of the trial.<br/> <sup>c</sup> Downgraded one level for indirectness, because of discrepancy in results of respiratory failure (results in text and figures appeared different).<br/> <sup>d</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> children with SMA type II<br/> <b>Setting:</b> hospital visits (24 hours' observation at trial site after first procedure, 6 hours' observation after subsequent injections)<br/> <b>Intervention:</b> intrathecal injected nusinersen<br/> <b>Comparison:</b> sham procedure </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham procedure</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intrathecal injected nusinersen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in disability score</b><br/> assessed with: HFMSE Score: 0–66<br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HFMSE in the control group was –1.9 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in HFMSE in the nusinersen‐treated group was 5.9 points higher than in the sham procedure group (3.7 higher to 8.1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 5.9</b> (3.7 to 8.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in disability score (3 point‐change)</b><br/> assessed with: HFMSE<br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 per 1000 (259 to 812)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.8</b> </p> <p>(0.99 to 3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/42 participants in the sham‐controlled group showed a 3‐point change on the HFMSE. 48/84 participants in the nusinersen group showed a 3‐point change on the HFMSE. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in muscle strength</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Acquiring the ability to stand or walk</b><br/> assessed with: WHO Motor Milestone criteria<br/> Follow‐up: 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/42 children in the sham‐controlled group acquired the ability to stand alone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/84 children treated with nusinersen acquired the ability to stand alone.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.5</b> (0.03 to 7.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to walk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0/42 children in the sham‐controlled group acquired the ability to walk with assistance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/84 children treated with nusinersen acquired the ability to walk with assistance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> (0.06 to 36.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in pulmonary function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> (0.9 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78/84 (93%) participants treated with nusinersen experienced an adverse event, while 42/42 (100%) participants treated in the sham‐controlled group had any adverse event. </p> <p>Adverse events were systematically, prospectively collected at every study visit. Adverse events included proteinuria, hyponatraemia, transient low platelet counts, vasculitis, pyrexia, headache, vomiting, back pain and epistaxis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFMSE:</b> Hammersmith Functional Motor Measure Expanded; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>MMT:</b> manual muscle testing; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>b</sup> Downgraded two levels for imprecision because of small sample size, low event rate and wide CI.<br/> <sup>c</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐ambulatory children and adolescents with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral olesoxime<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral olesoxime</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM (D1+D2)<br/> Scale: 0–75<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2 higher</b><br/> (0.25 lower to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MFM indicate better function. Combined analysis of participants assessed with MFM‐32 or MFM‐20. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM total score<br/> Scale: 0–96<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.04 higher</b><br/> (0.21 lower to 4.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MFM indicate better function. Combined analysis of participants assessed with MFM‐32 or MFM‐20. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM responder analysis<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.43</b><br/> (–0.98 to 2.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Higher scores on the MFM indicate better function. Participants were classified as 'responders' in case MFM‐32 or MFM‐20 showed no change or better scores compared to baseline, and 'non‐responders'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 100<br/> (–38 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: HFMS<br/> Scale: 0–40<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.72</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.94 higher</b><br/> (0.28 lower to 2.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMS indicate better function.<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: PedsQL Neuromuscular Module<br/> Score: 0–100<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.25</b><br/> (4.58 lower to 5.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate a better quality of life.</p> <p>Scores on participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was +6.16 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.88 % predicted lower</b><br/> (3.14 lower to 6.91 higher ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 participants died; 1 with cardiac arrest (olesoxime group) and 1 with increased bronchial secretions (placebo group). Deaths were not deemed to be related to treatment. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>950 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.91 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612 events occurred in 57 participants in the placebo group. 1104 events occurred in 108 participants in the olesoxime group. Adverse events were systematically, prospectively collected at every study visit. Adverse events: (upper) respiratory tract infection, gastroenteritis, influenza, vomiting, abdominal pain, diarrhoea, cough, pyrexia, pain in extremity, scoliosis, arthralgia, fall, headache. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMS:</b> Hammersmith Functional Motor Score; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>MMT:</b> manual muscle testing; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for indirectness because trial authors combined two different outcome measures (MFM‐32 and MFM20) to assess the primary outcome with no correction in analysis.<br/> <sup>b</sup> Downgraded one level for risk of bias because of differences between baseline groups.<br/> <sup>c</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>d</sup> Downgraded one level for imprecision because the small sample size was unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral phenylbutyrate compared to placebo for children with SMA type II</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral phenylbutyrate compared to placebo for children with SMA type II</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA type II<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral phenylbutyrate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral phenylbutyrate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: Hammersmith Functional Motor Scale (HFMS)<br/> Scale: 0–40<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.13 lower</b><br/> (0.84 lower to 0.58 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: handheld dynamometer (in Newtons)<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Leg megascore</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (leg megascore) was 3.22 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.04 N higher</b><br/> (2.46 lower to 4.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of muscle strength by myometry.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Arm megascore</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (arm megascore) was –0.42 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.98 N higher</b><br/> (1.67 lower to 5.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of muscle strength by myometry.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (% predicted)<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.01 % predicted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.04 % predicted higher</b><br/> (0.07 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of FVC.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: mean 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths were reported. No data available on ventilation.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>994 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 per 1000 (118 to 740)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.1</b> (1.25 to 7.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/53 participants had ≥ 1 adverse events in the phenylbutyrate and placebo group. 19/54 participants had ≥ 1 adverse events in the phenylbutyrate group. </p> <p>Adverse events were systematically and prospectively collected at every study visit. Adverse events included rash, drowsiness with hallucinations, nausea and constipation. No full report on types of adverse events was available. 3 participants discontinued the trial because of severe drowsiness, rash or constipation.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMS:</b> Hammersmith Functional Motor Score; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level because of risk of bias.<br/> <sup>b</sup> Downgraded one level for imprecision because the small sample size.<br/> <sup>c</sup> Downgraded one level because of imprecision on small sample size. Small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> subcutaneous somatotropin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous somatotropin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: HFMSE<br/> Scale: 0–66<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in disability score was –1.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median change 0.25 higher</b><br/> (1 lower to 2.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMSE indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MMT with hand‐held myometry from Citec (in Newtons)<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Upper limbs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (upper limbs) was 0.30 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.08 N lower</b><br/> (3.79 lower to 3.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Lower limbs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (lower limbs) was 0.95 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.23 N higher</b><br/> (2.19 lower to 6.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> <p>Follow‐up: 40 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The trial report states that the trial found no significant differences in quality of life between the somatotropin‐treated group and the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in litres)<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.11 L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.22 L higher</b><br/> (0.02 lower to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: mean 40 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No participant died or required full‐time ventilation in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 40 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578 per 1000 (278 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.57</b><br/> (0.78 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 adverse events occurred, 14 during somatotropin treatment and 9 during placebo treatment. Adverse events were systematically, prospectively collected at every study visit. Adverse events included headache, arthralgia, myalgia, oedema, elevated serum thyroid‐stimulating hormone and myalgia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMSE:</b> Hammersmith Functional Motor Score Expanded; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>MMT:</b> Manual Muscle Testing; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to risk of bias. HFMSE ranges were not available and because of the potential carry‐over effect due to the cross‐over design.<br/> <sup>b</sup> Downgraded one level for imprecision because of very small study size.<br/> <sup>c</sup> Downgraded one level because of potential bias from carry‐over effects due to the cross‐over design.<br/> <sup>d</sup> Downgraded two levels due to risk of bias. The report provided no information about how quality of life was measured and did not provide numerical data. There was a potential carry‐over effect due to the cross‐over design.<br/> <sup>e</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA types II and III<br/> <b>Setting:</b> in hospital treatment<br/> <b>Intervention:</b> intravenous TRH<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intravenous TRH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: hand‐held dynamometry (CSD‐500, Amitec; in pounds)<br/> Scale: 0–6<br/> Follow‐up: 5 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was 0.48 pounds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.34 pounds higher</b><br/> (0.54 lower to 1.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured but no deaths reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events in 3 participants treated with placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 events in 6 participants treated with TRH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included abdominal discomfort, flushing, nausea and vomiting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy; <b>TRH:</b> thyrotropin‐releasing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for sample size.<br/> <sup>b</sup> Downgraded two levels for baseline imbalance and lack of allocation concealment.<br/> <sup>c</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events.<br/> <sup>d</sup> Downgraded one level for indirectness, because data on adverse events was not collected systematically. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral valproic acid plus acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral valproic acid + acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐ambulatory children with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral valproic acid + acetyl‐L‐carnitine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral valproic acid + acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MHFMS<br/> Scale: 0–40<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.64 higher</b><br/> (1.1 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MHFMS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: myometry with myometer (in kg)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –0.25 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.43 kg higher</b><br/> (0.69 lower to 3.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: PedsQL<br/> Scale: 0–100<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was 0.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.2 lower</b><br/> (9.27 lower to 4.87 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate better quality of life. Only 54 participants completed PedsQL at follow‐up. Characteristics of this subset are unknown. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No numerical data available for analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0 deaths or no need for full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>581 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000 (534 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (0.92 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/31 participants in the placebo group had ≥ 1 adverse events. 23/30 participants in the valproic acid + acetyl‐L‐carnitine group had ≥ 1 adverse events. </p> <p>Adverse events were systematically, prospectively collected at every study visit.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded for imprecision because the small sample size.<br/> <sup>b</sup> Downgraded two levels because of very small sample size, inadequately for optimal information size (OIS). Cut off for OIS was the calculated sample size of the trial.<br/> <sup>c</sup> Downgraded one level due to risk of bias. Only a subset of participants completed PedsQL at follow‐up.<br/> <sup>d</sup> Downgraded one level due to inconsistency. Only a subset of participants completed follow‐up.<br/> <sup>e</sup> Downgraded one level due to risk of bias. Data on pulmonary function was not available.<br/> <sup>f</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD006282-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Oral valproic acid compared to placebo for ambulatory adults with SMA type III</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral valproic acid compared to placebo for ambulatory adults with SMA type III</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> ambulatory adults with SMA type III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral valproic acid<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral valproic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: SMAFRS<br/> Scale: 0–50<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.06 higher</b><br/> (1.32 lower to 1.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the SMAFRS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MVICT (in Newtons)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Arms</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength of arms was –0.01 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.23 N lower</b><br/> (1.03 lower to 0.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Legs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength of legs was 0.35 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.37 N lower</b><br/> (1.09 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: mini‐SIP<br/> Scale: 0–19<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was 0.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.1 lower</b><br/> (3.8 lower to 1.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher score on the mini‐SIP indicates a poorer health status.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was 0.53% predicted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.24% predicted lower</b><br/> (4.71 lower to 2.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths or full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 per 1000 (200 to 655)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b> (0.44 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 adverse events occurred, 66 in the placebo group and 30 in the valproic acid group. Adverse events were systematically, prospectively collected at every study visit and included upper airway tract infection or symptoms, dizziness, headache, peripheral neuropathy, tremor, fatigue, pain, abdominal pain, nausea, vomiting, decreased platelet count, weight gain and alopecia.<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>mini‐SIP:</b> mini‐Sickness Impact Profile; <b>MVICT:</b> maximum voluntary isometric contraction testing; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy; <b>SMAFRS:</b> Spinal Muscular Atrophy Rating Scale; <b>TRH:</b> thyrotropin‐releasing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level because of potential carry‐over effect due to the cross‐over design.<br/> <sup>b</sup> Downgraded one level for imprecision because of very small study size.<br/> <sup>c</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD006282-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD006282-sec-0037"></div> <section id="CD006282-sec-0038"> <h3 class="title" id="CD006282-sec-0038">Description of the condition</h3> <p>Spinal muscular atrophy (SMA) is a neuromuscular disorder of childhood and adolescence with an annual incidence of 1 in 6000 to 1 in 12,000 people (<a href="./references#CD006282-bbs2-0069" title="ArkbladE , TuliniusM , KroksmarkAK , HenricssonM , DarinN . A population‐based study of genotypic and phenotypic variability in children with spinal muscular atrophy. Acta Paediatrica2009;98(5):865‐72. ">Arkblad 2009</a>; <a href="./references#CD006282-bbs2-0103" title="CobbenJM , deVisserM , SchefferH . From gene to disease; 'survival' motor neuron protein and hereditary proximal spinal muscle atrophy. Nederlands Tijdschrift voor Geneeskunde2001;145(52):2525‐7. ">Cobben 2001</a>; <a href="./references#CD006282-bbs2-0200" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). It is caused by degeneration of anterior horn cells in the spinal cord and characterised by progressive muscle weakness (<a href="./references#CD006282-bbs2-0151" title="IannacconeST , BurghesAH . Spinal muscular atrophies. In: PourmandR , HaratiY editor(s). Neuromuscular Disorders. Philadelphia (PA): Lippincott Williams and Wilkins, 2001:83‐98. ">Iannaccone 2001</a>; <a href="./references#CD006282-bbs2-0242" title="TalbotK . Spinal muscular atrophy. Journal of Inherited Metabolic Disease1999;22(4):545‐54. ">Talbot 1999</a>). Other parts of the peripheral nervous system such as the neuromuscular junction (NMJ), and possibly muscles and other organs, may also be affected (<a href="./references#CD006282-bbs2-0088" title="BraunS , CroizatB , LagrangeMC , WarterJM , PoindronP . Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet1995;345(8951):694‐5. [PUBMED: 7741893] ">Braun 1995</a>; <a href="./references#CD006282-bbs2-0102" title="Cifuentes‐DiazC , NicoleS , VelascoME , Borra‐CebrianC , PanozzoC , FrugierT , et al. Neurofilament accumulation at the motor endplate and lack of axonal sprouting in a spinal muscular atrophy mouse model. Human Molecular Genetics2002;11(12):1439‐47. [PUBMED: 12023986] ">Cifuentes‐Diaz 2002</a>; <a href="./references#CD006282-bbs2-0156" title="KariyaS , ParkGH , Maeno‐HikichiY , LeykekhmanO , LutzC , ArkovitzMS , et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(16):2552‐69. [PUBMED: 18492800] ">Kariya 2008</a>; <a href="./references#CD006282-bbs2-0195" title="MurrayLM , ComleyLH , ThomsonD , ParkinsonN , TalbotK , GillingwaterTH . Selective vulnerability of motor neurons and dissociation of pre‐ and post‐synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(7):949‐62. [PUBMED: 18065780] ">Murray 2008</a>). </p> <p>SMA is an autosomal‐recessive disease caused by the homozygous deletion of the <i>SMN1</i> gene, which has been mapped to chromosome 5q11.2‐13.3 (<a href="./references#CD006282-bbs2-0092" title="BrzustowiczLM , LehnerT , CastillaLH , PenchaszadehGK , WilhelmsenKC , DanielsR , et al. Genetic mapping of chronic childhood‐onset spinal muscular atrophy to chromosome 5q11.2‐13.3. Nature1990;344(6266):540‐1. ">Brzustowicz 1990</a>; <a href="./references#CD006282-bbs2-0127" title="GilliamTC , BrzustowiczLM , CastillaLH , LehnerT , PenchaszadehGK , DanielsRJ , et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature1990;345(6278):823‐5. ">Gilliam 1990</a>; <a href="./references#CD006282-bbs2-0164" title="LefebvreS , BurglenL , ReboulletS , ClermontO , BurletP , ViolletL , et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell1995;80(1):155‐65. [MEDLINE: LEFEBVRE1995] ">Lefebvre 1995</a>; <a href="./references#CD006282-bbs2-0182" title="MelkiJ , AbdelhakS , ShethP , BachelotMF , BurletP , MarcadetA , et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature1990;344(6268):767‐8. ">Melki 1990a</a>; <a href="./references#CD006282-bbs2-0183" title="MelkiJ , ShethP , AbdelhakS , BurletP , BachelotMF , LathropMG , et al. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12‐q14. The French Spinal Muscular Atrophy Investigators. Lancet1990;336(8710):271‐3. ">Melki 1990b</a>). The deleted gene results in survival motor neuron (SMN) protein deficiency. Chromosome 5q11.2‐13.3 contains the duplicated <i>SMN1</i> and <i>SMN2</i> genes (<a href="./references#CD006282-bbs2-0150" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006282-bbs2-0200" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>). The <i>SMN1</i> and <i>SMN2</i> genes are almost identical, but a crucial C to T nucleotide difference in exon 7 results in the exclusion of exon 7 from most SMN2 messenger ribonucleic acid (mRNA) copies (<a href="./references#CD006282-bbs2-0164" title="LefebvreS , BurglenL , ReboulletS , ClermontO , BurletP , ViolletL , et al. Identification and characterization of a spinal muscular atrophy‐determining gene. Cell1995;80(1):155‐65. [MEDLINE: LEFEBVRE1995] ">Lefebvre 1995</a>; <a href="./references#CD006282-bbs2-0173" title="LorsonCL , HahnenE , AndrophyEJ , WirthB . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America1999;96(11):6307‐11. ">Lorson 1999</a>). The functional <i>SMN1</i> gene, which is transcribed into full‐length mRNA that produces the bulk of stable SMN protein, is lacking in people with SMA. The <i>SMN2</i> gene, which is 80% to 90% transcribed into a truncated form lacking exon 7, only produces residual levels of full‐length SMN mRNA and protein (<a href="./references#CD006282-bbs2-0097" title="CartegniL , HastingsML , CalarcoJA , deStanchinaE , KrainerAR . Determinants of exon 7 splicing in the spinal muscular atrophy genes, SMN1 and SMN2. American Journal of Human Genetics2006;78(1):63‐77. ">Cartegni 2006</a>; <a href="./references#CD006282-bbs2-0173" title="LorsonCL , HahnenE , AndrophyEJ , WirthB . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America1999;96(11):6307‐11. ">Lorson 1999</a>). The clinical severity of the disease is related to the number of copies of the <i>SMN2</i> gene (<a href="./references#CD006282-bbs2-0118" title="FeldkotterM , SchwarzerV , WirthR , WienkerTF , WirthB . Quantitative analyses of SMN1 and SMN2 based on real‐time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. American Journal of Human Genetics2002;70(2):358‐68. ">Feldkotter 2002</a>; <a href="./references#CD006282-bbs2-0138" title="HaradaY , SutomoR , SadewaAH , AkutsuT , TakeshimaY , WadaH , et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. Journal of Neurology2002;249(9):1211‐9. ">Harada 2002</a>; <a href="./references#CD006282-bbs2-0210" title="PiepersS , van denBergLH , BrugmanF , SchefferH , Ruiterkamp‐VersteegM , vanEngelenBG , et al. A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of Neurology2008;255(9):1400‐4. ">Piepers 2008</a>; <a href="./references#CD006282-bbs2-0239" title="SwobodaKJ , PriorTW , ScottCB , McNaughtTP , WrideMC , ReynaSP , et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Annals of Neurology2005;57(5):704‐12. ">Swoboda 2005</a>; <a href="./references#CD006282-bbs2-0257" title="WadmanRI , StamM , GijzenM , LemminkHH , SnoeckIN , WijngaardeCA , et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0‐4. Journal of Neurology, Neurosurgery, and Psychiatry2017;88(4):365‐7. ">Wadman 2017</a>). </p> <p>The cellular functions of the SMN protein are multiple (<a href="./references#CD006282-bbs2-0238" title="SumnerCJ . Molecular mechanisms of spinal muscular atrophy. Journal of Child Neurology2007;22(8):979‐89. ">Sumner 2007</a>), including ribonucleoprotein (RNP) assembly (<a href="./references#CD006282-bbs2-0093" title="BurghesAH , BeattieCE . Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience2009;10(8):597‐609. ">Burghes 2009</a>; <a href="./references#CD006282-bbs2-0126" title="GendronNH , MacKenzieAE . Spinal muscular atrophy: molecular pathophysiology. Current Opinion in Neurology1999;12(2):137‐42. ">Gendron 1999</a>; <a href="./references#CD006282-bbs2-0153" title="JablonkaS , RossollW , SchrankB , SendtnerM . The role of SMN in spinal muscular atrophy. Journal of Neurology2000;247 Suppl 1:I37‐42. ">Jablonka 2000</a>; <a href="./references#CD006282-bbs2-0165" title="LefebvreS , BurglenL , FrezalJ , MunnichA , MelkiJ . The role of the SMN gene in proximal spinal muscular atrophy. Human Molecular Genetics1998;7(10):1531‐6. ">Lefebvre 1998</a>; <a href="./references#CD006282-bbs2-0209" title="PellizzoniL , KataokaN , CharrouxB , DreyfussG . A novel function for SMN, the spinal muscular atrophy disease gene product, in pre‐mRNA splicing. Cell1998;95(5):615‐24. ">Pellizzoni 1998</a>), motor axon outgrowth and axonal transport (<a href="./references#CD006282-bbs2-0181" title="McWhorterML , MonaniUR , BurghesAH , BeattieCE . Knockdown of the survival motor neuron (SMN) protein in zebrafish causes defects in motor axon outgrowth and pathfinding. Journal of Cell Biology2003;162(5):919‐31. ">McWhorter 2003</a>; <a href="./references#CD006282-bbs2-0220" title="RossollW , JablonkaS , AndreassiC , KröningAK , KarleK , MonaniUR , et al. Smn, the spinal muscular atrophy‐determining gene product, modulates axon growth and localization of beta‐actin mRNA in growth cones of motoneurons. Journal of Cell Biology2003;163(4):801‐12. ">Rossoll 2003</a>), protection against <i>superoxide dismutase 1</i> (<i>SOD1</i>) toxicity (<a href="./references#CD006282-bbs2-0273" title="ZouT , IlangovanR , YuF , XuZ , ZhouJ . SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity. Biochemical and Biophysical Research Communication2007;364(4):850‐5. ">Zou 2007</a>), endocytosis (<a href="./references#CD006282-bbs2-0144" title="HosseinibarkooieS , PetersM , Torres‐BenitoL , RastetterRH , HupperichK , HoffmannA , et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. American Journal of Human Genetics2016;99(3):647‐65. ">Hosseinibarkooie 2016</a>; <a href="./references#CD006282-bbs2-0216" title="RiesslandM , KaczmarekA , SchneiderS , SwobodaKJ , LöhrH , BradlerC , et al. Neurocalcin delta suppression protects against spinal muscular atrophy in humans and across species by restoring impaired endocytosis. American Journal of Human Genetics2017;100(2):297‐315. ">Riessland 2017</a>), and ubiquitin homeostasis (<a href="./references#CD006282-bbs2-0261" title="WishartTM , MutsaersCA , RiesslandM , ReimerMM , HunterG , HannamML , et al. Dysregulation of ubiquitin homeostasis and β‐catenin signaling promote spinal muscular atrophy. Journal of Clinical Investigation2014;124(4):1821‐34. ">Wishart 2014</a>). </p> <p>Muscle weakness in SMA occurs predominantly in the axial and proximal muscle groups, with the lower limbs more affected than the upper limbs (<a href="./references#CD006282-bbs2-0162" title="KroksmarkAK , BeckungE , TuliniusM . Muscle strength and motor function in children and adolescents with spinal muscular atrophy II and III. European Journal of Paediatric Neurology2001;5(5):191‐8. [MEDLINE: KROKSMARK2001] ">Kroksmark 2001</a>; <a href="./references#CD006282-bbs2-0245" title="ThomasNH , DubowitzV . The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders1994;4(5‐6):497‐502. ">Thomas 1994</a>). In more severe cases of SMA, intercostal muscles are also weakened, usually with relative sparing of the diaphragm. Survival depends primarily on respiratory function and not necessarily on motor ability (<a href="./references#CD006282-bbs2-0112" title="DubowitzV . Chaos in the classification of SMA: a possible resolution. Neuromuscular Disorders1995;5(1):3‐5. ">Dubowitz 1995</a>; <a href="./references#CD006282-bbs2-0222" title="RussmanBS , IannaconeST , BuncherCR , SamahaFJ , WhiteM , PerkinsB , et al. Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema. Journal of Child Neurology1992;7(4):347‐53. ">Russman 1992</a>; <a href="./references#CD006282-bbs2-0242" title="TalbotK . Spinal muscular atrophy. Journal of Inherited Metabolic Disease1999;22(4):545‐54. ">Talbot 1999</a>). There is often a fine tremor in the fingers (<a href="./references#CD006282-bbs2-0150" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>). Although the face is often spared, tongue fasciculations and facial weakness are not unusual findings (<a href="./references#CD006282-bbs2-0149" title="IannacconeST , BrowneRH , SamahaFJ , BuncherCR . Prospective study of spinal muscular atrophy before age 6 years. DCN/SMA Group. Pediatric Neurology1993;9(3):187‐93. ">Iannaccone 1993</a>). Cognitive function of people with SMA is normal (<a href="./references#CD006282-bbs2-0150" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006282-bbs2-0245" title="ThomasNH , DubowitzV . The natural history of type I (severe) spinal muscular atrophy. Neuromuscular Disorders1994;4(5‐6):497‐502. ">Thomas 1994</a>). Electrophysiological examination shows denervation and reinnervation (<a href="./references#CD006282-bbs2-0150" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006282-bbs2-0200" title="NicoleS , DiazCC , FrugierT , MelkiJ . Spinal muscular atrophy: recent advances and future prospects. Muscle &amp; Nerve2002;26(1):4‐13. ">Nicole 2002</a>; <a href="./references#CD006282-bbs2-0239" title="SwobodaKJ , PriorTW , ScottCB , McNaughtTP , WrideMC , ReynaSP , et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Annals of Neurology2005;57(5):704‐12. ">Swoboda 2005</a>). </p> <p>Classification of SMA according to the International SMA Collaboration distinguishes five types (0 to IV), which are based on age of onset and maximal acquired motor function (<a href="./references#CD006282-bbs2-0119" title="FinkelR , BertiniE , MuntoniF , MercuriE , ENMC SMA Workshop Study Group. 209th ENMC International Workshop: outcome measures and clinical trial readiness in spinal muscular atrophy 7‐9 November 2014, Heemskerk, The Netherlands. Neuromuscular Disorders2015;25(7):593‐602. ">Finkel 2015</a>; <a href="./references#CD006282-bbs2-0186" title="MercuriE , BertiniE , IannacconeST . Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurology2012;11(5):443‐52. ">Mercuri 2012</a>; <a href="./references#CD006282-bbs2-0193" title="MunsatTL , DaviesKE . International SMA consortium meeting (26‐28 June 1992, Bonn, Germany). Neuromuscular Disorders1992;2(5‐6):423‐8. ">Munsat 1992</a>). SMA types 0, I and IV represent the two ends of the spectrum of SMA, which are outside the scope of this review. </p> <p>SMA type II is also known as intermediate SMA, juvenile SMA and chronic SMA. The age of onset is between six and 18 months. Children with SMA type II develop the ability to sit independently but are never able to walk without support. They often develop severe pulmonary and orthopaedic complications (<a href="./references#CD006282-bbs2-0076" title="BertiniE , BurghesA , BushbyK , Estournet‐MathiaudB , FinkelRS , HughesRA , et al. 134th ENMC International Workshop: outcome measures and treatment of spinal muscular atrophy, 11‐13 February 2005, Naarden, The Netherlands. Neuromuscular Disorders2005;15(11):802‐16. ">Bertini 2005</a>). The children generally survive beyond two years of age and usually live into adolescence or longer (<a href="./references#CD006282-bbs2-0223" title="RussmanBS , BuncherCR , WhiteM , SamahaFJ , IannacconeST . Function changes in spinal muscular atrophy II and III. The DCN/SMA Group. Neurology1996;47(4):973‐6. ">Russman 1996</a>; <a href="./references#CD006282-bbs2-0267" title="ZerresK , Rudnik‐SchonebornS . Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Archives of Neurology1995;52(5):518‐23. ">Zerres 1995</a>; <a href="./references#CD006282-bbs2-0268" title="ZerresK , Rudnik‐SchonebornS , ForrestE , LusakowskaA , BorkowskaJ , Hausmanowa‐PetrusewiczI . A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. Journal of the Neurological Sciences1997;146(1):67‐72. ">Zerres 1997</a>). </p> <p>SMA type III is known as Kugelberg‐Welander disease, Wohlfart‐Kugelberg‐Welander disease and mild SMA. The age of onset is after 18 months. Children with SMA type III develop the ability to walk independently at some time, although many lose this ability later in life. Most people with SMA type III have a normal life expectancy (<a href="./references#CD006282-bbs2-0222" title="RussmanBS , IannaconeST , BuncherCR , SamahaFJ , WhiteM , PerkinsB , et al. Spinal muscular atrophy: new thoughts on the pathogenesis and classification schema. Journal of Child Neurology1992;7(4):347‐53. ">Russman 1992</a>; <a href="./references#CD006282-bbs2-0267" title="ZerresK , Rudnik‐SchonebornS . Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Archives of Neurology1995;52(5):518‐23. ">Zerres 1995</a>; <a href="./references#CD006282-bbs2-0268" title="ZerresK , Rudnik‐SchonebornS , ForrestE , LusakowskaA , BorkowskaJ , Hausmanowa‐PetrusewiczI . A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. Journal of the Neurological Sciences1997;146(1):67‐72. ">Zerres 1997</a>). SMA type III is often further divided into SMA type IIIa (disease onset before 36 months of age) and SMA type IIIb (disease onset after 36 months of age) (<a href="./references#CD006282-bbs2-0267" title="ZerresK , Rudnik‐SchonebornS . Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Archives of Neurology1995;52(5):518‐23. ">Zerres 1995</a>). </p> </section> <section id="CD006282-sec-0039"> <h3 class="title" id="CD006282-sec-0039">Description of the intervention</h3> <p>Drug treatment to modify the course of SMA types II and III is urgently needed. Management of SMA until recently has consisted of preventing or treating complications of the condition (<a href="./references#CD006282-bbs2-0150" title="IannacconeST . Spinal muscular atrophy. Seminars in Neurology1998;18(1):19‐26. ">Iannaccone 1998</a>; <a href="./references#CD006282-bbs2-0224" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. ">Russman 2003</a>; <a href="./references#CD006282-bbs2-0122" title="FinkelRS , MercuriE , MeyerOH , SimondsAK , SchrothMK , GrahamRJ , et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders2018;28(3):197‐207. ">Finkel 2018</a>; <a href="./references#CD006282-bbs2-0187" title="MercuriE , FinkelRS , MuntoniF , WirthB , MontesJ , MainM , et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders2018;28(2):103‐15. ">Mercuri 2018</a>). Administration of agents capable of increasing the expression of SMN protein levels may improve the outcome in SMA (<a href="./references#CD006282-bbs2-0118" title="FeldkotterM , SchwarzerV , WirthR , WienkerTF , WirthB . Quantitative analyses of SMN1 and SMN2 based on real‐time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. American Journal of Human Genetics2002;70(2):358‐68. ">Feldkotter 2002</a>; <a href="./references#CD006282-bbs2-0125" title="GavrilinaTO , McGovernVL , WorkmanE , CrawfordTO , GogliottiRG , DiDonatoCJ , et al. Neuronal SMN expression corrects spinal muscular atrophy in severe SMA mice while muscle‐specific SMN expression has no phenotypic effect. Human Molecular Genetics2008;17(8):1063‐75. ">Gavrilina 2008</a>; <a href="./references#CD006282-bbs2-0173" title="LorsonCL , HahnenE , AndrophyEJ , WirthB . A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proceedings of the National Academy of Sciences of the United States of America1999;96(11):6307‐11. ">Lorson 1999</a>). Transcriptional SMN2 activation, facilitation or correction of SMN2 splicing, translational activation and stabilisation of the full‐length SMN protein are possible therapeutic strategies for SMA. Other strategies are improvement of motor neuron viability by neuroprotective or neurotrophic agents (<a href="./references#CD006282-bbs2-0175" title="LunnMR , WangCH . Spinal muscular atrophy. Lancet2008;371(9630):2120‐33. ">Lunn 2008</a>; <a href="./references#CD006282-bbs2-0246" title="ThurmondJ , ButchbachME , PalomoM , PeaseB , RaoM , BedellL , et al. Synthesis and biological evaluation of novel 2,4‐diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy. Journal of Medicinal Chemistry2008;51(3):449‐69. ">Thurmond 2008</a>; <a href="./references#CD006282-bbs2-0259" title="WirthB , BrichtaL , HahnenE . Spinal muscular atrophy: from gene to therapy. Seminars in Pediatric Neurology2006;13(2):121‐31. ">Wirth 2006a</a>). Recently, trials with splice‐site‐modulators (<a href="./references#CD006282-bbs2-0015" title="ChiribogaCA , SwobodaKJ , DarrasBT , IannacconeST , MontesJ , DeVivoDC , et al. Results from a phase 1 study of nusinersen (ISIS‐SMNRx) in children with spinal muscular atrophy. Neurology2016;86(10):890‐7. [ISIS 396443 ‐ CS1; ISIS 396443 ‐ CS10; NCT01494701; NCT01780246] ">Chiriboga 2016</a>; <a href="./references#CD006282-bbs2-0056" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (IONIS SMNRx) in participants with spinal muscular atrophy (SMA) (EMBRACE). clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [232SM202 ; EUCTR2014‐003657‐33‐DE; NCT02462759] ">EMBRACE 2015</a>; <a href="./references#CD006282-bbs2-0120" title="FinkelRS , ChiribogaCA , VajsarJ , DayJW , MontesJ , DeVivoDC , et al. Treatment of infantile‐onset spinal muscular atrophy with nusinersen: a phase 2, open‐label, dose‐escalation study. Lancet2016;388(10063):3017‐26. [NCT01839656] ">Finkel 2016</a>; <a href="./references#CD006282-bbs2-0121" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ . Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. [ENDEAR; IONIS SMNRx‐CS3B ; ISIS 396442‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0030" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74 Suppl 17:S128. NCT01703988 . An open‐label safety, tolerability and dose‐range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx ‐ CS2). clinicaltrials.gov/show/NCT01703988 (first received 8 October 2012). [IONIS SMNRx‐CS2 ; NCT01703988] ">NCT01703988</a>; <a href="./references#CD006282-bbs2-0031" title="NCT02052791 . An open‐label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx‐CS2 or IONIS SMNRx‐CS10. www.clinicaltrials.gov/show/NCT02052791 (first received 30 January 2014). [IONIS SMNRx‐CS12 ; ISIS 396443‐CS12 ; NCT02052791] ">NCT02052791</a>; <a href="./references#CD006282-bbs2-0197" title="NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1. clinicaltrial.gov/show/NCT02122952 (first received 23 April 2014). [AVXS‐101‐CL‐101; NCT02122952] ">NCT02122952</a>; <a href="./references#CD006282-bbs2-0198" title="NCT02268552 . An open label study of LMI070 in type 1 spinal muscular atrophy (SMA). clinicaltrials.gov/show/NCT02268552 (first received 1 October 2014). [CLMI070X2201; NCT02268552] ">NCT02268552</a>; <a href="./references#CD006282-bbs2-0040" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS‐SMNRx. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [EUCTR2015‐001870‐16‐DE; IONIS SMNRx‐CS11; ISIS 396443‐CS11 ; NCT02594124] ">SHINE 2015</a>), ribonucleic acid (RNA)‐degradation inhibitors (<a href="./references#CD006282-bbs2-0095" title="ButchbachME , SinghJ , ThorsteinsdottirM , SaievaL , SlominskiE , ThurmondJ , et al. Effects of 2,4‐diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophy. Human Molecular Genetics2010;19(3):454‐67. [PUBMED: 19897588] ">Butchbach 2010</a>; <a href="./references#CD006282-bbs2-0130" title="GogliottiRG , CardonaH , SinghJ , BailS , EmeryC , KuntzN , et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Human Molecular Genetics2013;22(20):4048‐101. ">Gogliotti 2013</a>; <a href="./references#CD006282-bbs2-0255" title="vanMeerbekeJP , GibbsRM , PlastererHL , MiaoW , FengZ , LinMY , et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Human Molecular Genetics2013;22(20):4074‐83. ">van Meerbeke 2013</a>), and compounds that replace the <i>SMN1</i> gene have started (<a href="./appendices#CD006282-sec-0254">Appendix 1</a>). </p> <p>Various drugs that might slow down or cure SMA have been tested in open and (un)controlled studies of people with SMA types II and III, including thyrotropin‐releasing hormone (TRH) (<a href="./references#CD006282-bbs2-0241" title="TakeuchiY , MiyanomaeY , KomatsuH , OomizonoY , NishimuraA , OkanoS , et al. Efficacy of thyrotropin‐releasing hormone in the treatment of spinal muscular atrophy. Journal of Child Neurology1994;9(3):287‐9. ">Takeuchi 1994</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>), gabapentin (<a href="./references#CD006282-bbs2-0028" title="MerliniL , SolariA , VitaG , BertiniE , MinettiC , MonginiT , et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology2003;18(8):537‐41. [PUBMED: 13677579] ">Merlini 2003</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>), phenylbutyrate (<a href="./references#CD006282-bbs2-0027" title="MercuriE , BertiniE , MessinaS , PelliccioniM , D'AmicoA , ColittoF , et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders2004;14(2):130‐5. [PUBMED: 14733959] ">Mercuri 2004</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0034" title="NCT00439569 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy types II or III. clinicaltrials.gov/show/NCT00439569 (first received 21 February 2007). [HHSN265200423611C; N01NS42361_NPTUNE01; NCT00439569; NPTUNE01] ">NPTUNE01 2007</a>; <a href="./references#CD006282-bbs2-0234" title="STOPSMA . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA). clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>), creatine (<a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), valproic acid (<a href="./references#CD006282-bbs2-0104" title="ConceicaoE , SilvaT , UmbertineR , Maria JoaquinaD . Analysis of motor skill acquisition among children with type I spinal muscular atrophy submitted to medication with valproic acid. Amyotrophic Lateral Sclerosis2010;11(Suppl 1):63‐71. ">Conceicao 2010</a>; <a href="./references#CD006282-bbs2-0021" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0025" title="KisselJT , ScottCB , ReynaSP , CrawfordTO , SimardLR , KrosschellKJ , et al. SMA CARNIVAL trial part II: a prospective, single‐armed trial of L‐carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PloS One2011;6(7):e21296. [PUBMED: 21754985] ">Kissel 2011</a>; <a href="./references#CD006282-bbs2-0057" title="NCT01671384 . Valproate and levocarnitine in children with spinal muscular atrophy. clinicaltrials.gov/show/NCT01671384 (first received 13 August 2012). [NCT01671384] ">NCT01671384</a>; <a href="./references#CD006282-bbs2-0039" title="SaitoT , NurputraDK , HarahapNI , HarahapIS , YamamotoH , MuneshigeE , et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience2014;3:49‐57. ">Saito 2014</a>; <a href="./references#CD006282-bbs2-0041" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=5544(first received August 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006282-bbs2-0058" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544 (first received 12 January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02</a>; <a href="./references#CD006282-bbs2-0042" title="SMART03 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: continuous administration trial. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=4602(first received August 2016). ">SMART03</a>; <a href="./references#CD006282-bbs2-0043" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PloS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), hydroxyurea (<a href="./references#CD006282-bbs2-0014" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002; Vol. 71 Suppl 4:2402. ">Chang 2002</a>; <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0026" title="LiangWC , YuoCY , ChangJG , ChenYC , ChangYF , WangHY , et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences2008;268(1‐2):87‐94. [PUBMED: 18166199] ">Liang 2008</a>; <a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a>), somatropin (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>), carnitine (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), salbutamol (<a href="./references#CD006282-bbs2-0019" title="GiovannettiAM , PasanisiMB , ČerniauskaitėM , BussolinoC , LeonardiM , MorandiL . Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study. Muscle &amp; Nerve2016;54(5):843‐9. PasanisiMB , GiovannettiAM , BussolinoC , CampanellaA , LeonardiM , MorandiL . Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscular Disorders2014;24(9‐10):914. ">Giovannetti 2016</a>; <a href="./references#CD006282-bbs2-0023" title="KhiraniS , DabajI , AmaddeoA , Olmo ArroyoJ , RopersJ , TirolienS , et al. Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatric Neurology2017;73:78‐87. ">Khirani 2017</a>; <a href="./references#CD006282-bbs2-0024" title="KinaliM , MercuriE , MainM , DeBiasiaF , KaratzaA , HigginsR , et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology2002;59(4):609‐10. [PUBMED: 12196659] ">Kinali 2002</a>; <a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>; <a href="./references#CD006282-bbs2-0036" title="PaneM , StaccioliS , MessinaS , D'AmicoA , PelliccioniM , MazzoneES , et al. Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders2008;18(7):536‐40. [PUBMED: 18579379] ">Pane 2008</a>; <a href="./references#CD006282-bbs2-0207" title="PasanisiMB , GiovannettiAM , BussolinoC , CampanellaA , LeonardiM , MorandiL . Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscular Disorders2014;24:9‐10. ">Pasanisi 2014</a>; <a href="./references#CD006282-bbs2-0038" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257 (Suppl 1):S101. [PUBMED: 20495927] ">Prufer de Queiroz Campos Araujo 2010</a>; <a href="./references#CD006282-bbs2-0044" title="TanC , WilliamsAN . Oral salbutamol in 2 wheelchair bound cases of SMA type II. Archives of Disease in Childhood2011;96 Suppl 1:G77(P). ">Tan 2011</a>), riluzole (<a href="./references#CD006282-bbs2-0011" title="AbbaraC , EstournetB , LacomblezL , LelièvreB , OuslimaniA , LehmannB , et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology2011;71(3):403‐10. [PUBMED: 21284699] ">Abbara 2011</a>; <a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>; <a href="./references#CD006282-bbs2-0224" title="RussmanBS , IannacconeST , SamahaFJ . A phase 1 trial of riluzole in spinal muscular atrophy. Archives of Neurology2003;60(11):1601‐3. ">Russman 2003</a>), lamotrigine (<a href="./references#CD006282-bbs2-0029" title="NascimentoOJ , OrsiniM , QuintanilhaG . Lamotrigine on motor symptoms of spinal muscular atrophies. Revista de Neurologia2010;50(2):127‐8. [PUBMED: 20112222] ">Nascimento 2010</a>), celecoxib (<a href="./references#CD006282-bbs2-0032" title="NCT02876094 . Effect of low‐dose celecoxib on SMN2 in patients with spinal muscular atrophy (SMA). www.clinicaltrials.gov/show/NCT02876094 (first received 9 August 2016). [NCT02876094] ">NCT02876094</a>), olesoxime (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>), <i>SMN1</i> gene therapy (<a href="./references#CD006282-bbs2-0184" title="MendellJR , Al‐ZaidyS , ShellR , ArnoldWD , Rodino‐KlapacL , KisselJT , et al. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Molecular Therapy2016;24(Suppl 1):S190. [WOS:000375264200475] ">Mendell 2016</a>; <a href="./references#CD006282-bbs2-0197" title="NCT02122952 . Gene transfer clinical trial for spinal muscular atrophy type 1. clinicaltrial.gov/show/NCT02122952 (first received 23 April 2014). [AVXS‐101‐CL‐101; NCT02122952] ">NCT02122952</a>; <a href="./references#CD006282-bbs2-0231" title="SprouleD , Al‐ZaidyS , ShellR , ArnoldD , Rodino‐KlapacL , KisselJ , et al. Interim safety, efficacy and achievement of developmental milestones in this phase 1, first‐in‐human study of the systemic delivery of AVXS‐101, an AAV9‐mediated gene therapy for children with spinal muscular atrophy (SMA) type 1. Annals of Neurology2016;80(Suppl 20):S368. ">Sproule 2016</a>), <i>SMN2</i> antisense oligonucleotides (ASO) (<a href="./references#CD006282-bbs2-0015" title="ChiribogaCA , SwobodaKJ , DarrasBT , IannacconeST , MontesJ , DeVivoDC , et al. Results from a phase 1 study of nusinersen (ISIS‐SMNRx) in children with spinal muscular atrophy. Neurology2016;86(10):890‐7. [ISIS 396443 ‐ CS1; ISIS 396443 ‐ CS10; NCT01494701; NCT01780246] ">Chiriboga 2016</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0030" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74 Suppl 17:S128. NCT01703988 . An open‐label safety, tolerability and dose‐range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx ‐ CS2). clinicaltrials.gov/show/NCT01703988 (first received 8 October 2012). [IONIS SMNRx‐CS2 ; NCT01703988] ">NCT01703988</a>; <a href="./references#CD006282-bbs2-0031" title="NCT02052791 . An open‐label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx‐CS2 or IONIS SMNRx‐CS10. www.clinicaltrials.gov/show/NCT02052791 (first received 30 January 2014). [IONIS SMNRx‐CS12 ; ISIS 396443‐CS12 ; NCT02052791] ">NCT02052791</a>; <a href="./references#CD006282-bbs2-0040" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS‐SMNRx. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [EUCTR2015‐001870‐16‐DE; IONIS SMNRx‐CS11; ISIS 396443‐CS11 ; NCT02594124] ">SHINE 2015</a>), small molecules (<a href="./references#CD006282-bbs2-0020" title="NCT03032172 . A study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish). clinicaltrials.gov/show/NCT03032172 (first received 24 January 2017). ">JEWELFISH 2017</a>; <a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>; <a href="./references#CD006282-bbs2-0054" title="NCT02644668 . A study of CK‐2127107 in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02644668 (first received 23 December 2015). [CY 5021; NCT02644668] RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17(Suppl 1):P261. ">NCT02644668</a>; <a href="./references#CD006282-bbs2-0059" title="SUNFISH . A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy participants (Sunfish). clinicaltrials.gov/show/NCT02908685 (first received 19 September 2016). ">SUNFISH 2016</a>), and NMJ‐interactors (<a href="./references#CD006282-bbs2-0017" title="NCT02227823 . Safety and efficacy study of pyridostigmine on patients with spinal muscular atrophy type 3. www.clinicaltrials.gov/show/NCT02227823 (first received 20 August 2014). [1376 ; NCT02227823] ">EMOTAS 2014</a>; <a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>; <a href="./references#CD006282-bbs2-0055" title="SPACE . SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐004369‐34‐NL(first received October 2016). [EUCTR2011‐004369‐34‐NL] ">SPACE</a>). </p> <p>Below we describe the working mechanisms, preclinical studies in SMA models, and results of studies and trials of the various drugs tested in people with SMA type II and III. </p> <p>It was not clear on clinical grounds whether the patient populations in studies on coenzyme Q10, lithium carbonate and guanidine hydrochloride had a genetically confirmed diagnosis of SMA, partially because <i>SMN</i> gene analysis was not possible prior to 1991 (<a href="./references#CD006282-bbs2-0066" title="AngeliniC , MicaglioGF , TrevisanC . Guanidine hydrochloride in infantile and juvenile spinal muscular atrophy. A double blind controlled study. Acta Neurologica1980;2(6):460‐5. [PUBMED: 7027754] ">Angelini 1980</a>; <a href="./references#CD006282-bbs2-0018" title="FolkersK , SimonsenR . Two successful double‐blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta1995;1271(1):281‐6. [PUBMED: 7599221] ">Folkers 1995</a>; <a href="./references#CD006282-bbs2-0152" title="Il'inaNA , AntipovaRI , KhokhlovAP . Use of lithium carbonate to treat Kugelberg‐Welander spinal amyotrophy [Primenenie uglekislogo litiia dlia lecheniia spinal'noi amiotrofii Kugel'berga‐Velandera]. Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova (Moscow, Russia)1980;80(11):1657‐60. [PUBMED: 7456914] ">Il'ina 1980</a>). Therefore, we have not discussed the therapeutic effects of these drugs. </p> <p>In vitro and animal studies have found several other compounds to have an effect on SMN expression, but they are as yet untested in people with SMA. Therefore, they are outside the scoop of this review. See <a href="./appendices#CD006282-sec-0256">Appendix 2</a> for a brief description of these compounds. </p> <p><i>SMN1</i> gene therapies are outside the scope of this review. We have added some information in <a href="./appendices#CD006282-sec-0254">Appendix 1</a> for overall completeness. </p> <section id="CD006282-sec-0040"> <h4 class="title">Antisense oligonucleotides</h4> <p>ASOs or 'morpholinos', are synthetic strands of nucleic acid that are able to interfere with (stimulate or inhibit) mRNA products of the target DNA sequence. In this way, ASOs can modify potential splice sites and interfere with splicing (<a href="./references#CD006282-bbs2-0211" title="PorenskyPN , BurghesAH . Antisense oligonucleotides for the treatment of spinal muscular atrophy. Human Gene Therapy2013;24(5):489‐98. ">Porensky 2013</a>). Multiple ASOs for the <i>SMN2</i> gene have been developed and investigated (<a href="./references#CD006282-bbs2-0082" title="BogdanikLP , OsborneMA , DavisC , MartinWP , AustinA , RigoF , et al. Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy. Proceedings of the National Academy of Sciences of United States of America2015;112(43):E5863‐72. ">Bogdanik 2015</a>; <a href="./references#CD006282-bbs2-0157" title="KeilJM , SeoJ , HowellMD , HsuWH , SinghRN , DiDonatoCJ . A short antisense oligonucleotide ameliorates symptoms of severe mouse models of spinal muscular atrophy. Molecular Therapy – Nucleic Acids2014;3:e174. ">Keil 2014</a>; <a href="./references#CD006282-bbs2-0202" title="NizzardoM , SimoneC , SalaniS , RueppMD , RizzoF , RuggieriM , et al. Effect of combined systemic and local morpholino treatment on the spinal muscular atrophy Δ7 mouse model phenotype. Clinical Therapeutics2014;36(3):340‐56. ">Nizzardo 2014</a>; <a href="./references#CD006282-bbs2-0205" title="OsmanEY , MillerMR , RobbinsKL , LombardiAM , AtkinsonAK , BrehmAJ , et al. Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models. Human Molecular Genetics2014;23(18):4832‐45. ">Osman 2014</a>; <a href="./references#CD006282-bbs2-0228" title="ShababiM , LorsonCL . Optimization of SMN trans‐splicing through the analysis of SMN introns. Journal Molecular Neuroscience2012;46(3):459‐69. ">Shababi 2012</a>; <a href="./references#CD006282-bbs2-0230" title="SkordisLA , DunckleyMG , YueB , EperonIC , MuntoniF . Bifunctional antisense oligonucleotides provide a trans‐acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proceedings of National Academy of Sciences of the United States of America2003;100(7):4114‐9. ">Skordis 2003</a>; <a href="./references#CD006282-bbs2-0232" title="StaropoliJF , LiH , ChunSJ , AllaireN , CullenP , ThaiA , et al. Rescue of gene‐expression changes in an induced mouse model of spinal muscular atrophy by an antisense oligonucleotide that promotes inclusion of SMN2 exon 7. Genomics2015;105(4):220‐8. ">Staropoli 2015</a>; <a href="./references#CD006282-bbs2-0271" title="ZhouH , JanghraN , MitrpantC , DickinsonRL , AnthonyK , PriceL , et al. A novel morpholino oligomer targeting ISS‐N1 improves rescue of severe spinal muscular atrophy transgenic mice. Human Gene Therapies2013;24(3):331‐42. ">Zhou 2013</a>; <a href="./references#CD006282-bbs2-0272" title="ZhouH , MengJ , MarrosuE , JanghraN , MorganJ , MuntoniF . Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response. Human Molecular Genetics2015;24(22):6265‐77. ">Zhou 2015</a>). The intronic splice silencer in intron 7 of <i>SMN2</i> is called nusinersen (formerly known as SMN Rx 39443, IONIS SMN Rx or ISIS‐SMN Rx). This compound specifically targets the splice silencer in intron 7 and ensures the inclusion of <i>SMN2</i> exon 7, which results in increased SMN2 full‐length mRNA and protein production (<a href="./references#CD006282-bbs2-0146" title="HuaY , SahashiK , HungG , RigoF , PassiniMA , BennettCF , et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes &amp; Development2010;24(15):1634‐44. ">Hua 2010</a>). Nusinersen has subsequently demonstrated improved performance and survival in SMA animal models (<a href="./references#CD006282-bbs2-0147" title="HuaY , SahashiK , RigoF , HungG , HorevG , BennettCF , et al. Peripheral SMN restoration is essential for long‐term rescue of a severe SMA mouse model. Nature2011;478(7367):123‐6. ">Hua 2011</a>; <a href="./references#CD006282-bbs2-0208" title="PassiniMA , BuJ , RichardsAM , KinnecomC , SardiSP , StanekLM , et al. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Science Translational Medicine2011;3(72):72ra18. ">Passini 2011</a>). Nusinersen is an intrathecally injected therapy. </p> </section> <section id="CD006282-sec-0041"> <h4 class="title">Carnitine</h4> <p>L‐carnitine, an essential cofactor for the beta‐oxidation of long‐chain fatty acids, inhibits mitochondrial injury and apoptosis both in vitro and in vivo (<a href="./references#CD006282-bbs2-0079" title="BiginiP , LariniS , PasqualiC , MuzioV , MenniniT . Acetyl‐L‐carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neuroscience Letters2002;329(3):334‐8. ">Bigini 2002</a>; <a href="./references#CD006282-bbs2-0089" title="BresolinN , FreddoL , TegazzinV , BetL , ArmaniM , AngeliniC . Carnitine and acyltransferase in experimental neurogenic atrophies: changes with treatment. Journal of Neurology1984;231(4):170‐5. ">Bresolin 1984</a>). Acetyl‐L‐carnitine, the acetylated derivative of L‐carnitine, shows neuroprotective and neurotrophic activity in motor neuron cultures (<a href="./references#CD006282-bbs2-0079" title="BiginiP , LariniS , PasqualiC , MuzioV , MenniniT . Acetyl‐L‐carnitine shows neuroprotective and neurotrophic activity in primary culture of rat embryo motoneurons. Neuroscience Letters2002;329(3):334‐8. ">Bigini 2002</a>). L‐carnitine treatment restored the level of free carnitine in one animal model of SMA (<a href="./references#CD006282-bbs2-0089" title="BresolinN , FreddoL , TegazzinV , BetL , ArmaniM , AngeliniC . Carnitine and acyltransferase in experimental neurogenic atrophies: changes with treatment. Journal of Neurology1984;231(4):170‐5. ">Bresolin 1984</a>). </p> </section> <section id="CD006282-sec-0042"> <h4 class="title">Celecoxib</h4> <p>Treatment with celecoxib increased SMN RNA and protein levels in vitro and in models of severe SMA mice by activating the p38 pathway (<a href="./references#CD006282-bbs2-0117" title="FarooqF , Abadía‐MolinaF , MacKenzieD , HadwenJ , ShamimF , O'ReillyS , et al. Celecoxib increases SMN and survival in a severe spinal muscular atrophy mouse model via p38 pathway activation. Human Molecular Genetics2013;22(17):3415‐24. ">Farooq 2013</a>), and might have a neuroprotective effect by inhibition of glutamate release (<a href="./references#CD006282-bbs2-0078" title="BezziP , CarmignotoG , PastiL , VesceS , RossiD , RizziniBL , et al. Prostaglandins stimulate calcium‐dependent glutamate release in astrocytes. Nature1998;391(6664):281‐5. ">Bezzi 1998</a>). Glutamate is released after presynaptic depolarisation and if not efficiently cleared, leads to increased levels of free radicals, and potentially to degeneration of motor neurons (<a href="./references#CD006282-bbs2-0091" title="BrysonHM , FultonB , BenfieldP . Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs1996;52(4):549‐63. ">Bryson 1996</a>). </p> </section> <section id="CD006282-sec-0043"> <h4 class="title">Creatine</h4> <p>Creatine might have therapeutic benefit by increasing muscle mass and strength through its role as an energy shuttle between mitochondria and working musculature, and is thought to exert neuroprotective effects (<a href="./references#CD006282-bbs2-0077" title="BessmanSP , GeigerPJ . Transport of energy in muscle: the phosphorylcreatine shuttle. Science1981;211(4481):448‐52. ">Bessman 1981</a>; <a href="./references#CD006282-bbs2-0116" title="EllisAC , RosenfeldJ . The role of creatine in the management of amyotrophic lateral sclerosis and other neurodegenerative disorders. CNS Drugs2004;18(14):967‐80. ">Ellis 2004</a>; <a href="./references#CD006282-bbs2-0243" title="TarnopolskyM , MartinJ . Creatine monohydrate increases strength in patients with neuromuscular disease. Neurology1999;52(4):854‐7. ">Tarnopolsky 1999</a>). </p> </section> <section id="CD006282-sec-0044"> <h4 class="title">Gabapentin</h4> <p>Gabapentin has a neuroprotective role by diminishing the excitotoxicity of glutamate (<a href="./references#CD006282-bbs2-0131" title="GreensmithL , VrbovaG . Possible strategies for treatment of SMA patients: a neurobiologist's view. Neuromuscular Disorders1995;5(5):359‐69. ">Greensmith 1995</a>; <a href="./references#CD006282-bbs2-0028" title="MerliniL , SolariA , VitaG , BertiniE , MinettiC , MonginiT , et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology2003;18(8):537‐41. [PUBMED: 13677579] ">Merlini 2003</a>; <a href="./references#CD006282-bbs2-0244" title="TaylorCP , GeeNS , SuTZ , KocsisJD , WeltyDF , BrownJP , et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Research1998;29(3):233‐49. ">Taylor 1998</a>). </p> </section> <section id="CD006282-sec-0045"> <h4 class="title">Hydroxyurea</h4> <p>Hydroxyurea is a histone deacetylase inhibitor. Studies have suggested a therapeutic role for these agents in SMA, as they appear to activate <i>SMN2</i> transcription (<a href="./references#CD006282-bbs2-0107" title="DarrasBT , KangPB . Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics2007;19(6):675‐9. ">Darras 2007</a>; <a href="./references#CD006282-bbs2-0158" title="KernochanLE , RussoML , WoodlingNS , HuynhTN , AvilaAM , FischbeckKH , et al. The role of histone acetylation in SMN gene expression. Human Molecular Genetics2005;14(9):1171‐82. ">Kernochan 2005</a>; <a href="./references#CD006282-bbs2-0260" title="WirthB , BrichtaL , HahnenE . Spinal muscular atrophy and therapeutic prospects. Progress in Molecular and Subcellular Biology2006;44:109‐32. ">Wirth 2006b</a>). In vitro, hydroxyurea increases <i>SMN2</i> gene expression and production of SMN protein in cultured lymphocytes of people with SMA (<a href="./references#CD006282-bbs2-0132" title="GrzeschikSM , GantaM , PriorTW , HeavlinWD , WangCH . Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Annals of Neurology2005;58(2):194‐202. ">Grzeschik 2005</a>; <a href="./references#CD006282-bbs2-0026" title="LiangWC , YuoCY , ChangJG , ChenYC , ChangYF , WangHY , et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences2008;268(1‐2):87‐94. [PUBMED: 18166199] ">Liang 2008</a>). </p> </section> <section id="CD006282-sec-0046"> <h4 class="title">Lamotrigine</h4> <p>Lamotrigine is a glutamate inhibitor and might prevent motor neuron death (<a href="./references#CD006282-bbs2-0099" title="CasanovasA , RiberaJ , HukkanenM , Riveros‐MorenoV , EsquerdaJE . Prevention by lamotrigine, MK‐801 and N omega‐nitro‐l‐arginine methyl ester of motoneuron cell death after neonatal axotomy. Neuroscience1996;71:313‐25. ">Casanovas 1996</a>). </p> </section> <section id="CD006282-sec-0047"> <h4 class="title">Olesoxime</h4> <p>The experimental drug olesoxime (TRO19622) is thought to modulate the mitochondrial permeability transition pore (mPTP) opening, which might influence cell apoptosis of, for example, motor neurons (<a href="./references#CD006282-bbs2-0083" title="BordetT , BuissonB , MichaudM , DrouotC , GaléaP , DelaageP , et al. Identification and characterization of cholest‐4‐en‐3‐one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. Journal of Pharmacology and Experimental Therapeutics2007;322(2):709‐20. ">Bordet 2007</a>; <a href="./references#CD006282-bbs2-0084" title="BordetT , BernaP , AbitbolJ‐L , PrussRM . Olesoxime (TRO19622): a novel mitochondrial‐targeted neuroprotective compound. Pharmaceuticals (Basel)2010;3(2):345‐68. ">Bordet 2010</a>). </p> </section> <section id="CD006282-sec-0048"> <h4 class="title">Phenylbutyrate</h4> <p>Phenylbutyrate is a histone deacetylase inhibitor. In fibroblast cultures and leukocytes of people with SMA, phenylbutyrate increased SMN transcript expression (<a href="./references#CD006282-bbs2-0061" title="Also‐RalloE , AliasL , Martinez‐HernandezR , CasellesL , BarceloMJ , BaigetM , et al. Treatment of spinal muscular atrophy cells with drugs that upregulate SMN expression reveals inter‐ and intra‐patient variability. European Journal of Human Genetics2011;19:1059‐65. ">Also‐Rallo 2011</a>; <a href="./references#CD006282-bbs2-0064" title="AndreassiC , AngelozziC , TizianoFD , VitaliT , DeVincenziE , BoninsegnaA , et al. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. European Journal of Human Genetics2004;12(1):59‐65. ">Andreassi 2004</a>; <a href="./references#CD006282-bbs2-0012" title="BraheC , VitaliT , TizianoFD , AngelozziC , PintoAM , BorgoF , et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics2005;13(2):256‐9. [PUBMED: 15523494] ">Brahe 2005</a>). </p> </section> <section id="CD006282-sec-0049"> <h4 class="title">Valproate</h4> <p>Valproate is another histone deacetylase inhibitor that increases SMN protein in vitro by increasing transcription of <i>SMN2</i> gene (<a href="./references#CD006282-bbs2-0158" title="KernochanLE , RussoML , WoodlingNS , HuynhTN , AvilaAM , FischbeckKH , et al. The role of histone acetylation in SMN gene expression. Human Molecular Genetics2005;14(9):1171‐82. ">Kernochan 2005</a>; <a href="./references#CD006282-bbs2-0046" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. [PUBMED: 16775228] ">Weihl 2006</a>). It also has an antiglutamatergic effect (<a href="./references#CD006282-bbs2-0159" title="KimJE , KimDS , KwakSE , ChoiHC , SongHK , ChoiSY , et al. Anti‐glutamatergic effect of riluzole: comparison with valproic acid. Neuroscience2007;147(1):136‐45. ">Kim 2007</a>). Valproate has been tested in various models of SMA and showed positive results on SMN expression in vitro (<a href="./references#CD006282-bbs2-0090" title="BrichtaL , HofmannY , HahnenE , SiebzehnrublFA , RaschkeH , BlumckeI , et al. Valproic acid increases the SMN2 protein level: a well‐known drug as a potential therapy for spinal muscular atrophy. Human Molecular Genetics2003;12(19):2481‐9. ">Brichta 2003</a>; <a href="./references#CD006282-bbs2-0013" title="BrichtaL , HolkerI , HaugK , KlockgetherT , WirthB . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology2006;59(6):970‐5. [PUBMED: 16607616] ">Brichta 2006</a>; <a href="./references#CD006282-bbs2-0237" title="SumnerCJ , HuynhTN , MarkowitzJA , PerhacJS , HillB , CoovertDD , et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Annals of Neurology2003;54(5):647‐54. ">Sumner 2003</a>) and in vivo (<a href="./references#CD006282-bbs2-0037" title="PiepersS , CobbenJM , SodaarP , JansenMD , WadmanRI , Meester‐DelverA , et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. Journal of Neurology, Neurosurgery, and Psychiatry2011;82(8):850‐2. [PUBMED: 20551479] ">Piepers 2011</a>). </p> </section> <section id="CD006282-sec-0050"> <h4 class="title">Salbutamol</h4> <p>Some studies have documented positive effects of oral beta<sub>2</sub>‐adrenoceptor agonists on human skeletal muscle (<a href="./references#CD006282-bbs2-0098" title="CarusoJF , SignorileJF , PerryAC , LeblancB , WilliamsR , ClarkM , et al. The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Medicine and Science in Sports and Exercise1995;27(11):1471‐6. ">Caruso 1995</a>; <a href="./references#CD006282-bbs2-0160" title="KindermannW . Do inhaled beta(2)‐agonists have an ergogenic potential in non‐asthmatic competitive athletes?. Sports Medicine2007;37(2):95‐102. ">Kindermann 2007</a>; <a href="./references#CD006282-bbs2-0176" title="MackSG , CookDJ , DhurjatiP , ButchbachME . Systems biology investigation of cAMP modulation to increase SMN levels for the treatment of spinal muscular atrophy. PloS One2014;16(9):e115473. ">Mack 2014</a>; <a href="./references#CD006282-bbs2-0177" title="MartineauL , HoranMA , RothwellNJ , LittleRA . Salbutamol, a beta 2‐adrenoceptor agonist, increases skeletal muscle strength in young men. Clinical Science (London)1992;83(5):615‐21. ">Martineau 1992</a>). Trials investigating effects of oral beta<sub>2</sub>‐adrenoceptor agonists in people with NMJ disorders have demonstrated improvement of motor function (<a href="./references#CD006282-bbs2-0094" title="BurkeG , HiscockA , KleinA , NiksEH , MainM , ManzurAY , et al. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations. Neuromuscular Disorders2013;23(2):170‐5. ">Burke 2013</a>; <a href="./references#CD006282-bbs2-0168" title="LiewluckT , SelcenD , EngelAG . Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok‐7 myasthenia. Muscle &amp; Nerve2011;44(5):789‐94. ">Liewluck 2011</a>; <a href="./references#CD006282-bbs2-0172" title="LorenzoniPJ , ScolaRH , KayCS , FillaL , MirandaAP , PinheiroJM , et al. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation. Journal of the Neurological Sciences2013;331:155‐7. ">Lorenzoni 2013</a>; <a href="./references#CD006282-bbs2-0219" title="Rodríguez CruzPM , PalaceJ , RamjattanH , JayawantS , RobbSA , BeesonD . Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology2015;85:1043‐7. ">Rodríguez Cruz 2015</a>). Since abnormal development of the NMJ and dysfunction of neuromuscular synaptic transmission occur in SMA (<a href="./references#CD006282-bbs2-0088" title="BraunS , CroizatB , LagrangeMC , WarterJM , PoindronP . Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet1995;345(8951):694‐5. [PUBMED: 7741893] ">Braun 1995</a>; <a href="./references#CD006282-bbs2-0156" title="KariyaS , ParkGH , Maeno‐HikichiY , LeykekhmanO , LutzC , ArkovitzMS , et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(16):2552‐69. [PUBMED: 18492800] ">Kariya 2008</a>; <a href="./references#CD006282-bbs2-0161" title="KongL , WangX , ChoeDW , PolleyM , BurnettBG , Bosch‐MarcéM , et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. Journal of Neuroscience2009;29(3):842‐51. ">Kong 2009</a>; <a href="./references#CD006282-bbs2-0195" title="MurrayLM , ComleyLH , ThomsonD , ParkinsonN , TalbotK , GillingwaterTH . Selective vulnerability of motor neurons and dissociation of pre‐ and post‐synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(7):949‐62. [PUBMED: 18065780] ">Murray 2008</a>; <a href="./references#CD006282-bbs2-0256" title="WadmanRI , VranckenAF , van denBergLH , van derPolWL . Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology2012;79(20):2050‐5. ">Wadman 2012a</a>), beta<sup>2</sup>‐adrenoceptor agonists might have an positive effect on muscles and NMJs in SMA. In fibroblasts of people with SMA, salbutamol increases the levels of SMN2 full‐length mRNA and the SMN protein (<a href="./references#CD006282-bbs2-0067" title="AngelozziC , BorgoF , TizianoFD , MartellaA , NeriG , BraheC . Salbutamol increases SMN mRNA and protein levels in spinal muscular atrophy cells. Journal of Medical Genetics2008;45(1):29‐31. ">Angelozzi 2008</a>). In 12 people with SMA types II and III who received six months of treatment with oral salbutamol, leukocytes showed a significant and constant increase in SMN2 full‐length transcript levels (<a href="./references#CD006282-bbs2-0249" title="TizianoFD , LomastroR , PintoAM , MessinaS , D'AmicoA , FioriS , et al. Salbutamol increases survival motor neuron (SMN) transcript levels in leucocytes of spinal muscular atrophy (SMA) patients: relevance for clinical trial design. Journal of Medical Genetics2010;47(12):856‐8. ">Tiziano 2010</a>). </p> </section> <section id="CD006282-sec-0051"> <h4 class="title">Small molecules</h4> <section id="CD006282-sec-0052"> <h5 class="title">RO6885247/RG7800</h5> <p>The small molecule RO6885247/RG7800 selectively modulates <i>SMN2</i> splicing towards the inclusion of exon 7 and thereby stimulates production of full‐length SMN2 mRNA. Administration of RO6885247/RG7800 improves and almost rescues motor function and survival of SMA mice (<a href="./references#CD006282-bbs2-0196" title="NaryshkinNA , WeetallM , DakkaA , NarasimhanJ , ZhaoX , FengZ , et al. SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science2014;345(6197):688‐93. ">Naryshkin 2014</a>). </p> </section> <section id="CD006282-sec-0053"> <h5 class="title">RO7034067/RG7916</h5> <p>The small molecule RO7034067/RG7916 modulates <i>SMN2</i> splicing, but exact details of its structure and pharmacology are not available. One phase I trial with RO7034067/RG7916 combined with itraconazole in healthy volunteers showed a dose‐dependent increase of SMN2 mRNA transcripts, but results were only reported in a conference abstract, with further publication of data pending (<a href="./references#CD006282-bbs2-0199" title="NCT02633709 . A study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO7034067 (RG7916) given by mouth in healthy volunteers. clinicaltrials.gov/show/NCT02633709 (first received 15 December 2015). [2015‐004605‐16; BP29840; NCT02633709] ">NCT02633709</a>; <a href="./references#CD006282-bbs2-0236" title="SturmS , GuntherA , NaveS , JordanP , Al KotbiN , ParkarN , et al. The SMN2 splicing modifier RG7916 induces a dose‐dependent increase of full length SMN2 mRNA. Annals of Neurology2016;80(Suppl 20):S293‐4. ">Sturm 2016</a>). </p> </section> <section id="CD006282-sec-0054"> <h5 class="title">CK‐2127107</h5> <p>CK‐2127107/CK‐107 (2‐aminoalkyl‐5‐N‐heteroarylpyrimidine) is a small‐molecule fast skeletal troponin activator candidate that has been tested in conditions of muscle weakness, fatigue and heart failure (<a href="./references#CD006282-bbs2-0148" title="HweeDT , KennedyAR , HartmanJJ , RyansJ , DurhamN , MalikFI , et al. The small‐molecule fast skeletal troponin activator, CK‐2127107, improves exercise tolerance in a rat model of heart failure. Journal of Pharmacology and Experimental Therapeutics2015;353:159‐68. ">Hwee 2015</a>). It might have a beneficial effect in SMA because of muscle protection, increased muscle strength in skeletal muscle, and delay of onset and extent of muscle fatigue (<a href="./references#CD006282-bbs2-0065" title="AndrewsJA , MillerTM , VijayakumarV , StoltzR , JamesJK , MengL , et al. CK‐2127107 amplifies skeletal muscle response to nerve activation in humans. Muscle &amp; Nerve2018;57(5):729‐34. ">Andrews 2018</a>). One report of a phase I study in healthy men reported that the drug was well tolerated and there were no serious adverse events (<a href="./references#CD006282-bbs2-0221" title="RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17:214. ">Rudnicki 2016</a>). </p> </section> </section> <section id="CD006282-sec-0055"> <h4 class="title">Somatropin</h4> <p>Somatropin, also called growth hormone or somatomedin C, is a small polypeptic hormone produced in the pituitary gland. It interacts with growth hormone receptors primarily in the muscles and liver, in which it induces insulin‐like growth factor‐1 (IGF‐1). Because of its primary role in liver and muscle metabolism, IGF‐1 seems to play an important role during muscle development and induces muscle regeneration after injury and denervation (<a href="./references#CD006282-bbs2-0111" title="DuanC , RenH , GaoS . Insulin‐like growth factors (IGFs), IGF receptors, and IGF‐binding proteins: roles in skeletal muscle growth and differentiation. General and Comparative Endocrinology2010;167:344‐51. ">Duan 2010</a>). IGF‐1 stimulates myoblast and motor neuron proliferation, induces myogenic differentiation and generates myocyte hypertrophy in vitro and in vivo (<a href="./references#CD006282-bbs2-0085" title="Bosch‐MarcéM , WeeCD , MartinezTL , LipkesCE , ChoeDW , KongL , et al. Increased IGF‐1 in muscle modulates the phenotype of severe SMA mice. Human Molecular Genetics2011;20(9):1844‐53. ">Bosch‐Marcé 2011</a>; <a href="./references#CD006282-bbs2-0194" title="MurdoccaM , MalgieriA , LuchettiA , SaievaL , DobrowolnyG , deLeonibusE , et al. IPLEX administration improves motor neuron survival and ameliorates motor functions in a severe mouse model of spinal muscular atrophy. Molecular Medicine2012;18:1076‐85. ">Murdocca 2012</a>). In vitro studies of motor neuron tissue cultures of rat spinal cord showed that IGF‐1 was one of the neuroprotective hormones that enhanced the survival of motor neurons and reduced their susceptibility to glutamate‐induced neurotoxicity (<a href="./references#CD006282-bbs2-0105" title="CorseAM , BilakMM , BilakSR , LeharM , RothsteinJD , KunclRW . Preclinical testing of neuroprotective neurotrophic factors in a model of chronic motor neuron degeneration. Neurobiology of Disease1999;6:335‐46. ">Corse 1999</a>). One study showed that intracerebroventricular injections of IGF‐1 next to a SMN trans‐splicing RNA vector had a positive effect on disease severity and prolonged survival of severe SMA mice (<a href="./references#CD006282-bbs2-0227" title="ShababiM , GlascockJ , LorsonCL . Combination of SMN trans‐splicing and a neurotrophic factor increases the life span and body mass in a severe model of spinal muscular atrophy. Human Gene Therapy2011;22(2):135‐44. ">Shababi 2011</a>). One study showed that overexpression of IGF‐1 increased muscle mass, and that administration of a combination of IGF‐1 and trichostatin‐A improved survival and motor function in SMA mice (<a href="./references#CD006282-bbs2-0085" title="Bosch‐MarcéM , WeeCD , MartinezTL , LipkesCE , ChoeDW , KongL , et al. Increased IGF‐1 in muscle modulates the phenotype of severe SMA mice. Human Molecular Genetics2011;20(9):1844‐53. ">Bosch‐Marcé 2011</a>). <a href="./references#CD006282-bbs2-0080" title="BiondiO , BranchuJ , SalahAB , HoudebineL , BertinL , ChaliF , et al. IGF‐1R Reduction triggers neuroprotective signaling pathways in spinal muscular atrophy mice. Journal of Neuroscience2015;35(34):12063‐79. ">Biondi 2015</a> showed that underexpression of IGF‐1 receptors alone improved the motor function and the life span of SMA mice. Two studies investigated intracerebral injection of AVV‐IGF‐1 in SMA mice and showed variable results, with slightly improved motor function and survival due to prevention of muscle atrophy and preservation of NMJs (<a href="./references#CD006282-bbs2-0250" title="TsaiLK , ChenYC , ChengWC , TingCH , DodgeJC , HwuW‐L , et al. IGF‐1 delivery to CNS attenuates motor neuron cell death but does not improve motor function in type III SMA mice. Neurobiology of Disease2012;45:272‐9. ">Tsai 2012</a>; <a href="./references#CD006282-bbs2-0251" title="TsaiLK , ChenCL , TingCH , Lin‐ChaoS , HwuWL , DodgeJC , et al. Systemic administration of a recombinant AAV1 vector encoding IGF‐1 improves disease manifestations in SMA mice. Molecular Therapy2014;22(8):1450‐9. ">Tsai 2014</a>). </p> </section> <section id="CD006282-sec-0056"> <h4 class="title">Thyrotropin‐releasing hormone</h4> <p>The precise mechanism of action of TRH, a tripeptide produced by the hypothalamus, is unknown. It may have a neurotrophic effect on spinal motor neurons (<a href="./references#CD006282-bbs2-0241" title="TakeuchiY , MiyanomaeY , KomatsuH , OomizonoY , NishimuraA , OkanoS , et al. Efficacy of thyrotropin‐releasing hormone in the treatment of spinal muscular atrophy. Journal of Child Neurology1994;9(3):287‐9. ">Takeuchi 1994</a>). </p> </section> <section id="CD006282-sec-0057"> <h4 class="title">Riluzole</h4> <p>Riluzole is thought to have a neuroprotective effect on motor neurons by blocking the presynaptic release of glutamate. In a mouse model of SMA, riluzole attenuated disease progression (<a href="./references#CD006282-bbs2-0134" title="HaddadH , Cifuentes‐DiazC , MiroglioA , RoblotN , JoshiV , MelkiJ . Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle &amp; Nerve2003;28(4):432‐7. ">Haddad 2003</a>). </p> </section> <section id="CD006282-sec-0058"> <h4 class="title">Other neurotrophic factors</h4> <p>Other neurotrophic factors have been considered as potential therapies for motor neuron diseases (<a href="./references#CD006282-bbs2-0068" title="ApfelSC . Neurotrophic factor therapy – prospects and problems. Clinical Chemistry and Laboratory Medicine2001;39(4):351‐5. ">Apfel 2001</a>). In a mouse model of SMA, cardiotrophin‐1 seemed effective in slowing down disease progression (<a href="./references#CD006282-bbs2-0166" title="LesbordesJC , Cifuentes‐DiazC , MiroglioA , JoshiV , BordetT , KahnA , et al. Therapeutic benefits of cardiotrophin‐1 gene transfer in a mouse model of spinal muscular atrophy. Human Molecular Genetics2003;12(11):1233‐9. ">Lesbordes 2003</a>). </p> </section> <section id="CD006282-sec-0059"> <h4 class="title">Neuromuscular junction interactors</h4> <p>Studies in SMN‐deficient mouse models of SMA have uncovered significant abnormalities in the morphology of the NMJ in SMA, in addition to the well‐known motor neuron degeneration (<a href="./references#CD006282-bbs2-0088" title="BraunS , CroizatB , LagrangeMC , WarterJM , PoindronP . Constitutive muscular abnormalities in culture in spinal muscular atrophy. Lancet1995;345(8951):694‐5. [PUBMED: 7741893] ">Braun 1995</a>; <a href="./references#CD006282-bbs2-0156" title="KariyaS , ParkGH , Maeno‐HikichiY , LeykekhmanO , LutzC , ArkovitzMS , et al. Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(16):2552‐69. [PUBMED: 18492800] ">Kariya 2008</a>; <a href="./references#CD006282-bbs2-0161" title="KongL , WangX , ChoeDW , PolleyM , BurnettBG , Bosch‐MarcéM , et al. Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. Journal of Neuroscience2009;29(3):842‐51. ">Kong 2009</a>; <a href="./references#CD006282-bbs2-0195" title="MurrayLM , ComleyLH , ThomsonD , ParkinsonN , TalbotK , GillingwaterTH . Selective vulnerability of motor neurons and dissociation of pre‐ and post‐synaptic pathology at the neuromuscular junction in mouse models of spinal muscular atrophy. Human Molecular Genetics2008;17(7):949‐62. [PUBMED: 18065780] ">Murray 2008</a>). Additionally, there was abnormal aggregation of acetylcholine receptors at the muscle endplates in people with SMA type I (<a href="./references#CD006282-bbs2-0070" title="ArnoldAS , GueyeM , Guettier‐SigristS , Courdier‐FruhI , CoupinG , PoindronP , et al. Reduced expression of nicotinic AChRs in myotubes from spinal muscular atrophy I patients. Laboratory Investigation2014;84(10):1271‐8. ">Arnold 2004</a>). Electrophysiological studies in people with SMA have shown neurophysiological alterations of the NMJ, which may correspond with the symptoms of fatigability (<a href="./references#CD006282-bbs2-0113" title='DunawayS , MontesJ , GarberCE , CarrB , KramerSS , Kamil‐RosenbergS , et al. Performance of the timed "up &amp; go" test in spinal muscular atrophy. Muscle &amp; Nerve2014;50(2):273‐7. '>Dunaway 2014</a>; <a href="./references#CD006282-bbs2-0192" title="MontesJ , BlumenschineM , DunawayS , AlterAS , EngelstadK , RaoAK , et al. Weakness and fatigue in diverse neuromuscular diseases. Journal of Child Neurology2013;28(10):1277‐83. ">Montes 2013</a>; <a href="./references#CD006282-bbs2-0256" title="WadmanRI , VranckenAF , van denBergLH , van derPolWL . Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology2012;79(20):2050‐5. ">Wadman 2012a</a>). Drugs such as pyridostigmine and neostigmine, which have an inhibitory effect on acetylcholinesterase, might directly interact with the NMJ and could improve its function. Other potential NMJ interactors are 3‐4 diaminopyridine (3‐4 DAP) and 4‐aminopyridine (4‐AP), which are potassium channel blockers that are presumed to prolong repolarisation and to facilitate the generation of the action potential at the NMJ. </p> </section> </section> <section id="CD006282-sec-0060"> <h3 class="title" id="CD006282-sec-0060">Why it is important to do this review</h3> <p>There has been no treatment to slow progression or cure SMA types II or III (<a href="./references#CD006282-bbs2-0274" title="BosboomWM , VranckenAF , van denBergLH , WokkeJH , IannacconeST . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006282.pub2] ">Bosboom 2009</a>; <a href="./references#CD006282-bbs2-0275" title="WadmanRI , van derPolWL , BosboomWM , van denBergLH , IannacconeST , VranckenAF . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006282.pub4] ">Wadman 2012b</a>). </p> <p>Many studies have explored the effects of various drugs in SMA animal models or in people with SMA. Currently, several drugs and compounds tested in uncontrolled, unblinded and non‐randomised settings have shown possible positive effects on the course of SMA through neuroprotection (e.g. cardiotrophin‐1, creatine, gabapentin, lamotrigine and riluzole), induction of <i>SMN2</i> activity (histone deacetylase inhibitors, e.g. valproic acid, phenylbutyrate and hydroxyurea), improvement of NMJ transmission (e.g. pyridostigmine), modification of SMN2 RNA (ASOs or small molecules, e.g. nusinersen), genetic restoration of the <i>SMN1</i> gene using viral vectors, improvement of muscle metabolism and strength (e.g. creatine), and other (unknown) mechanisms (e.g. somatotropin, salbutamol, TRH). Overall, these studies provide conflicting evidence about the effects of these compounds on muscle strength, motor function and survival in SMA. </p> <p>The number of studies and trials for drug treatment in SMA has expanded rapidly, which has created a need for a clear, thorough and systematic review of these trials and their results. We used Cochrane Systematic Review methods (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and the GRADE approach (<a href="./references#CD006282-bbs2-0072" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>), to review all randomised studies and trials on drug treatment in people with SMA types ii and III to analyse the effect of drug treatments on disability, muscle strength, ability to stand or walk, quality of life, time to death or full‐time ventilation and adverse events. </p> <p>This is an update of a review first published in 2009 and first updated in 2012 (<a href="./references#CD006282-bbs2-0274" title="BosboomWM , VranckenAF , van denBergLH , WokkeJH , IannacconeST . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews2009, Issue 1. [DOI: 10.1002/14651858.CD006282.pub2] ">Bosboom 2009</a>; <a href="./references#CD006282-bbs2-0275" title="WadmanRI , van derPolWL , BosboomWM , van denBergLH , IannacconeST , VranckenAF . Drug treatment for spinal muscular atrophy types II and III. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD006282.pub4] ">Wadman 2012b</a>). Drug treatment for SMA type I is the subject of a separate Cochrane Review (<a href="./references#CD006282-bbs2-0258" title="WadmanRI , van derPolWL , BosboomWMJ , AsselmanF‐L , van denBergLH , IannacconeST , VranckenAFJE . Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews2019, Issue 12. [DOI: 10.1002/14651858.CD006281.pub5] ">Wadman 2019</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD006282-sec-0061" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD006282-sec-0061"></div> <p>To evaluate if drug treatment is able to slow or arrest the disease progression of SMA types II and III, and to assess if such therapy can be given safely. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD006282-sec-0062" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD006282-sec-0062"></div> <section id="CD006282-sec-0063"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD006282-sec-0064"> <h4 class="title">Types of studies</h4> <p>All randomised or quasi‐randomised (alternate or other systematic treatment allocation) studies examining the effect of drug treatment designed to slow or arrest disease progression in children or adults with SMA types II and III. Placebo‐controlled cross‐over studies were also considered to be eligible for inclusion. </p> </section> <section id="CD006282-sec-0065"> <h4 class="title">Types of participants</h4> <p>Children or adults with SMA types II and III fulfilling the criteria outlined in <a href="#CD006282-tbl-0011">Table 1</a>. </p> <div class="table" id="CD006282-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic criteria for SMA types II and III</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMA type II: age of onset between 6 and 18 months and have been able to sit independently, but never been able to walk without assistance. </p> <p>SMA type III: age of onset after 18 months and has/had the ability to walk without assistance. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genetic analysis to confirm the diagnosis, with deletion or mutation of the SMN1 gene (5q11.2‐13.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Supporting criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symmetrical muscle weakness of limb and trunk.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proximal muscles more affected than distal muscles and lower limbs more than upper limbs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No abnormality of sensory function.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum creatine kinase activity ≤ 5 times the upper limit of normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denervation on electrophysiological examination, and no nerve conduction velocities &lt; 70% of the lower limit of normal. No abnormal sensory nerve action potentials. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle biopsy showing atrophic fibres of both types, hypertrophic fibres of one type (usually type I), and in chronic cases type grouping. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No involvement of the central neurological systems, such as hearing or vision.</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD006282-bbs2-0269" title="ZerresK , DaviesKE . 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17‐19 April 1998, Soestduinen, The Netherlands. Neuromuscular Disorders1999;9(4):272‐8. ">Zerres 1999</a> </p> </div> </div> </section> <section id="CD006282-sec-0066"> <h4 class="title">Types of interventions</h4> <p>Any drug treatment, alone or in combination, designed to slow or arrest the progress of the disease compared to placebo (or sham) treatment, with no restrictions on the route of administration. </p> </section> <section id="CD006282-sec-0067"> <h4 class="title">Types of outcome measures</h4> <p>We assessed outcome measures within or up to one year after the onset of treatment and compared to baseline. This is a list of the outcomes of interest within whichever studies are included in the review; we did not use outcomes as criteria for including studies. </p> <section id="CD006282-sec-0068"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD006282-list-0001"> <li> <p>Change in disability score (e.g. Gross Motor Function Measure (GMFM), Hammersmith Functional Motor Score (HFMS), Motor Function Measure (MFM) and SMA Functional Rating Scale (SMAFRS)) as determined by the original study authors. </p> </li> </ul> </p> </section> <section id="CD006282-sec-0069"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD006282-list-0002"> <li> <p>Change in muscle strength (e.g. dynamometry, isometric strength testing, manual muscle testing (MMT) or Medical Research Council (MRC) score). </p> </li> <li> <p>Acquiring the ability to stand within one year after the onset of treatment.</p> </li> <li> <p>Acquiring the ability to walk or improvement of walking within one year after the onset of treatment. </p> </li> <li> <p>Change in quality of life as determined by quality of life scales.</p> </li> <li> <p>Change in pulmonary function (forced vital capacity (FVC) as a percentage of FVC predicted for height). This was not stated in the original protocol, but many trials included a measure of pulmonary function or the strength of respiratory muscles. </p> </li> <li> <p>Time from beginning of treatment until death or full‐time ventilation (a requirement for 16 hours of ventilation out of 24 hours regardless of whether this was with tracheostomy, a tube or mask). </p> </li> <li> <p>Adverse events attributable to treatment during the whole study period, separated into severe (requiring or lengthening hospitalisation, life threatening or fatal) and others. </p> </li> </ul> </p> </section> </section> </section> <section id="CD006282-sec-0070"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD006282-sec-0071"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases on 22 October 2018.</p> <p> <ul id="CD006282-list-0003"> <li> <p>Cochrane Neuromuscular Specialised Register (in the Cochrane Register of Studies (<i>CRS</i>); <a href="./appendices#CD006282-sec-0257">Appendix 3</a>). </p> </li> <li> <p>Cochrane Central Register of Studies (CENTRAL) (in the Cochrane Register of Studies Online (<i>CRSO</i>); <a href="./appendices#CD006282-sec-0258">Appendix 4</a>). </p> </li> <li> <p>MEDLINE (1991 to October week 43 2018; <a href="./appendices#CD006282-sec-0259">Appendix 5</a>). </p> </li> <li> <p>Embase (1991 to October week 43 2018; <a href="./appendices#CD006282-sec-0260">Appendix 6</a>). </p> </li> <li> <p>ISI Web of Science Conference Proceedings Citation Index (1991 to October 2018; <a href="./appendices#CD006282-sec-0261">Appendix 7</a>). </p> </li> </ul> </p> <p>We consulted the following registries on 22 October 2018 to identify additional trials that had not yet been published. </p> <p> <ul id="CD006282-list-0004"> <li> <p>clinical trials registry of the US National Institute of Health (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="./appendices#CD006282-sec-0262">Appendix 8</a>). </p> </li> <li> <p>the WHO international Clinical trials Registry (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en/</a>; <a href="./appendices#CD006282-sec-0263">Appendix 9</a>). </p> </li> </ul> </p> <p>Searches were performed from 1991 onwards because at that time genetic analysis of the <i>SMN1</i> gene became widely available and could be used to establish the diagnosis of SMA. </p> </section> <section id="CD006282-sec-0072"> <h4 class="title">Searching other resources</h4> <p>We handsearched the reference lists of relevant cited studies, reviews, meta‐analyses, textbooks and conference proceedings to identify additional studies. We invite readers to suggest studies, particularly in other languages, that should be considered for inclusion. </p> </section> </section> <section id="CD006282-sec-0073"> <h3 class="title" id="CD006282-sec-0073">Data collection and analysis</h3> <section id="CD006282-sec-0074"> <h4 class="title">Selection of studies</h4> <p>For this updated review, two review authors (RW and AV) independently checked titles and abstracts obtained from literature searches to identify potentially relevant trials for full review. </p> <p>We identified and excluded duplicates and collated multiple reports of the same study so that each study rather than each report was the unit of interest in the review. </p> <p>From the full texts, two review authors (RW and AV) independently selected trials for inclusion that met the selection criteria. The review authors were not blinded to the trial author and source institution. The review authors resolved disagreement by reaching consensus. We presented an adapted PRISMA flowchart of study selection (<a href="#CD006282-fig-0001">Figure 1</a>), and recorded details of excluded studies in the <a href="./references#CD006282-sec-0274" title="">Characteristics of excluded studies</a> table. </p> <div class="figure" id="CD006282-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD006282-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD006282-sec-0075"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (RW and AV) independently extracted data using a specially designed data extraction form. We extracted study characteristics from included studies on study design and setting, characteristics of participants (SMA type and age), eligibility criteria, intervention details, the outcomes assessed, source(s) of study funding and any conflicts of interest among investigators and recorded them in the <a href="./references#CD006282-sec-0273" title="">Characteristics of included studies</a> table. </p> <p>We obtained missing data from the trial authors or pharmaceutical company whenever possible. </p> <p>Disagreement did not occur, but we would have resolved differences by reaching consensus or with third party adjudication, if necessary. </p> </section> <section id="CD006282-sec-0076"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>The 'Risk of bias' assessment took into account allocation concealment, security of randomisation, participant blinding (parent blinding), blinding of outcome assessors, incomplete outcome data (including use of intention‐to‐treat (ITT) analysis), selective reporting and 'other bias'. We scored each 'Risk of bias' item according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), as 'low', 'high' or 'unclear'. </p> <p>Statistical considerations involved a trade‐off between bias and precision. We assessed the risk of bias as 'unclear' when too few details were available to make a judgement of 'high' or 'low' risk, when the risk of bias was genuinely unknown despite sufficient information about the conduct of the study, or when an entry was not relevant to a study. All studies were described by a precise risk of bias. </p> <p>Two review authors (RW and AV) independently graded the risk of bias in included studies. In the event of disagreement, the review authors reassessed studies and reached agreement by consensus. </p> </section> <section id="CD006282-sec-0077"> <h4 class="title">Measures of treatment effect</h4> <p>We initially intended to analyse continuous outcomes using mean differences (MDs) with 95% confidence intervals (CIs) in the outcome measures with standard deviation (SD) to quantify the effects of the drug treatment (such as change in disability scores, MRC muscle strength, quality of life) and dichotomous outcomes using a risk ratio (RR) with 95% CIs (such as ability to stand or walk and adverse events). We reported median </p> <p>For survival or time to full‐time ventilation, we would have reported results from Kaplan‐Meier survival analyses if data been presented in this way. </p> </section> <section id="CD006282-sec-0078"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred in cross‐over trials. We did not anticipate finding cluster‐randomised trials and did not anticipate that multiple observations for the same outcome would occur in the included studies. </p> <p>Where multiple trial arms were reported in a single trial, we would have included only the treatment arms relevant to the review topic. If two comparisons (e.g. drug A versus placebo and drug B versus placebo) were combined in the same meta‐analysis, we would have followed the guidance in Section 16.5.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to avoid double‐counting (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Our preferred approach would have been to perform a multiple‐treatments meta‐analysis using the indirect comparison method. In case of such analysis in the next update of this review, we will have expert statistical support, as well as subject expertise to analyse the data. </p> <section id="CD006282-sec-0079"> <h5 class="title">Cross‐over trials</h5> <p>If neither carry‐over nor period effects were present in cross‐over trials and individual participant data or the mean and SD (or standard error) of the participant‐specific differences between experimental intervention and control intervention measurements were available, we would have analysed continuous data using a paired t‐test in the two‐period, two‐intervention setting. The effect estimate would have been included in any meta‐analysis using the generic inverse variance function in Review Manager 5 (<a href="./references#CD006282-bbs2-0213" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). In the absence of data for such an analysis, we would have analysed the treatment and placebo group as if they were parallel groups with the risk of a unit‐of‐analysis error. In the event of potential carry‐over or period effects, we would have analysed data from only the first period. </p> </section> </section> <section id="CD006282-sec-0080"> <h4 class="title">Dealing with missing data</h4> <p>We carefully evaluated important numerical data, such as the number of screened, randomised participants as well as ITT, as‐treated and per protocol populations. We investigated attrition rates (i.e. dropouts, losses to follow‐up and withdrawals), and critically appraised issues of missing data and imputation methods (e.g. last observation carried forward (LOCF)). In case of missing outcome data, we would have performed an ITT analysis. If SDs for outcomes were not reported, we would have imputed these values by assuming the SD of the missing outcome to be the mean of the SDs from studies where this information was reported (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>Where there were missing data, we contacted the trial investigators, who provided additional data (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> </section> <section id="CD006282-sec-0081"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical, methodological or statistical heterogeneity, we would not have reported study results as the pooled effect estimate in a meta‐analysis. We would have identified heterogeneity by visual inspection of the forest plots and by using a standard Chi² test with a significance level of alpha = 0.1, in view of the low power of this test. </p> <p>We would have examined heterogeneity using the I² statistic, which quantifies inconsistency across studies, to assess the impact of heterogeneity on the meta‐analysis. </p> <p>We would have used the approximate guide to interpretation of the I² statistic as outlined in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, as follows: </p> <p> <ul id="CD006282-list-0005"> <li> <p>0% to 40%: might not be important;</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD006282-sec-0082"> <h4 class="title">Assessment of reporting biases</h4> <p>We reviewed and included studies from trial registries to assess the magnitude of publication bias (<a href="./appendices#CD006282-sec-0262">Appendix 8</a>; <a href="./appendices#CD006282-sec-0263">Appendix 9</a>). If trials were completed but not yet published, we tried to retrieve results by contacting the principal investigators of the trials. </p> </section> <section id="CD006282-sec-0083"> <h4 class="title">Data synthesis</h4> <p>We would only have pooled results of studies with the same class of drug treatment.</p> <p>We would have calculated MDs or RRs with corresponding 95% CI for the pooled data if studies were sufficiently comparable. For continuous outcomes measured using different but comparable scales, we would have calculated standardised mean differences (SMD) and 95% CI, taking care to ensure a consistent direction of effect. If data were not sufficiently comparable between studies, we would have used the standard Review Manager 5 generic inverse variance (GIV) analysis using treatment effect differences with their standard errors. </p> <p>The review authors estimated differences in medians and CI for the median from participant‐level data from <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> and <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a> using a Hodges‐Lehmann estimator. </p> <p>We would have pooled survival data using the GIV approach. If studies to be pooled had different follow‐up periods, we would have used appropriate adjustments, if necessary Poisson regression allowing for the aggregate person‐time‐at‐risk in the study groups. </p> <p>When Chi² analysis showed the data to be heterogeneous, we would have used a random‐effects model with a maximum likelihood estimation, carrying out a sensitivity analysis with a fixed‐effect model (Mantel‐Haenszel RR method). Formal comparisons of intervention effects according to risk of bias would have been done using meta‐regression. The major approach to incorporating 'Risk of bias' assessments would have been to incorporate and restrict meta‐analyses to studies at low (or lower) risk of bias. </p> <section id="CD006282-sec-0084"> <h5 class="title">'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables using the following outcomes depending on the outcomes used in the included studies: </p> <p> <ul id="CD006282-list-0006"> <li> <p>change in disability score (e.g. GMFM, HFMS and MFM);</p> </li> <li> <p>change in muscle strength (e.g. dynamometry, isometric strength testing, MMT or MRC;</p> </li> <li> <p>acquiring the ability to stand or walk within one year after the onset of treatment;</p> </li> <li> <p>change in quality of life as determined by quality of life scales;</p> </li> <li> <p>change in pulmonary function (FVC; reported preferably as a percentage of FVC predicted for height or age (or both) or alternatively as total volume in litres); </p> </li> <li> <p>time from beginning of treatment until death or full‐time ventilation;</p> </li> <li> <p>adverse events (reported preferably as number of adverse events or alternatively as number of people with adverse events). </p> </li> </ul> </p> <p>We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the certainty of a body of evidence (studies that contributed data for the prespecified outcomes). We used methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) using GRADEpro GDT software (<a href="https://gradepro.org" target="_blank">gradepro.org</a>). We justified all decisions to down‐ or upgrade the certainty of studies using footnotes and made comments to aid reader's understanding of the review where necessary. Although studies might be graded as high risk in any of the GRADE domains, we would not have excluded the particular study. </p> </section> </section> <section id="CD006282-sec-0085"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We would have attempted to determine potential reasons for heterogeneity by examining individual study and subgroup characteristics. </p> <p>We would have performed subgroup analyses as follows to explore the influence of the following factors (if applicable) on effect sizes: </p> <p> <ul id="CD006282-list-0007"> <li> <p>SMA type (II versus III);</p> </li> <li> <p>SMN2 copy number.</p> </li> </ul> </p> <p>Subgroup analysis based on SMA type and SMN2 copy number is needed, since the subgroups contain a different disease course with potential, significant different effects from or interaction with the intervention. </p> <p>We would have compared subgroups using the formal tests for subgroup differences in Review Manager 5 (<a href="./references#CD006282-bbs2-0213" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). </p> </section> <section id="CD006282-sec-0086"> <h4 class="title">Sensitivity analysis</h4> <p>We would have performed sensitivity analyses as follows to explore the influence of the following factors (if applicable) on effect sizes. We would have restricted the analysis: </p> <p> <ul id="CD006282-list-0008"> <li> <p>by taking into account risk of bias;</p> </li> <li> <p>to outlier studies (very long, very large, very short or very small) to establish the extent to which they dominated the results. </p> </li> </ul> </p> <p>We would also have tested the robustness of the results by repeating the analysis using different measures of effect size (RR, odds ratios, etc.) and different statistical models (fixed‐effect and random‐effects models). </p> <section id="CD006282-sec-0087"> <h5 class="title">Non‐randomised evidence</h5> <p>We did not include non‐randomised studies in our review. In the <a href="#CD006282-sec-0223">Discussion</a> section, we reviewed the results from open and uncontrolled studies. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD006282-sec-0088" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD006282-sec-0088"></div> <section id="CD006282-sec-0089"> <h3 class="title">Description of studies</h3> <section id="CD006282-sec-0090"> <h4 class="title">Results of the search</h4> <p>For this updated review, the numbers of new references found by the searches were: Cochrane Neuromuscular Specialised Register 67 (37 new), CENTRAL 173 (90 new), MEDLINE 676 (351 new), Embase 196 (123 new) and ISI Web of Knowledge 402 (277 new). </p> <p>Studies with no published data yet, were named by their acronym, or after their trial register code (<a href="http://www.clinicaltrial.gov" target="_blank">www.clinicaltrial.gov</a>). </p> <p>See <a href="#CD006282-fig-0001">Figure 1</a> for a flow diagram of the study selection process. </p> </section> <section id="CD006282-sec-0091"> <h4 class="title">Included studies</h4> <p>Ten trials fulfilled the selection criteria and remained for inclusion (see <a href="./references#CD006282-bbs1-0001" title="">Included studies</a>). There were two studies with the same class of drug treatment (valproic acid) (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), but one of these trials used L‐carnitine as add‐on medication (<a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>). Two studies only included people with SMA type II (<a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>), one study only included ambulatory people with SMA type III (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>), and one study included only non‐ambulatory children and adolescents with SMA types II and IIIa (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). Six studies did not make a distinction between the SMA subtypes for inclusion (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> <section id="CD006282-sec-0092"> <h5 class="title">Oral creatine versus placebo</h5> <p><a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a> was a double‐blind randomised placebo‐controlled trial that compared oral creatine with placebo in 55 participants divided into two age groups. Of the 22 participants aged two to five years, 10 received creatine 2 g once a day and 12 received placebo. Of the 33 participants aged five to 18 years, 17 received creatine 5 g once a day and 16 received placebo. Duration of treatment was six months with follow‐up at nine months. </p> <p>Muscle strength for knee extension, knee flexion and elbow flexion were measured bilaterally with the Richmond Quantitative Measurement System. Hand grip strength was measured bilaterally with handheld dynamometry. The best scores were added to obtain a total, upper body and lower body quantitative muscle testing (QMT) score. </p> <p>Treatment efficacy for each age group was evaluated by ITT analysis of continuous endpoints using analysis of covariance (ANCOVA), which included the qualifying screening measure as the baseline covariate, treatment group as between‐subject effect, time as within‐subject effect and a subject by time interaction. </p> <p>The primary endpoint was the change in GMFM from baseline. Secondary endpoints were the changes in muscle strength and pulmonary function tests (e.g. FVC) from baseline in children five to 18 years of age, and change in quality of life (assessed by a neuromuscular module of the parent questionnaire for the Pediatric Quality of Life Inventory (PedsQL)) from baseline. Adverse events were routinely assessed at each visit. </p> </section> <section id="CD006282-sec-0093"> <h5 class="title">Oral gabapentin versus placebo</h5> <p><a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> was a double‐blind, randomised, placebo‐controlled trial that compared oral gabapentin 1200 mg three times a day with placebo in 84 participants at least 21 years old. Duration of treatment was 12 months with follow‐up at quarterly intervals while on the treatment. </p> <p>Muscle strength was measured bilaterally by maximum voluntary isometric contraction (MVIC) of elbow flexion and hand grip. Linear regression analysis was used to determine the change in muscle strength, FVC, SMAFRS and a combined measure of the functional capacity of the lower limbs and quality of life (mini‐Sickness Impact Profile: mini‐SIP) over time. </p> <p>Treatment efficacy was determined by comparing the mean percentage change for the treatment and placebo groups in the ITT population (defined as participants with at least two study visits: 37 participants in the treatment group and 39 participants in the placebo group) using the Mann‐Whitney test. </p> <p>The primary endpoint was mean percentage change in muscle strength from baseline. Secondary endpoints were the mean percentage change of FVC, SMAFRS and mini‐SIP from baseline, and the occurrence of adverse events. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0094"> <h5 class="title">Oral hydroxyurea versus placebo</h5> <p>A phase II/III double‐blind randomised placebo‐controlled trial compared oral hydroxyurea with placebo in 57 participants with SMA types II and III aged above five years (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>). Participants received an escalated daily dose over four weeks to a final daily dose of 20 mg/kg/day hydroxyurea or placebo. For the first four weeks, participants received 10 mg/kg/day and for the second four weeks the dose was escalated to 15 mg/kg/day. Duration of treatment was 18 months. Follow‐up of post‐treatment effects was at six months. </p> <p>The safety and tolerability of hydroxyurea were measured through serum level measurement. Muscle strength and motor function were measured with the MMT and the GMFM. The GMFM and MMT were performed in all 57 participants. The Modified Hammersmith Functional Motor Scale (MHFMS) was performed in 28 participants with SMA type II and 10 participants with SMA type III who were already non‐ambulatory at the beginning of the trial. Lung function was evaluated by FVC measurements. In all participants, quantitative full‐length SMN mRNA was measured. Adverse events and serious adverse events were monitored at each assessment by a full blood count, chemistry profiles of liver and renal function, and completion of a questionnaire. </p> <p>Treatment efficacy was evaluated by ITT analysis with a LOCF approach. Changes in GMFM, MHFMS, MMT, FVC and serum full‐length SMN mRNA were analysed by ANCOVA. Measures at time points of the treatment period and the post‐treatment period for primary and secondary endpoints were compared by mixed models with adjusted covariates. A two‐tailed t‐test was used to compare the incidence of adverse events and serious adverse events during the treatment phase. </p> <p>The primary endpoints were GMFM, MMT and serum full‐length SMN mRNA level. Secondary endpoints were the MHFMS and FVC. Adverse events were systematically assessed by a questionnaire at each visit. </p> </section> <section id="CD006282-sec-0095"> <h5 class="title">Intrathecal nusinersen versus sham procedure</h5> <p><a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a> was a phase III double‐blind randomised, sham‐procedure controlled study that compared intrathecally injected nusinersen with a sham procedure in 126 participants with SMA type II, aged two to 12 years. Inclusion criteria included a minimal score of 10 and maximum score of 54 on the HMFSE. Participants were randomised 2:1 (nusinersen: sham‐procedure) to receive intrathecally injected nusinersen or the sham‐procedure. Participants received their treatment or sham‐procedure at days one, 29, 85 and 274. </p> <p>Participants in the treatment group received nusinersen 12 mg intrathecally. The sham‐procedure consisted of a small needle prick on the lower back at the location where the lumbar puncture (LP) injection is normally made. The needle would break the skin but no LP injection or needle insertion occurred. The needle prick was covered with the same bandage that was used to cover the LP injection in the treatment group. Treatment period was planned to be 15 months, but was stopped after interim analysis showing beneficiary effects of nusinersen compared to the sham procedure. </p> <p>Motor abilities were assessed by HFMSE and Upper Limb Module Test (ULMT). Motor milestone development was monitored, including standing and walking with or without support. Assessment of vital signs, weight changes and neurological examination were included. Adverse events and serious adverse events were monitored using laboratory parameters, urine analysis and electrocardiogram. </p> <p>The interim analysis on treatment efficacy was done by ITT analysis with a LOCF approach and multiple‐imputation method to account for missing data. Interim analysis was performed when all the children had been enrolled for at least six months and at least 39 children had completed their 15‐month assessment. In the final analysis, the least squares mean changes in the total HFMSE score, the number of World Health Organization motor milestones achieved per child, and the Revised Upper Limb Module (RULM) score and least‐squares MDs in change between groups were based on an ANCOVA, with group assignment as a fixed effect and with adjustment for each child's age at screening and the value at baseline. The primary endpoint was change from baseline between treatment groups in the HFMSE. Secondary outcome measures were dichotomised analysis of the HFMSE scores (responder analysis of a 3‐point change in HFMSE), change from baseline in ULMT, milestone development and adverse events. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0096"> <h5 class="title">Oral olesoxime versus placebo</h5> <p>Bertini and colleagues performed a double‐blind, randomised, placebo‐controlled trial compared oral olesoxime with placebo in 165 non‐ambulatory participants with SMA types II and IIIa aged three to 25 years (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). Participants were randomised 2:1 (olesoxime:placebo) to receive oral liquid suspension of olesoxime 10 mg/kg once daily or oral liquid suspension of placebo. Treatment period was 24 months. </p> <p>Participants started with a screening and baseline visit. Follow‐up visits were scheduled four and 13 weeks after baseline, with follow‐up every 13 weeks during the treatment period of 24 months. </p> <p>Motor abilities were assessed by MFM at weeks 26, 52, 78 and 104, and the HMFS at weeks 13, 39, 65, 91 and 104. Children younger aged younger than six years (n = 48) were assessed with the adapted version of the MFM‐32, the MFM‐20, where participants older than six years (n = 112) were tested with the MFM‐32. Electromyography, including compound muscle action potential (CMAP) and motor unit number estimation (MUNE) assessments of ulnar and hypothenar nerves, were performed at weeks 26, 52, 78 and 104. FVC was tested at weeks 13, 26, 39, 52, 78 and 104. The PedsQL was tested every visit. Clinical examination and electrocardiogram were performed every visit as well. Safety laboratory studies were performed at baseline and every consecutive visit. Serum levels of olesoxime were reviewed at weeks four, 13 and 52. </p> <p>Data analysis was done with ITT analyses using mixed‐effects repeated measure model. An interim analysis was performed at 12 months with predefined criteria to assess whether the trial should be continued or terminated. </p> <p>The primary endpoint was the change from baseline between treatment groups in MFM, parts D1+D2. Secondary outcome measures were responder analyses of change from baseline in total MFM scores and individual MFM domains and change from baseline in HFMS, CMAP amplitude, MUNE, Clinical Global Impression, FVC and PedsQL. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0097"> <h5 class="title">Oral phenylbutyrate versus placebo</h5> <p><a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a> was a phase II, double‐blind, randomised, placebo‐controlled trial that compared oral phenylbutyrate 500 mg/kg/day, divided into five doses and using an intermittent schedule (seven days on treatment, seven days off treatment), with placebo in 107 participants with SMA type II. Duration of treatment was 13 weeks with follow‐up at the end of the study period (also at 13 weeks). </p> <p>Motor function was assessed in all participants. In addition, muscle strength and FVC were assessed in children older than five years. Muscle strength was measured by handheld dynamometry of elbow flexion, hand grip, 3‐point pinch, knee flexion and knee extension; the best scores were added to obtain an arm megascore and a leg megascore. </p> <p>Treatment efficacy was evaluated by ITT analysis in 90 participants (45 in the treatment group and 45 in the placebo group) with continuous endpoints at five and 13 weeks' follow‐up using ANCOVA which included the baseline outcome values as covariates, treatment group and age as between‐patient factors, time as a within‐patient factor, and possible interaction between treatment group, time and age. </p> <p>The primary endpoint was the change in HFMS from baseline. Secondary endpoints were the change in muscle strength and FVC from baseline and the occurrence of adverse events. Adverse events were systematically assessed at each visit by means of a questionnaire. </p> </section> <section id="CD006282-sec-0098"> <h5 class="title">Subcutaneous somatotropin versus placebo</h5> <p>A double‐blind, randomised, placebo‐controlled, cross‐over pilot trial compared subcutaneous injections of somatropin with subcutaneous injections of placebo in 20 participants with SMA types II and III aged between six and 36 years old (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>). Participants were randomised to two cohorts, in which one started with treatment for 12 weeks and crossed over to placebo for 12 weeks after a washout period of eight weeks, while the other cohort started with placebo for 12 weeks and crossed over to treatment for 12 weeks after a washout period of eight weeks. During the 12‐week period, participants received either somatotropin 0.015 mg/kg/day subcutaneously in the first week which was increased after one week up to 0.03 mg/kg/day for weeks two to 12 or placebo at the same dose regimen. Duration of the trial was 40 weeks. Follow‐up after the last treatment was eight weeks. </p> <p>Muscle strength was measured with MVIC using hand‐held myometry and MRC scale in elbow flexion, handgrip, knee flexion and knee extension at baseline and weeks four, 12, 20, 24 and 32. Motor function was evaluated with the HFMSE, 10‐metre walking time and Gowers' time at baseline and weeks four, 12, 20, 24 and 32. Pulmonary functioning test were assessed with FVC and peak cough flow at baseline and weeks 12, 20 and 32. Laboratory studies included IGF‐1 serum concentrations and endocrinological measurements at baseline and weeks four, 12, 20, 24, 32 and 40. </p> <p>Data analysis was done with a modified ITT concept using t‐test and Wilcoxon test.</p> <p>The primary endpoint was change in quantitative muscle strength of upper limb using hand‐held myometry in elbow flexion and handgrip. Secondary outcomes measures were change in quantitative muscle strength of lower limb, muscle strength with MMT in seven muscles, change in HFMSE, change in Gowers' time, change in qualitative Gowers' manoeuvre, change in FVC and peak cough flow, and adverse events. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0099"> <h5 class="title">Intravenous thyrotropin‐releasing hormone versus placebo</h5> <p><a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a> was a double‐blind, randomised, placebo‐controlled trial that compared intravenous TRH 0.1 mg/kg once a day with placebo. Six participants were treated with TRH and three received placebo. The duration of treatment was 29 days over a 34‐day period with follow‐up and conclusion of the study at five weeks. </p> <p>Muscle strength was evaluated by dynamometry of the deltoids, biceps, triceps, wrist extensors, hand grip, hip flexors, quadriceps and hamstrings. </p> <p>Comparisons of total mean muscle strength and electrodiagnostic measures at baseline and at the end of the five‐week study period were made using paired t‐tests. </p> <p>The primary endpoint was the change in total mean muscle strength from baseline. Secondary endpoints were change in electrodiagnostic measures and the occurrence of adverse events related to the treatment. Adverse events were collected when spontaneous reported by the participants. </p> </section> <section id="CD006282-sec-0100"> <h5 class="title">Oral valproic acid (valproate) plus acetyl‐L‐carnitine versus placebo</h5> <p>One double‐blind, placebo‐controlled trial compared combination therapy with oral valproic acid and acetyl‐L‐carnitine to placebo in 61 non‐ambulatory children aged between two and eight years (<a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>). Thirty‐one children received treatment with valproic acid 125 mg, given in divided doses two to three times a day and sufficient to maintain overnight trough levels of 100 mg/dL, and acetyl‐L‐carnitine doses at 50 mg/kg/day divided into two daily doses. Thirty children received a double placebo. The duration of treatment was 12 months in the active treatment arm and six months in the placebo. After six months the placebo group switched over to active treatment per protocol. </p> <p>In all participants, the MHFMS and GMFM were used to measure functional motor ability at baseline, three, six and 12 months after the start of treatment. The degree of innervation by the ulnar nerve was estimated using maximum ulnar CMAP amplitude. Myometry measurements were performed in children aged five years and older (24 children) with no significant contractures: three times for right and left elbow flexion and for right and left knee extension. Also in the children aged five years and older, pulmonary function testing was performed, which included FVC, forced expiratory volume (FEV), and maximum inspiratory and expiratory pressures (MIP and MEP). Quality of life was assessed using the PedsQL, filled in by parents at each visit. Children aged five years or older completed the age‐appropriate PedsQL. Bone mineral density and bone mineral content were measured with dual‐energy X‐ray absorptiometry (DEXA). </p> <p>All analyses were performed on an ITT population of 61 people that was defined as all participants randomised to receive study medication. The analysis of variance (ANOVA) test was used to compare treatment groups for change in MHFMS from the baseline data. Non‐normally distributed data were tested with the Wilcoxon rank sum test. </p> <p>The primary endpoints were laboratory safety data, adverse event data and change in MHFMS from baseline after six months. Secondary endpoints included measurement from baseline at six and 12 months in MHFMS, estimates of CMAPs, DEXA, body composition and bone density, quantitative SMN mRNA and quality of life. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0101"> <h5 class="title">Oral valproic acid (valproate) versus placebo</h5> <p><a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>, a double‐blind, placebo‐controlled, cross‐over trial, compared oral valproic acid with placebo in 33 ambulatory participants with SMA type III aged above 18 years old. Participants were divided over two cohorts. Cohort one (16 participants) was first treated with oral valproic acid 10 mg/kg/day to 20 mg/kg/day divided over two or three doses (doses depending on serum levels of valproic acid with preferred levels of 50 mg/dL) for six months, after this period this cohort switched to equal dosage of oral placebo for six months. Cohort two (17 participants) started with six months' treatment with placebo and afterwards crossed over to oral valproic acid 10 mg/kg/day to 20 mg/kg/day divided over two to three doses (doses depending on serum levels of valproic acid with preferred levels of 50 mg/dL) for six months. Total duration of the trial was 12 months. </p> <p>Participants started with two baseline visits within a six‐week period to assure that the methodologies were reliable and to assure test–retest stability. Clinical assessments were done at three, six and 12 months. Motor abilities were assessed by maximum voluntary isometric contraction testing (MVICT) in bilateral elbow flexors, elbow extensors, knee flexors, knee extensors and grip. Functional motor abilities were tested with modified SMAFRS, the ability to climb four standard stairs and endurance during the six‐minute walk test. Muscle mass was measured by DEXA scanning. The degree of innervation by the ulnar nerve was estimated using maximum ulnar CMAP. Pulmonary function testing was performed, which included FVC, FEV and MIP. Quality of life was assessed using the mini‐SIP. Safety laboratory studies (chemistry profile, blood and platelet count, transaminases, carnitine profile, amylase, lipase, valproic acid levels) were performed at baseline, two to three weeks after initiation, at thee, six and 12 months and one additional time between six and 12 months. Serum levels of SMN protein and mRNA were performed. </p> <p>The two baseline visits and the visit closest to the start of the treatment were used as baseline evaluation. Changes from baseline between treatment and placebo at six months were analysed with t‐tests and at 12 months with mixed‐effects models. </p> <p>The primary endpoint was the change in MVICT at six months. Secondary outcomes included laboratory safety data, adverse event and change in muscle scores of upper and lower extremities, SMAFRS, CMAPs of the ulnar nerve, DEXA, muscle mass, pulmonary functioning tests, SMN protein levels and mRNA levels from baseline after six and 12 months. Adverse events were systematically assessed at each visit. </p> </section> <section id="CD006282-sec-0102"> <h5 class="title">Funding</h5> <p>In three trials, pharmaceutical companies were involved in funding, analysis, reporting of results, or a combination of these (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>). In six trials, pharmaceutical companies provided the study drug without cost and they had no involvement in study design, or analysis and reporting of results (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). Authors of one trial were reported to have a patent on the study drug (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>). </p> </section> </section> <section id="CD006282-sec-0103"> <h4 class="title">Excluded studies</h4> <p>We identified and assessed 59 studies (36 new) for possible inclusion in the review. We excluded 36 studies (see <a href="./references#CD006282-sec-0274" title="">Characteristics of excluded studies</a> table) because they were not randomised or were uncontrolled (<a href="./references#CD006282-bbs2-0011" title="AbbaraC , EstournetB , LacomblezL , LelièvreB , OuslimaniA , LehmannB , et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology2011;71(3):403‐10. [PUBMED: 21284699] ">Abbara 2011</a>; <a href="./references#CD006282-bbs2-0012" title="BraheC , VitaliT , TizianoFD , AngelozziC , PintoAM , BorgoF , et al. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. European Journal of Human Genetics2005;13(2):256‐9. [PUBMED: 15523494] ">Brahe 2005</a>; <a href="./references#CD006282-bbs2-0013" title="BrichtaL , HolkerI , HaugK , KlockgetherT , WirthB . In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Annals of Neurology2006;59(6):970‐5. [PUBMED: 16607616] ">Brichta 2006</a>; <a href="./references#CD006282-bbs2-0014" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002; Vol. 71 Suppl 4:2402. ">Chang 2002</a>; <a href="./references#CD006282-bbs2-0015" title="ChiribogaCA , SwobodaKJ , DarrasBT , IannacconeST , MontesJ , DeVivoDC , et al. Results from a phase 1 study of nusinersen (ISIS‐SMNRx) in children with spinal muscular atrophy. Neurology2016;86(10):890‐7. [ISIS 396443 ‐ CS1; ISIS 396443 ‐ CS10; NCT01494701; NCT01780246] ">Chiriboga 2016</a>; <a href="./references#CD006282-bbs2-0016" title="DarbarIA , PlaggertPG , ResendeMBD , ZanotelliE , ReedUC . Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurology2011;11:36. [PUBMED: 21435220] ">Darbar 2011</a>; <a href="./references#CD006282-bbs2-0017" title="NCT02227823 . Safety and efficacy study of pyridostigmine on patients with spinal muscular atrophy type 3. www.clinicaltrials.gov/show/NCT02227823 (first received 20 August 2014). [1376 ; NCT02227823] ">EMOTAS 2014</a>; <a href="./references#CD006282-bbs2-0018" title="FolkersK , SimonsenR . Two successful double‐blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies. Biochimica et Biophysica Acta1995;1271(1):281‐6. [PUBMED: 7599221] ">Folkers 1995</a>; <a href="./references#CD006282-bbs2-0019" title="GiovannettiAM , PasanisiMB , ČerniauskaitėM , BussolinoC , LeonardiM , MorandiL . Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study. Muscle &amp; Nerve2016;54(5):843‐9. PasanisiMB , GiovannettiAM , BussolinoC , CampanellaA , LeonardiM , MorandiL . Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscular Disorders2014;24(9‐10):914. ">Giovannetti 2016</a>; <a href="./references#CD006282-bbs2-0020" title="NCT03032172 . A study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish). clinicaltrials.gov/show/NCT03032172 (first received 24 January 2017). ">JEWELFISH 2017</a>; <a href="./references#CD006282-bbs2-0021" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006282-bbs2-0022" title="KatoZ , OkudaM , OkumuraY , AraiT , TeramotoT , NishimuraM , et al. Oral administration of the thyrotropin‐releasing hormone (TRH) analogue, taltireline hydrate, in spinal muscular atrophy. Journal of Child Neurology2009;24(8):1010‐2. [PUBMED: 19666885] ">Kato 2009</a>; <a href="./references#CD006282-bbs2-0023" title="KhiraniS , DabajI , AmaddeoA , Olmo ArroyoJ , RopersJ , TirolienS , et al. Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatric Neurology2017;73:78‐87. ">Khirani 2017</a>; <a href="./references#CD006282-bbs2-0024" title="KinaliM , MercuriE , MainM , DeBiasiaF , KaratzaA , HigginsR , et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology2002;59(4):609‐10. [PUBMED: 12196659] ">Kinali 2002</a>; <a href="./references#CD006282-bbs2-0025" title="KisselJT , ScottCB , ReynaSP , CrawfordTO , SimardLR , KrosschellKJ , et al. SMA CARNIVAL trial part II: a prospective, single‐armed trial of L‐carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PloS One2011;6(7):e21296. [PUBMED: 21754985] ">Kissel 2011</a>; <a href="./references#CD006282-bbs2-0026" title="LiangWC , YuoCY , ChangJG , ChenYC , ChangYF , WangHY , et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences2008;268(1‐2):87‐94. [PUBMED: 18166199] ">Liang 2008</a>; <a href="./references#CD006282-bbs2-0032" title="NCT02876094 . Effect of low‐dose celecoxib on SMN2 in patients with spinal muscular atrophy (SMA). www.clinicaltrials.gov/show/NCT02876094 (first received 9 August 2016). [NCT02876094] ">NCT02876094</a>; <a href="./references#CD006282-bbs2-0027" title="MercuriE , BertiniE , MessinaS , PelliccioniM , D'AmicoA , ColittoF , et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders2004;14(2):130‐5. [PUBMED: 14733959] ">Mercuri 2004</a>; <a href="./references#CD006282-bbs2-0028" title="MerliniL , SolariA , VitaG , BertiniE , MinettiC , MonginiT , et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology2003;18(8):537‐41. [PUBMED: 13677579] ">Merlini 2003</a>; <a href="./references#CD006282-bbs2-0029" title="NascimentoOJ , OrsiniM , QuintanilhaG . Lamotrigine on motor symptoms of spinal muscular atrophies. Revista de Neurologia2010;50(2):127‐8. [PUBMED: 20112222] ">Nascimento 2010</a>; <a href="./references#CD006282-bbs2-0030" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74 Suppl 17:S128. NCT01703988 . An open‐label safety, tolerability and dose‐range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx ‐ CS2). clinicaltrials.gov/show/NCT01703988 (first received 8 October 2012). [IONIS SMNRx‐CS2 ; NCT01703988] ">NCT01703988</a>; <a href="./references#CD006282-bbs2-0031" title="NCT02052791 . An open‐label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx‐CS2 or IONIS SMNRx‐CS10. www.clinicaltrials.gov/show/NCT02052791 (first received 30 January 2014). [IONIS SMNRx‐CS12 ; ISIS 396443‐CS12 ; NCT02052791] ">NCT02052791</a>; <a href="./references#CD006282-bbs2-0033" title="NCT03709784 . Spinraza in adult spinal muscular atrophy (SAS). clinicaltrials.gov/ct2/show/NCT03709784 (first received 17 October 2018). ">NCT03709784</a>; <a href="./references#CD006282-bbs2-0034" title="NCT00439569 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy types II or III. clinicaltrials.gov/show/NCT00439569 (first received 21 February 2007). [HHSN265200423611C; N01NS42361_NPTUNE01; NCT00439569; NPTUNE01] ">NPTUNE01 2007</a>; <a href="./references#CD006282-bbs2-0035" title="NCT02628743 . A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02628743 (first received 1 December 2015). [2015‐001589‐25; BN29854 ; EUCTR2015‐001589‐25‐GB; NCT02628743] ">OLEOS</a>; <a href="./references#CD006282-bbs2-0036" title="PaneM , StaccioliS , MessinaS , D'AmicoA , PelliccioniM , MazzoneES , et al. Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders2008;18(7):536‐40. [PUBMED: 18579379] ">Pane 2008</a>; <a href="./references#CD006282-bbs2-0037" title="PiepersS , CobbenJM , SodaarP , JansenMD , WadmanRI , Meester‐DelverA , et al. Quantification of SMN protein in leucocytes from spinal muscular atrophy patients: effects of treatment with valproic acid. Journal of Neurology, Neurosurgery, and Psychiatry2011;82(8):850‐2. [PUBMED: 20551479] ">Piepers 2011</a>; <a href="./references#CD006282-bbs2-0038" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257 (Suppl 1):S101. [PUBMED: 20495927] ">Prufer de Queiroz Campos Araujo 2010</a>; <a href="./references#CD006282-bbs2-0039" title="SaitoT , NurputraDK , HarahapNI , HarahapIS , YamamotoH , MuneshigeE , et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience2014;3:49‐57. ">Saito 2014</a>; <a href="./references#CD006282-bbs2-0040" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS‐SMNRx. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [EUCTR2015‐001870‐16‐DE; IONIS SMNRx‐CS11; ISIS 396443‐CS11 ; NCT02594124] ">SHINE 2015</a>; <a href="./references#CD006282-bbs2-0041" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=5544(first received August 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>; <a href="./references#CD006282-bbs2-0042" title="SMART03 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: continuous administration trial. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=4602(first received August 2016). ">SMART03</a>; <a href="./references#CD006282-bbs2-0043" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PloS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006282-bbs2-0044" title="TanC , WilliamsAN . Oral salbutamol in 2 wheelchair bound cases of SMA type II. Archives of Disease in Childhood2011;96 Suppl 1:G77(P). ">Tan 2011</a>; <a href="./references#CD006282-bbs2-0045" title="TsaiLK , YangCC , HwuWL , LiH . Valproic acid treatment in six patients with spinal muscular atrophy. European Journal of Neurology2007;14(12):e8‐9. [PUBMED: 18028187] ">Tsai 2007</a>; <a href="./references#CD006282-bbs2-0046" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. [PUBMED: 16775228] ">Weihl 2006</a>). We could exclude 13 unpublished studies because they were not randomised or were uncontrolled, with eight of these studies still being ongoing (<a href="./references#CD006282-bbs2-0017" title="NCT02227823 . Safety and efficacy study of pyridostigmine on patients with spinal muscular atrophy type 3. www.clinicaltrials.gov/show/NCT02227823 (first received 20 August 2014). [1376 ; NCT02227823] ">EMOTAS 2014</a>; <a href="./references#CD006282-bbs2-0020" title="NCT03032172 . A study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish). clinicaltrials.gov/show/NCT03032172 (first received 24 January 2017). ">JEWELFISH 2017</a>; <a href="./references#CD006282-bbs2-0021" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006282-bbs2-0032" title="NCT02876094 . Effect of low‐dose celecoxib on SMN2 in patients with spinal muscular atrophy (SMA). www.clinicaltrials.gov/show/NCT02876094 (first received 9 August 2016). [NCT02876094] ">NCT02876094</a>; <a href="./references#CD006282-bbs2-0033" title="NCT03709784 . Spinraza in adult spinal muscular atrophy (SAS). clinicaltrials.gov/ct2/show/NCT03709784 (first received 17 October 2018). ">NCT03709784</a>; <a href="./references#CD006282-bbs2-0035" title="NCT02628743 . A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02628743 (first received 1 December 2015). [2015‐001589‐25; BN29854 ; EUCTR2015‐001589‐25‐GB; NCT02628743] ">OLEOS</a>; <a href="./references#CD006282-bbs2-0040" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS‐SMNRx. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [EUCTR2015‐001870‐16‐DE; IONIS SMNRx‐CS11; ISIS 396443‐CS11 ; NCT02594124] ">SHINE 2015</a>; <a href="./references#CD006282-bbs2-0042" title="SMART03 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: continuous administration trial. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=4602(first received August 2016). ">SMART03</a>), and five studies being completed but not yet published at time of the search (<a href="./references#CD006282-bbs2-0030" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74 Suppl 17:S128. NCT01703988 . An open‐label safety, tolerability and dose‐range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx ‐ CS2). clinicaltrials.gov/show/NCT01703988 (first received 8 October 2012). [IONIS SMNRx‐CS2 ; NCT01703988] ">NCT01703988</a>; <a href="./references#CD006282-bbs2-0031" title="NCT02052791 . An open‐label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx‐CS2 or IONIS SMNRx‐CS10. www.clinicaltrials.gov/show/NCT02052791 (first received 30 January 2014). [IONIS SMNRx‐CS12 ; ISIS 396443‐CS12 ; NCT02052791] ">NCT02052791</a>; <a href="./references#CD006282-bbs2-0034" title="NCT00439569 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy types II or III. clinicaltrials.gov/show/NCT00439569 (first received 21 February 2007). [HHSN265200423611C; N01NS42361_NPTUNE01; NCT00439569; NPTUNE01] ">NPTUNE01 2007</a>; <a href="./references#CD006282-bbs2-0038" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257 (Suppl 1):S101. [PUBMED: 20495927] ">Prufer de Queiroz Campos Araujo 2010</a>; <a href="./references#CD006282-bbs2-0041" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=5544(first received August 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>). </p> <section id="CD006282-sec-0104"> <h5 class="title">Studies awaiting classification</h5> <p>Nine trials were completed but no data were available for analysis (<a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>; <a href="./references#CD006282-bbs2-0048" title="CHICTR‐TRC‐10001093 . Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=8445 (first received 11 February 2010). [ChiCTR‐TRC‐10001093] ">CHICTR‐TRC‐10001093</a>; <a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>; <a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>; <a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>; <a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a>; <a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>; <a href="./references#CD006282-bbs2-0054" title="NCT02644668 . A study of CK‐2127107 in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02644668 (first received 23 December 2015). [CY 5021; NCT02644668] RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17(Suppl 1):P261. ">NCT02644668</a>; <a href="./references#CD006282-bbs2-0055" title="SPACE . SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐004369‐34‐NL(first received October 2016). [EUCTR2011‐004369‐34‐NL] ">SPACE</a>) (see <a href="./references#CD006282-sec-0275" title="">Characteristics of studies awaiting classification</a> table). Results of two trials, the EUROsmart trial with acetyl‐L‐carnitine (<a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>), and a trial with salbutamol (<a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>), were only published in conference abstracts which did not include enough data for analysis (<a href="./references#CD006282-bbs2-0188" title="MerliniL , BasogluB , Dahna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejonskaM , et al. Eurosmart: European spinal muscular atrophy randomised trial of acetyl‐L‐carnitine in spinal muscular atrophy. Revue Neurologique2010;166(3):359. ">Merlini 2010</a>; <a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>). We also could not obtain the results of three completed randomised, placebo‐controlled trials with hydroxyurea (<a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a>), with riluzole in SMA types II and III (<a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>), and with 4AP in adults with SMA type III (<a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>). One trial was terminated for safety reasons and results are not yet published (<a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>). We tried to obtain data and preliminary results for all of these completed but unpublished trials, but data were not available upon request at time of writing. </p> <p>We could not obtain information about the trial methods or results of the completed two‐armed trial on rat nerve growth factor and, therefore, this study is awaiting classification (<a href="./references#CD006282-bbs2-0048" title="CHICTR‐TRC‐10001093 . Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=8445 (first received 11 February 2010). [ChiCTR‐TRC‐10001093] ">CHICTR‐TRC‐10001093</a>). </p> </section> <section id="CD006282-sec-0105"> <h5 class="title">Ongoing studies</h5> <p>Four trials were ongoing at the time of this search (<a href="./references#CD006282-bbs2-0056" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (IONIS SMNRx) in participants with spinal muscular atrophy (SMA) (EMBRACE). clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [232SM202 ; EUCTR2014‐003657‐33‐DE; NCT02462759] ">EMBRACE 2015</a>; <a href="./references#CD006282-bbs2-0057" title="NCT01671384 . Valproate and levocarnitine in children with spinal muscular atrophy. clinicaltrials.gov/show/NCT01671384 (first received 13 August 2012). [NCT01671384] ">NCT01671384</a>; <a href="./references#CD006282-bbs2-0058" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544 (first received 12 January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02</a>; <a href="./references#CD006282-bbs2-0059" title="SUNFISH . A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy participants (Sunfish). clinicaltrials.gov/show/NCT02908685 (first received 19 September 2016). ">SUNFISH 2016</a>) (see <a href="./references#CD006282-sec-0276" title="">Characteristics of ongoing studies</a> table). </p> </section> </section> </section> <section id="CD006282-sec-0106"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessments for the 10 included trials are shown in the <a href="./references#CD006282-sec-0273" title="">Characteristics of included studies</a> table and summarised in <a href="#CD006282-fig-0002">Figure 2</a> and <a href="#CD006282-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD006282-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 10 included studies." data-id="CD006282-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 10 included studies. </p> </div> </div> </div> <div class="figure" id="CD006282-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006282-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD006282-sec-0107"> <h4 class="title">Allocation</h4> <p>The randomisation method was not clear in four trials (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), but was at low risk of bias in the remaining six trials. Allocation concealment was not clear in four trials (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), but adequately reported in five trials, which we judged at low risk of bias (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>). Allocation concealment was at high risk of bias in one trial (<a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>), which used a coin toss method. In one trial, there were baseline differences probably due to inadequate randomisation, since muscle strength in the cohort of children aged five to 18 years in the creatine treatment group was slightly weaker than in the placebo group (<a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> </section> <section id="CD006282-sec-0108"> <h4 class="title">Blinding</h4> <p>Blinding of parents, participants and observers were adequate and at low risk of bias in all trials except <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>, for which the risk of bias related to blinding was unclear. </p> </section> <section id="CD006282-sec-0109"> <h4 class="title">Incomplete outcome data</h4> <p>Four trials were at high risk of bias from attrition and three at unclear risk of bias. The method for modified ITT analysis was unknown in <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a> and we assessed this trial at high risk of bias. In one trial, the risk of attrition bias was high because fewer than expected numbers of participants provided data for some outcome measures (<a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>). A difference in the number of children over five years of age providing data on myometry and FVC was unexplained, with data on adverse events limited in <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>. This resulted in a high‐risk assessment. Follow‐up was below 80% in two trials (<a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> performed an ITT analysis but participants withdrew for unknown reasons and the number analysed was not the number initially included. We judged the risk of bias in <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> to be high and in <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a> to be unclear. Participants withdrew for unknown reasons in two other studies; however, ITT analysis possibly minimised the risk of bias, which we judged unclear (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>: n = 17; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>: n = 4). </p> <p>Risk of attrition bias in the other trials was low (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>). </p> </section> <section id="CD006282-sec-0110"> <h4 class="title">Selective reporting</h4> <p>Primary outcome measures were adequately stated in all trials. Trial authors provided data to complete analysis of primary and secondary outcomes, including muscle strength (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), disability scores (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), pulmonary function (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), quality of life (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), and adverse events (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> <p>We assessed four trials at high risk of reporting bias. Two studies dichotomised data post hoc for analysis (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>). A third study measured quality of life but the reporting was incomplete (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>). We also judged <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a> at high risk of reporting bias. Although all outcomes were reported, the statistical plan was limited and unclear. <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> was at unclear risk of bias, as adverse events were not reported. We judged the other five trials at low risk of selective reporting (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>), </p> </section> <section id="CD006282-sec-0111"> <h4 class="title">Other potential sources of bias</h4> <p>Two studies were at high risk from other potential sources of bias (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>) and four at unclear risk (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> <p>The cross‐over design with potential carry‐over effects placed two studies at unclear risk of bias (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>) and one study at high risk of bias (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>). </p> <p>In four trials, there were baseline differences, with other potential bias graded as unclear (<a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>) or high (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). In <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>, there were baseline differences in gender as the valproic acid plus acetyl‐L‐carnitine treatment group consisted of 36.6% females compared to 56% females in the placebo group, and there were differences in body mass index. In <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>, we judged the risk as unclear, since the baseline differences resulted in more severely affected children in the nusinersen‐treated group. However, there was a beneficial significant effect on motor function in the nusinersen group, the effects of nusinersen even being underestimated in more severely affected children. No definite conclusions on this subject could be drawn. In <a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>, we judged the risk of bias as high because there were differences in mean and median ages between the olesoxime and placebo group, with a higher mean and median age in the placebo group, and the proportion of males and females was uneven between the two treatment groups. </p> <p>Four trials were at low risk of other potential sources of bias (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>). </p> </section> </section> <section id="CD006282-sec-0112"> <h3 class="title" id="CD006282-sec-0112">Effects of interventions</h3> <p>See: <a href="./full#CD006282-tbl-0001"><b>Summary of findings for the main comparison</b> Oral creatine compared to placebo for children with SMA types II and III</a>; <a href="./full#CD006282-tbl-0002"><b>Summary of findings 2</b> Oral gabapentin compared to placebo for adults with SMA types II and III</a>; <a href="./full#CD006282-tbl-0003"><b>Summary of findings 3</b> Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</a>; <a href="./full#CD006282-tbl-0004"><b>Summary of findings 4</b> Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</a>; <a href="./full#CD006282-tbl-0005"><b>Summary of findings 5</b> Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</a>; <a href="./full#CD006282-tbl-0006"><b>Summary of findings 6</b> Oral phenylbutyrate compared to placebo for children with SMA type II</a>; <a href="./full#CD006282-tbl-0007"><b>Summary of findings 7</b> Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</a>; <a href="./full#CD006282-tbl-0008"><b>Summary of findings 8</b> Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</a>; <a href="./full#CD006282-tbl-0009"><b>Summary of findings 9</b> Oral valproic acid plus acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</a>; <a href="./full#CD006282-tbl-0010"><b>Summary of findings 10</b> Oral valproic acid compared to placebo for ambulatory adults with SMA type III</a> </p> <p>Meta‐analysis was not possible due to the extensive variation in the drug treatments, outcomes and outcome measures, analyses, follow‐ups, study designs and the reporting of results in the 10 studies included in the review. We present the detailed results of each trial in tables (<a href="#CD006282-tbl-0012">Table 2</a>; <a href="#CD006282-tbl-0013">Table 3</a>; <a href="#CD006282-tbl-0014">Table 4</a>; <a href="#CD006282-tbl-0015">Table 5</a>; <a href="#CD006282-tbl-0016">Table 6</a>; <a href="#CD006282-tbl-0017">Table 7</a>; <a href="#CD006282-tbl-0018">Table 8</a>; <a href="#CD006282-tbl-0019">Table 9</a>; <a href="#CD006282-tbl-0020">Table 10</a>; <a href="#CD006282-tbl-0021">Table 11</a>). </p> <div class="table" id="CD006282-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral creatine versus placebo outcomes (Wong 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (‐1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in quality of life (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7 (‐11 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age 2 to 5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (‐4 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in QoL (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (‐8 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age 5 to 18 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability and QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (‐2 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in quality of life (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6 (‐15 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (69%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in arms muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.34 (6.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (8.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.83 (‐8.75 to 5.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in legs muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (4.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (‐2.70 to 3.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (9.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.42 (10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.25 (‐10.1 to 7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC % of predicted value in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (14.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.83 (11.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (‐10.75 to 11.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.51 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (death by respiratory failure)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; GMFM: Gross Motor Function Measure; NA: not available; PedsQL: Pediatric Quality of Life Inventory; QMT: quantitative muscle test; QoL: quality of life; SD: standard deviation. </p> </div> </div> <div class="table" id="CD006282-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Oral gabapentin versus placebo outcomes (Miller 2001a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Follow‐up at 12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (SMAFRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (‐1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in quality of life (mini‐SIP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36 (‐0.29 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis grip muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in grip muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (‐2.5 to 11.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis arms muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in arms muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (‐2.5 to 6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis feet muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in feet muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (‐8.3 to 8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis total muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in total muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (‐6.9 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis development of walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with development of walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in pulmonary function (FVC % of predicted value)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐4.1 to 1.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; mini‐SIP: mini Sickness Impact Profile; MVC: maximum voluntary contraction; NA: not available; SMAFRS: Spinal Muscular Atrophy‐Functional Rating Scale. </p> </div> </div> <div class="table" id="CD006282-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Oral hydroxyurea versus placebo outcomes (Chen 2010)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (GMFM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.02 (0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.88 (‐3.89 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis muscle strength (MMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in muscle strength (MMT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.58 (0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.55 (‐2.65 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for pulmonary function (FVC in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SE) change in pulmonary function (FVC in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.22 (0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (‐0.25 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in disability score (MHFMS) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (‐0.12 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse event episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number (SD) of adverse event episodes per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.05 (3.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.45 (2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.4 (‐2.21 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse event episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number (SD) of severe adverse event episodes per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (‐0.77 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FVC: forced vital capacity; GMFM: Gross Motor Function Measure; MHFMS: Modified Hammersmith Functional Motor Scale; MMT: manual muscle testing; SD: standard deviation; SE: standard error. </p> </div> </div> <div class="table" id="CD006282-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Intrathecal injected nusinersen versus placebo outcomes (Mercuri 2018)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interim analysis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in HFMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9 (3.7 to 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in HFMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (3.1 to 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of participants with 3‐point‐change on HFMSE (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5 (12.7 to 48.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage (number) of children who achieved ≥ 1 new WHO motor milestone (% (number))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (‐7 to 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage (number) of children who achieved ability to stand alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 (0.03 to 7.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage (number) of children who achieved ability to walk with assistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (0.06 to 36.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.9 to 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; HFMSE: Hammersmith Functional Motor Scale Expanded; WHO: World Health Organization. </p> <p><sup>a</sup> Conducted in children who completed at least six months of the trial. Data of children who had not yet completed the 15‐month period were imputed.<br/> <sup>b</sup> Included 35 participants in the nusinersen group and 19 participants in the control group who completed the 15‐month assessment. Data for 49 participants in the nusinersen group and 23 participants in the control group were imputed.<br/> <sup>c</sup> The number of children with observed data for the 15‐month assessment was 66 in the nusinersen group and 34 in the control group, and the number of children with imputed data was 18 in the nusinersen group and eight in the control group. </p> </div> </div> <div class="table" id="CD006282-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Oral olesoxime versus placebo outcomes (Bertini 2017)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Estimated difference (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis MFM‐32 D1+D2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>ab</sup> change (95% CI) in disability score (MFM D1+D2) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐1.30 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.82 (‐3.68 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (‐0.25 to 4.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis MFM total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>ab</sup> change (95% CI) in disability score (MFM total score) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (‐0.9 to 2.070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.45 (‐3.31 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (‐0.21 to 4.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> change (95% CI) in disability score (HFMS) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.78 (‐1.60 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.72 (‐2.74 to ‐0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (‐0.28 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of nerve innervation value (CMAP) (in mV) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in total amplitude CMAP from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 (‐0.49 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (‐0.74 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of MUNE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (53%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in total MUNE from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.51 (‐12.21 to 3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.69 (‐16.86 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in FVC from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.28 (‐0.32 to 8.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.16 (1.00 to 11.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.88 (‐3.14 to 6.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of quality of life (PedsQL) from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in quality of life (PedsQL) from baseline to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (‐4.58 to 5.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for responder analysis MFM‐32 score D1+D2 (24 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with good response according to MFM‐32 score D1+D2<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (‐0.98 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1104 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.91 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (25%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.37 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; CMAP: compound muscle action potential; FVC: forced vital capacity; HFMS: Hammersmith Functional Motor Scale; MFM: Motor Function Measure; MFM D1+D2: functional domains 1 and 2 of the Motor Function Measure; MUNE: motor unit number estimation; NA: not available; PedsQL: Pediatric Quality of Life Inventory; SD: standard deviation. </p> <p><sup>a</sup> Least squared mean of MFM, including MFM‐32 and MFM‐20 assessments.<br/> <sup>b</sup> Calculated with available data.<br/> <sup>c</sup> Participants with no change or improvement of scores were considered 'responders', participants with a decline in score were considered 'non‐responders'. </p> </div> </div> <div class="table" id="CD006282-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oral phenylbutyrate versus placebo outcomes (Mercuri 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenylbutyrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (9.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8 (9.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.7 (‐4.78 to 3.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in HFMS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.13 (‐0.84 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age &gt; 5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength arm megascore (dynamometry)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.42 (8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (‐1.67 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change muscle strength leg megascore (dynamometry)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.26 (8.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.22 (6.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (‐2.46 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC % of predicted value in litres)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (‐0.07 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenylbutyrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (1.25 to 7.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of withdrawals because of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.86 (0.49 to 7.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.96 (0.18 to 21.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; HFMS: Hammersmith Functional Motor Scale; SD: standard deviation; </p> <p><sup>a</sup>Mean change from baseline. </p> </div> </div> <div class="table" id="CD006282-tbl-0018"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Subcutaneous somatotropin versus placebo outcomes (Kirschner 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants randomised (cross‐over setting)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Somatropin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants completing phase 1 of study protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants completing phase 2 of study protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength of upper limb (hand‐held myometry in megascore of biceps and handgrip) (Newton) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (6.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (10.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.35 (‐7.12 to 4.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability score (HFMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (SD) change in disability score (HFMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (5.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (‐1 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis arm megascore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in arm megascore (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (6.42;<br/> ‐11 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (10.60;<br/> ‐18 to 34.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (‐3.79 to 3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis leg megascore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in leg megascore (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.96 (7.64; ‐10 to 24.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (9.93; ‐18 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 (‐2.19 to 6.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis muscle strength (MRC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change MRC (% of maximum score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.31 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43 (7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.74 (‐6.7 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function (FVC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in pulmonary function (FVC improvement in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.25; ‐0.4 to 0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11 (0.40; ‐1.4 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (‐0.01 to 0.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Somatropin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk Ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.78 to 3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; HFMSE: Hammersmith Functional Motor Scale Expanded; MRC: Medical Research Council; SD: standard deviation. </p> </div> </div> <div class="table" id="CD006282-tbl-0019"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intravenous TRH versus placebo outcomes (Tzeng 2000)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRH</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength (dynamometry in pounds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (‐0.54 to 1.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRH</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; NA: not available; SD: standard deviation; TRH: thyrotropin‐releasing hormone. </p> </div> </div> <div class="table" id="CD006282-tbl-0020"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Oral valproic acid plus acetylcarnitine versus placebo outcomes (Swoboda 2010)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid + acetyl‐L‐carnitine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (‐1.1 to 2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of nerve innervation value (CMAP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total amplitude CMAP from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.10 (0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (‐0.33 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of quality of life (PedsQL) from baseline to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in quality of life (PedsQL) from baseline to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9 (13.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (12.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2 (‐9.27 to 4.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age &lt; 3 years old</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (5.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (‐3.28 to 3.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aged 3–8 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFSM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (45%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (3.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.41 (2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (‐1.25 to 2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aged</b> ≥ <b>5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in arms (myometry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in arm muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (‐0.45 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in legs (myometry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in leg muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.85 (2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (‐1.98 to 4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in both arms and legs (myometry) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.25 (2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.69 to 3.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis pulmonary function (FVC in % of predicted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC in % of predicted) from baseline to 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid + acetyl‐L‐carnitine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with adverse events (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32 (0.92 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with severe adverse events (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (0.60 to 12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; CMAP: compound maximum action potential; FVC: forced vital capacity; MHFMS: Modified Hammersmith Functional Motor Scale; PedsQL: Pediatric Quality of Life Inventory; SD: standard deviation. </p> <p><sup>a</sup> Underpowered. </p> </div> </div> <div class="table" id="CD006282-tbl-0021"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oral valproic acid versus placebo outcomes (Kissel 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants randomised first 6 months (cross‐over setting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Analysis after 6 months before cross‐over</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis SMAFRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in SMAFRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.29 (1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (‐1.32 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis upper extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in MVICT upper extremity (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.23 (‐1.03 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis lower extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in lower extremity MVICT (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.37 (‐1.09 to 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function (FVC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in pulmonary function (FVC improvement in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.34 (‐0.94 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for QoL analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in mini‐SIP for QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19 (2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (4.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐3.8 to 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.44 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.15 to 6.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; mini‐SIP: mini‐Sickness Illness Profile; MVICT: maximum voluntary isometric contraction; NA: not available; QoL: quality of life; SD: standard deviation; SMAFRS: Spinal Muscular Atrophy Functional Rating Scale. </p> <p><sup>a</sup>Calculated with available data. </p> </div> </div> <p>We re‐analysed the data from four trials according to our predefined primary and secondary outcome measures (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). To enable this analysis, we obtained the raw study data from the principal investigators of two studies (<a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). We performed additional analysis on the available data of one study to retrieve MDs and CIs of data (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>). We obtained additional data for one study to complete information on effect sizes and CIs (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>). The results of this re‐analysis are shown separately for each included trial in <a href="#CD006282-tbl-0012">Table 2</a>, <a href="#CD006282-tbl-0013">Table 3</a>, <a href="#CD006282-tbl-0018">Table 8</a>, <a href="#CD006282-tbl-0019">Table 9</a>, and <a href="#CD006282-tbl-0021">Table 11</a>. </p> <section id="CD006282-sec-0113"> <h4 class="title">Oral creatine versus placebo</h4> <p><a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a> compared creatine versus placebo and reported outcomes at nine months. See <a href="#CD006282-tbl-0012">Table 2</a> for numerical results and <a href="./full#CD006282-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD006282-sec-0114"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0115"> <h6 class="title">Change in disability score</h6> <p>Change in disability, assessed by the GMFM was a primary outcome in <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>. Trial authors supplied additional data on GMFM for re‐analysis. The change in disability scores showed little or no difference between the treatment and placebo groups (n = 40; moderate‐certainty evidence, downgraded one level for imprecision owing to a small sample size). </p> </section> </section> <section id="CD006282-sec-0116"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0117"> <h6 class="title">Change in muscle strength</h6> <p>The study measured muscle strength via quantitative myometry, but (re‐)analysis of data showed no evidence of a difference for change in hand, arm, feet, leg or total muscle strength between the treatment and placebo groups (n = 22; low‐certainty evidence, downgraded one level for imprecision owing to a small sample size and one level for inconsistency due to unknown cohort representation). </p> </section> <section id="CD006282-sec-0118"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0119"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0120"> <h6 class="title">Change in quality of life</h6> <p>The study measured quality of life using the mini‐SIP and PedsQL. There was no evidence of a difference in quality of life measures between the treatment and placebo groups (n = 38; low‐certainty evidence, downgraded one level for imprecision owing to a small sample size and one level for inconsistency). </p> </section> <section id="CD006282-sec-0121"> <h6 class="title">Change in pulmonary function</h6> <p>The study measured change in FVC in participants more than five years old. There was no evidence of a difference in pulmonary function between the treatment and placebo groups (n = 23; low‐certainty evidence, downgraded one level for imprecision owing to a small sample size and one level for inconsistency due to unknown cohort representation). </p> </section> <section id="CD006282-sec-0122"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>One participant in <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a> died. The death was reported not to be related to the study treatment and occurred in the placebo group. None of the participants reached the state of more than 16 hours' ventilation a day (n = 40; moderate‐certainty evidence, downgraded one level for imprecision owing to a small sample size). </p> </section> <section id="CD006282-sec-0123"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>, adverse events rates were similar in the creatine and placebo groups: 13/27 participants who received creatine and 16/28 participants who received placebo had an adverse event (n = 40; low‐certainty evidence, downgraded two levels for study limitations (risk of bias) and because it is unlikely the trial captured uncommon adverse events (risk of imprecision). The report did not include information on type of adverse events. Data on the number of adverse events were available for analysis, but the trial authors were unable to provide other data on (severe) adverse events on request. </p> </section> </section> </section> <section id="CD006282-sec-0124"> <h4 class="title">Oral gabapentin versus placebo</h4> <p><a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> compared gabapentin versus placebo and reported outcomes at 12 months. See <a href="#CD006282-tbl-0013">Table 3</a> for numerical results and <a href="./full#CD006282-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD006282-sec-0125"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0126"> <h6 class="title">Change in disability score</h6> <p>Change in disability, measured with the SMAFRS, was a primary outcome in <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>. </p> <p>There was no evidence of a difference for change in disability scores between the treatment and placebo groups (n = 66; low‐certainty evidence, downgraded two levels for study limitations (risk of bias and imprecision)). </p> </section> </section> <section id="CD006282-sec-0127"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0128"> <h6 class="title">Change in muscle strength</h6> <p>The trial measured muscle strength using quantitative myometry. There was no evidence of a difference for change in hand, arm, feet, leg or total muscle strength between the treatment and placebo groups. </p> <p>In <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>, some participants were unable to perform all of the muscle strength tests and, therefore, these were not included in the analyses. Moreover, the raw data from this trial showed several extreme values of muscle strength in one particular participating centre. Therefore, we re‐analysed the data with and without these outliers, but this did not result in a different statistical outcome. For a limited number of participants in this trial, data were available at 12 months' follow‐up. Re‐analysis of these limited data also showed no clinically or statistically significant difference for change in muscle strength between the treatment and placebo groups (for total muscle strength, n = 50; low‐certainty evidence, downgraded one level for study limitations (risk of bias) and one level for imprecision; <a href="#CD006282-tbl-0013">Table 3</a>). </p> </section> <section id="CD006282-sec-0129"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0130"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>In <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>, none of the participants who were unable to walk before treatment acquired this ability after treatment, and none of the participants who could walk lost this ability in either the treatment or placebo group (n = 73; low‐certainty evidence, downgraded one level for study limitations (risk of bias) and one level for imprecision). </p> </section> <section id="CD006282-sec-0131"> <h6 class="title">Change in quality of life</h6> <p>Quality of life was measured with the use of mini‐SIP. There was no evidence of a difference in quality of life between the treatment and placebo groups (n = 73; low‐certainty evidence, downgraded one level for study limitations (risk of bias) and one level for imprecision). </p> </section> <section id="CD006282-sec-0132"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> included only adults and measured the change in FVC. There was no evidence of a difference in pulmonary function between the treatment and placebo groups (n = 65; low‐certainty evidence, downgraded one level for study limitations (risk of bias) and one level for imprecision). </p> </section> <section id="CD006282-sec-0133"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 84; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> <section id="CD006282-sec-0134"> <h6 class="title">Adverse events, separated into severe and others</h6> <p><a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a> did not provide specific information on adverse events (n = 65; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> </section> </section> <section id="CD006282-sec-0135"> <h4 class="title">Oral hydroxyurea versus placebo</h4> <p><a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a> compared oral hydroxyurea versus placebo, with a follow‐up of 18 months. See <a href="#CD006282-tbl-0014">Table 4</a> for numerical results. and <a href="./full#CD006282-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD006282-sec-0136"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0137"> <h6 class="title">Change in disability score</h6> <p><a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a> measured change in disability as a primary outcome using the GMFM. There was no evidence of a difference in change from baseline between the treatment and placebo groups (n = 57; low‐certainty evidence, downgraded two levels for imprecision (wide CIs and small sample size)). The trial also measured the MHFMS in non‐ambulatory participants as a secondary outcome. There were no clinically or statistically significant difference between the hydroxyurea and placebo groups (n = 38; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0138"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0139"> <h6 class="title">Change in muscle strength</h6> <p>Muscle strength was measured via quantitative myometry. There was no evidence of a difference for change in hand, arm, feet, leg or total muscle strength between the treatment and placebo groups (n = 57; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> <section id="CD006282-sec-0140"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0141"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0142"> <h6 class="title">Change in quality of life</h6> <p>The study did not measure quality of life.</p> </section> <section id="CD006282-sec-0143"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a> measured change in FVC in participants more than five years old. There was no evidence of a difference in pulmonary function between the treatment and placebo groups (n = 57; low‐certainty evidence, downgraded one level for indirectness and one level for imprecision). </p> </section> <section id="CD006282-sec-0144"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>One participant in the treatment group died. The death was reported not to be related to the study treatment. No other deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 57; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> <section id="CD006282-sec-0145"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>, all participants had at least one adverse event (n = 57; moderate‐certainty evidence, downgraded one level for imprecision) and 19/61 participants had a severe adverse event. </p> </section> </section> </section> <section id="CD006282-sec-0146"> <h4 class="title">Intrathecal nusinersen versus sham procedure</h4> <p><a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a> compared intrathecal nusinersen versus placebo. Results were reported after 15 months of treatment. See <a href="#CD006282-tbl-0015">Table 5</a> for numerical results and <a href="./full#CD006282-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD006282-sec-0147"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0148"> <h6 class="title">Change in disability score</h6> <p>Change in disability measured using the HFMSE was a primary outcome in <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>. There were significant differences in HFMSE score in favour of the nusinersen‐treated participants compared to the sham procedure‐treated participants (n = 126; moderate‐certainty evidence, downgraded one level for imprecision). More participants in the nusinersen‐treated group than the sham procedure‐treated group had a 3‐point change in disability score (n = 126; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0149"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0150"> <h6 class="title">Change in muscle strength</h6> <p><a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a> did not report change in muscle strength. </p> </section> <section id="CD006282-sec-0151"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>One child treated with nusinersen and one child treated with the sham procedure acquired the ability to stand alone (n = 126; low‐certainty evidence, downgraded two levels for imprecision). </p> </section> <section id="CD006282-sec-0152"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>One child treated with nusinersen acquired the ability to walk with assistance compared to no children in the sham‐controlled group (n = 126; low‐certainty evidence, downgraded two levels for imprecision). </p> </section> <section id="CD006282-sec-0153"> <h6 class="title">Change in quality of life</h6> <p>The study did not measure quality of life.</p> </section> <section id="CD006282-sec-0154"> <h6 class="title">Change in pulmonary function</h6> <p>The study did not measure pulmonary function.</p> </section> <section id="CD006282-sec-0155"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 126; moderate‐certainty evidence). </p> </section> <section id="CD006282-sec-0156"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>, 78/84 (93%) participants treated with nusinersen experienced an adverse event, while 42/42 (100%) participants treated with the sham procedure had any adverse event (n = 126; moderate‐certainty evidence, downgraded one level for imprecision). Serious adverse events were reported in 14/84 (17%) participants in the nusinersen group and in 12/42 (29%) participants in the sham procedure group. </p> </section> </section> </section> <section id="CD006282-sec-0157"> <h4 class="title">Oral olesoxime versus placebo</h4> <p><a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a> compared oral olesoxime versus placebo and reported outcomes at 24 months. See <a href="#CD006282-tbl-0016">Table 6</a> for numerical results and <a href="./full#CD006282-tbl-0005">summary of findings Table 5</a>. </p> <section id="CD006282-sec-0158"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0159"> <h6 class="title">Change in disability score</h6> <p>Change in disability, measured using the MFM was a primary outcome in <a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>. There was no evidence of a difference in change in disability scores between the treatment and placebo groups (n = 160; very low‐certainty evidence, downgraded one level for study limitations (risk of bias), one level for imprecision and one level for indirectness). The trial also measured motor function using the HFMS, with little or no difference in the change from baseline between the treatment and placebo groups (n = 160; low‐certainty evidence, downgraded one level for study limitations (risk of bias) and one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0160"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0161"> <h6 class="title">Change in muscle strength</h6> <p>The study did not measure muscle strength.</p> </section> <section id="CD006282-sec-0162"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0163"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0164"> <h6 class="title">Change in quality of life</h6> <p><a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a> measured quality of life using the PedsQL Neuromuscular Module. There was no evidence of a difference in quality of life between the olesoxime‐treated group and the placebo group (n = 108; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0165"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a> measured the change in FVC in participants more than five years old. There was no evidence of a difference in pulmonary function between the treatment and placebo groups (n = 102; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0166"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>Two participants died, one in the olesoxime group and one in the placebo group. Deaths were reported not to be related to the study treatment. There were no other deaths and none of the participants reached the state of more than 16 hours' ventilation a day (n = 160; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> <section id="CD006282-sec-0167"> <h6 class="title">Adverse events, separated into severe and others</h6> <p><a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a> reported that 103 (95%) participants receiving olesoxime and 57 (100%) participants receiving placebo had at least one adverse event, with a total of 1104 adverse events in the olesoxime and 612 in the placebo group (n = 165; moderate‐certainty evidence, downgraded one level for imprecision). Severe adverse events occurred in 18 (17%) participants in the olesoxime group and 14 (25%) participants in the placebo group (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). </p> </section> </section> </section> <section id="CD006282-sec-0168"> <h4 class="title">Oral phenylbutyrate versus placebo</h4> <p><a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a> compared oral phenylbutyrate versus placebo. See <a href="#CD006282-tbl-0017">Table 7</a> for numerical results and <a href="./full#CD006282-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD006282-sec-0169"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0170"> <h6 class="title">Change in disability score</h6> <p>Change in disability, measured on the HFMSE was a primary outcome in <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>. There was no evidence of a difference for change in disability scores between the treatment and placebo groups (n = 90; low‐certainty evidence, downgraded one level because of risk of bias and one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0171"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0172"> <h6 class="title">Change in muscle strength</h6> <p>Muscle strength was measured via quantitative myometry. There was no evidence of a difference for change in arm or leg megascore between the treatment and placebo groups (both measurements n = 70; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0173"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0174"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0175"> <h6 class="title">Change in quality of life</h6> <p>The study did not measure quality of life.</p> </section> <section id="CD006282-sec-0176"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a> measured the change in FVC in participants aged more than five years. There was no evidence of a difference in pulmonary function between the treatment and placebo groups (n = 67; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0177"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported (n = 107; low‐certainty evidence, downgraded one level for imprecision and one level for risk of bias). </p> </section> <section id="CD006282-sec-0178"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>, 2/54 participants treated with phenylbutyrate, compared with 1/53 participants treated with placebo had adverse events. Only one person in each group had a severe adverse event (n = 107; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> </section> </section> <section id="CD006282-sec-0179"> <h4 class="title">Subcutaneous somatotropin versus placebo</h4> <p><a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>, which was a cross‐over study, compared subcutaneous somatotropin with placebo. See <a href="#CD006282-tbl-0018">Table 8</a> for numerical results and <a href="./full#CD006282-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD006282-sec-0180"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0181"> <h6 class="title">Change in disability score</h6> <p><a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a> measured disability as a secondary outcome using the HFMSE. Trial authors supplied additional data on the HFMSE for re‐analysis. </p> <p>There was no evidence of a difference between the treatment and placebo periods in the change in disability scores (n = 19; very low‐certainty evidence, downgraded two levels for risk of bias and one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0182"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0183"> <h6 class="title">Change in muscle strength</h6> <p>Muscle strength was measured via quantitative myometry (MMT). Trial authors supplied additional data upon request. There was no evidence of a difference between the treatment and placebo periods for change in muscle strength in the upper limbs (n = 19; low‐certainty evidence) or in the lower limbs (n = 19; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> <section id="CD006282-sec-0184"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0185"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0186"> <h6 class="title">Change in quality of life</h6> <p>The trial report states that significant differences were not detected between somatotropin and placebo in quality of life measures, but the report does not specify the measures used or provide numerical data. </p> </section> <section id="CD006282-sec-0187"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a> measured the change in FVC in participants aged more than five years. Trial authors supplied additional data on pulmonary function for re‐analysis. There was no evidence of a difference in pulmonary function between the treatment and placebo periods (n = 19; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> <section id="CD006282-sec-0188"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached more than 16 hours' ventilation a day (n = 19; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> <section id="CD006282-sec-0189"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>, 11 participants (55%) experienced 14 adverse events attributed to treatment while receiving somatotropin. Five events were classified as 'moderate' and two as 'severe', which resulted in termination of trial participation. In the placebo phase, a slightly smaller proportion of participants experienced adverse events, with seven participants reporting nine adverse events (n = 19; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> </section> </section> <section id="CD006282-sec-0190"> <h4 class="title">Intravenous thyrotropin‐releasing hormone versus placebo</h4> <p><a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a> compared intravenous TRH versus placebo. See <a href="#CD006282-tbl-0019">Table 9</a> for numerical results and <a href="./full#CD006282-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD006282-sec-0191"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0192"> <h6 class="title">Change in disability score</h6> <p>The study did not measure change in disability score.</p> </section> </section> <section id="CD006282-sec-0193"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0194"> <h6 class="title">Change in muscle strength</h6> <p><a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a> measured muscle strength via quantitative myometry. There was no evidence of a difference for change in hand, arm, feet, leg or total muscle strength except in one participant treated with TRH (n = 9; very low‐certainty evidence, downgraded one level for imprecision and two levels for study limitations). </p> <p>No comparison was made by the study investigators between the treatment and placebo groups because the study size was considered too small. </p> </section> <section id="CD006282-sec-0195"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0196"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0197"> <h6 class="title">Change in quality of life</h6> <p>The study did not measure quality of life.</p> </section> <section id="CD006282-sec-0198"> <h6 class="title">Change in pulmonary function</h6> <p>The study did not measure pulmonary function.</p> </section> <section id="CD006282-sec-0199"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 9; low‐certainty evidence, downgraded one level for imprecision and one level for study limitations). </p> </section> <section id="CD006282-sec-0200"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>, the six participants treated with TRH had 12 adverse events, compared to no adverse events in the three participants in the placebo group (n = 9; very low‐certainty evidence, downgraded two levels for imprecision and one level for study limitations and indirectness). </p> </section> </section> </section> <section id="CD006282-sec-0201"> <h4 class="title">Oral valproic acid (valproate) plus acetyl‐L‐carnitine versus placebo</h4> <p><a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a> compared oral valproate plus ACL versus placebo. See <a href="#CD006282-tbl-0020">Table 10</a> for numerical results and <a href="./full#CD006282-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD006282-sec-0202"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0203"> <h6 class="title">Change in disability score</h6> <p>Change in disability was a primary outcome in <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>. The scale used was the GMFM. There was no evidence of a difference for change in disability scores between the treatment and placebo groups (n = 61; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0204"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0205"> <h6 class="title">Change in muscle strength</h6> <p><a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a> measured change in muscle strength via quantitative myometry. There was no evidence of a difference for change in hand, arm, feet, leg or total muscle strength between the treatment and placebo groups (n = 16; low‐certainty evidence, downgraded two levels for imprecision because of very small sample size). </p> </section> <section id="CD006282-sec-0206"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0207"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0208"> <h6 class="title">Change in quality of life</h6> <p>Quality of life was measured in <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a> with the Profile Pediatric Quality of Life Inventory. There was no evidence of a difference in quality of life between the treatment and placebo groups (n = 16; very low‐certainty evidence, downgraded one level for risk of bias, one level for indirectness and one level for imprecision). </p> <p>In <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a> there was no statistically significant association between quality of life and change in MHFMS, but there was a non‐significant trend towards deterioration of quality of life as MHFMS declined. </p> </section> <section id="CD006282-sec-0209"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a> measured the change in FVC in participants aged more than five years. There was no evidence of a difference in pulmonary function between the treatment and placebo groups. The trial was noted to have insufficient power to observe a statistically significant association (n = 24; low‐certainty evidence, downgraded one level for risk of bias and one level for imprecision). </p> </section> <section id="CD006282-sec-0210"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 61; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> <section id="CD006282-sec-0211"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>In <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>, 23/30 (77%) participants receiving treatment with valproic acid plus ALC had one or more adverse event compared to 18/31 (58%) participants in the placebo group. Severe adverse events occurred in 20% of the participants treated with valproic acid plus ALC and in 6% of the placebo group (n = 61; moderate‐certainty evidence, downgraded one level for imprecision). </p> </section> </section> </section> <section id="CD006282-sec-0212"> <h4 class="title">Oral valproic acid (valproate) versus placebo</h4> <p><a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a> compared oral valproic acid (valproate) versus placebo. See <a href="#CD006282-tbl-0021">Table 11</a> for numerical results and <a href="./full#CD006282-tbl-0010">summary of findings Table 10</a>. </p> <section id="CD006282-sec-0213"> <h5 class="title">Primary outcome</h5> <section id="CD006282-sec-0214"> <h6 class="title">Change in disability score</h6> <p>Change in disability was a secondary outcome in <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>. The scale used was the SMAFRS. The trial authors made additional data available. There was no evidence of a difference for change in disability scores between treatment and placebo periods (n = 31; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> </section> <section id="CD006282-sec-0215"> <h5 class="title">Secondary outcomes</h5> <section id="CD006282-sec-0216"> <h6 class="title">Change in muscle strength</h6> <p>Muscle strength was measured via quantitative myometry. There was no evidence of a difference for change in hand, arm, feet, leg or total muscle strength between treatment and placebo periods(n = 30; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0217"> <h6 class="title">Acquiring the ability to stand within one year after the onset of treatment</h6> <p>The study did not measure ability to stand.</p> </section> <section id="CD006282-sec-0218"> <h6 class="title">Acquiring the ability to walk or improvement of walking within one year after the onset of treatment </h6> <p>The study did not measure ability to walk.</p> </section> <section id="CD006282-sec-0219"> <h6 class="title">Change in quality of life</h6> <p>Change in quality of life was assessed with the mini‐SIP. Additional data were made available by the trial authors for re‐analysis. There was no evidence of a difference between treatment and placebo periods (n = 28; moderate‐certainty evidence, downgraded one level for study limitations). </p> </section> <section id="CD006282-sec-0220"> <h6 class="title">Change in pulmonary function</h6> <p><a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a> included only adults and measured the change in FVC. Additional data were made available by the trial authors for re‐analysis. There was no evidence of a difference in pulmonary function between treatment and placebo periods (n = 24; low‐certainty evidence, downgraded one level for study limitations and one level for imprecision). </p> </section> <section id="CD006282-sec-0221"> <h6 class="title">Time from beginning of treatment until death or full‐time ventilation</h6> <p>No deaths were reported and none of the participants reached the state of more than 16 hours' ventilation a day (n = 33; low‐certainty evidence, downgraded one level for imprecision and one level for study limitations) </p> </section> <section id="CD006282-sec-0222"> <h6 class="title">Adverse events, separated into severe and others</h6> <p>The trial reported 96 adverse events. Trial authors supplied additional information on the types and number of adverse events. Thirty of the adverse events occurred in the valproic acid treatment period and 60 occurred in the placebo treatment period. Two of the events led to early termination of trial participation. Additionally, there were five serious adverse events; two in the valproic acid treatment period and three in the placebo treatment period, but all five were classified as unrelated to treatment (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>) (n = 33; low‐certainty evidence, downgraded one level for imprecision and one level for study limitations). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD006282-sec-0223" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD006282-sec-0223"></div> <section id="CD006282-sec-0224"> <h3 class="title" id="CD006282-sec-0224">Summary of main results</h3> <p>We found 10 randomised controlled trials (including 717 participants) with data available to evaluate the efficacy of drug treatment in people with SMA types II and III (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). Two of these trials included only people with SMA type II (<a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>), and one trial only included ambulatory participants with SMA type III (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>). Two RCTs included solely non‐ambulatory participants with SMA types II and III (<a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), and types II and IIIa (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). The treatments investigated were oral creatine, oral gabapentin, oral hydroxyurea, intrathecally injected nusinersen, oral olesoxime, oral phenylbutyrate, subcutaneous injections of somatropin, intravenous TRH, and oral therapy with valproic acid with or without oral acetyl‐L‐carnitine. </p> <p>Intrathecally injected nusinersen was an effective treatment for the improvement of motor function in SMA type II (<a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>), with moderate‐certainty evidence of improvement on the primary outcome (HFMSE) in the treatment group compared to a mean decline of motor scores in the sham‐procedure group. </p> <p>Although open and uncontrolled trials with other drugs had seemed promising, none of the other included nine trials showed any efficacy on any of the primary outcome measures (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> <p>One RCT did not demonstrate efficacy of oral gabapentin in adults aged 21 years and older with SMA types II and III (<a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>). Efficacy of oral hydroxyurea was not established in one trial in 57 participants (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>). </p> <p>One RCT of olesoxime in 165 participants with SMA types II and III suggested beneficial effects from olesoxime compared to placebo with stabilisation or slight improvement of motor function in post hoc responder analysis (dichotomous analysis), but there was no effect on the original primary or secondary outcomes (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). The RCT in 107 participants with SMA type II showed no efficacy after three months of treatment with phenylbutyrate (<a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>). The cross‐over RCT of subcutaneous somatotropin in 20 participants with SMA types II and III showed no effect on muscle strength, motor function or pulmonary function (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>). Two trials investigated the effects of valproic acid in SMA, but both the trial of the combined therapy of valproic acid plus ALC in non‐ambulatory and the trial of monotherapy with valproic acid showed no significant improvement of motor function and muscle strength compared to placebo treatment (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>). </p> <p>Our confidence in these findings of little or no effect was very low for TRH; low to very low for olesoxime and somatotropin; low for valproic acid, phenylbutyrate, gabapentin and hydroxyurea; and moderate for nusinersen, creatine and valproic acid plus ALC. </p> <p>Nine additional RCTs investigating 4‐aminopyridine, ALC, CK‐2121707 hydroxyurea, pyridostigmine, riluzole, RO6885247/RG7800, salbutamol and valproic acid were completed but no data for analysis were available at the time of writing and they could not be included in the final assessment (<a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>; <a href="./references#CD006282-bbs2-0048" title="CHICTR‐TRC‐10001093 . Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=8445 (first received 11 February 2010). [ChiCTR‐TRC‐10001093] ">CHICTR‐TRC‐10001093</a>; <a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>; <a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>; <a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>; <a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a>; <a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>; <a href="./references#CD006282-bbs2-0054" title="NCT02644668 . A study of CK‐2127107 in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02644668 (first received 23 December 2015). [CY 5021; NCT02644668] RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17(Suppl 1):P261. ">NCT02644668</a>; <a href="./references#CD006282-bbs2-0055" title="SPACE . SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐004369‐34‐NL(first received October 2016). [EUCTR2011‐004369‐34‐NL] ">SPACE</a>). We consider it unlikely that the results of <a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a> (last update received 2007), <a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a> (last update received 2008) and <a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a> (last update received 2011) will be published in the future, because publication of the results has already been delayed many years. </p> <section id="CD006282-sec-0225"> <h4 class="title">Evidence from other studies in spinal muscular atrophy</h4> <p>We discuss the results of treatment with each of these drugs from unreported and non‐randomised trials in SMA types II and III. Result of treatment in SMA type I is the topic of another Cochrane Review (<a href="./references#CD006282-bbs2-0258" title="WadmanRI , van derPolWL , BosboomWMJ , AsselmanF‐L , van denBergLH , IannacconeST , VranckenAFJE . Drug treatment for spinal muscular atrophy type I. Cochrane Database of Systematic Reviews2019, Issue 12. [DOI: 10.1002/14651858.CD006281.pub5] ">Wadman 2019</a>). </p> <section id="CD006282-sec-0226"> <h5 class="title">Carnitine</h5> <p>One RCT of treatment with ALC in 110 people with SMA types II and III is completed, but results are not available (<a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>). </p> </section> <section id="CD006282-sec-0227"> <h5 class="title">Celecoxib</h5> <p>One open‐label trial in children and adults with SMA types II and III is planned to investigate the effect of different dosages of celecoxib on SMN protein levels in peripheral leukocytes (<a href="./references#CD006282-bbs2-0032" title="NCT02876094 . Effect of low‐dose celecoxib on SMN2 in patients with spinal muscular atrophy (SMA). www.clinicaltrials.gov/show/NCT02876094 (first received 9 August 2016). [NCT02876094] ">NCT02876094</a>). </p> </section> <section id="CD006282-sec-0228"> <h5 class="title">CK‐2127107</h5> <p>One phase II RCT in 72 participants with SMA types II, III and IV to investigate safety and efficacy of CK‐2127107 150 mg or 450 mg daily compared to placebo is completed, but results are not yet available (see <a href="./references#CD006282-sec-0275" title="">Characteristics of studies awaiting classification</a>; <a href="./references#CD006282-bbs2-0054" title="NCT02644668 . A study of CK‐2127107 in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02644668 (first received 23 December 2015). [CY 5021; NCT02644668] RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17(Suppl 1):P261. ">NCT02644668</a>). </p> </section> <section id="CD006282-sec-0229"> <h5 class="title">Creatine</h5> <p>There are no known trials or studies on creatine in SMA, apart from the trial included in this review (<a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> </section> <section id="CD006282-sec-0230"> <h5 class="title">Gabapentin</h5> <p>In one large randomised, unblinded and uncontrolled trial with gabapentin in 120 participants with SMA types II and III, there was a trend for improvement in the strength in favour of gabapentin treatment observed after 12 months, with no effect on FVC or other functional tests (<a href="./references#CD006282-bbs2-0028" title="MerliniL , SolariA , VitaG , BertiniE , MinettiC , MonginiT , et al. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. Journal of Child Neurology2003;18(8):537‐41. [PUBMED: 13677579] ">Merlini 2003</a>). </p> </section> <section id="CD006282-sec-0231"> <h5 class="title">Hydroxyurea</h5> <p>In one uncontrolled pilot trial in two people with SMA type I, five people with SMA type II and two people with SMA type III, hydroxyurea showed an improvement in muscle strength without adverse effects (<a href="./references#CD006282-bbs2-0014" title="ChangJG , TsaiFJ , WangWY , JongYJ . Treatment of spinal muscular atrophy by hydroxyurea. American Journal of Human Genetics2002; Vol. 71 Suppl 4:2402. ">Chang 2002</a>). One larger randomised uncontrolled trial from the same investigators, included 33 people with SMA types II and III and treated them with three different doses of hydroxyurea for eight weeks (<a href="./references#CD006282-bbs2-0026" title="LiangWC , YuoCY , ChangJG , ChenYC , ChangYF , WangHY , et al. The effect of hydroxyurea in spinal muscular atrophy cells and patients. Journal of the Neurological Sciences2008;268(1‐2):87‐94. [PUBMED: 18166199] ">Liang 2008</a>). This trial showed increased SMN gene expression and a trend towards improvement in clinical outcome measures. </p> </section> <section id="CD006282-sec-0232"> <h5 class="title">Lamotrigine</h5> <p>One case series of two people with SMA types II (aged 28 years) and III (aged 37 years) described the use of lamotrigine 50 mg/day for 10 years and reported no deterioration in motor function over five years of treatment (<a href="./references#CD006282-bbs2-0029" title="NascimentoOJ , OrsiniM , QuintanilhaG . Lamotrigine on motor symptoms of spinal muscular atrophies. Revista de Neurologia2010;50(2):127‐8. [PUBMED: 20112222] ">Nascimento 2010</a>). </p> </section> <section id="CD006282-sec-0233"> <h5 class="title">Neuromuscular junction interactors</h5> <p>Two out of four participants with SMA type II and III reported improved endurance in daily activities after taking pyridostigmine 4 mg/day divided over multiple daily doses (<a href="./references#CD006282-bbs2-0256" title="WadmanRI , VranckenAF , van denBergLH , van derPolWL . Dysfunction of the neuromuscular junction in spinal muscular atrophy types 2 and 3. Neurology2012;79(20):2050‐5. ">Wadman 2012a</a>). One placebo‐controlled, cross‐over trial in people with SMA types II to IV on the effect of the acetylcholine esterase inhibitor pyridostigmine versus placebo is completed, but results are not yet available (<a href="./references#CD006282-bbs2-0055" title="SPACE . SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐004369‐34‐NL(first received October 2016). [EUCTR2011‐004369‐34‐NL] ">SPACE</a>). One double‐blind RCT in 12 participants with SMA type III aged 18 to 50 years has investigated the effect of 4‐aminopyridine 10 mg twice daily versus placebo. This trial is completed and results are pending (<a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>). </p> </section> <section id="CD006282-sec-0234"> <h5 class="title">Nusinersen</h5> <p>Two phase I/II studies (one open‐label phase I study and its long‐term extension) in 28 participants with SMA types II or III aged two to 14 years showed no safety or tolerability concerns with intrathecal nusinersen treatment (<a href="./references#CD006282-bbs2-0015" title="ChiribogaCA , SwobodaKJ , DarrasBT , IannacconeST , MontesJ , DeVivoDC , et al. Results from a phase 1 study of nusinersen (ISIS‐SMNRx) in children with spinal muscular atrophy. Neurology2016;86(10):890‐7. [ISIS 396443 ‐ CS1; ISIS 396443 ‐ CS10; NCT01494701; NCT01780246] ">Chiriboga 2016</a>; <a href="./references#CD006282-bbs2-0108" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74(Suppl 17):S128. ">Darras 2013</a>; <a href="./references#CD006282-bbs2-0133" title="HachéM , SwobodaKJ , SethnaN , Farrow‐GillespieA , KhandjiA , XiaS , et al. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. Journal of Child Neurology2016;31(7):899‐906. ">Haché 2016</a>). One RCT investigating one dose of nusinersen compared to a sham‐procedure is ongoing and includes participants with atypical SMA type I, while excluding infants with a typical type I presentation (age at onset less than six months and having two <i>SMN2</i> copies) (<a href="./references#CD006282-bbs2-0056" title="NCT02462759 . A study to assess the safety and tolerability of ISIS 396443 (IONIS SMNRx) in participants with spinal muscular atrophy (SMA) (EMBRACE). clinicaltrials.gov/show/NCT02462759 (first received 14 May 2015). [232SM202 ; EUCTR2014‐003657‐33‐DE; NCT02462759] ">EMBRACE 2015</a>). One trial is including genetically confirmed, presymptomatic infants with probable SMA type I (<a href="./references#CD006282-bbs2-0204" title="NCT02386553 . A study of multiple doses of IONIS SMNRx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE). www.clinicaltrials.gov/show/NCT02386553 (first received 27 February 2015). [2014‐002098‐12; 232SM201; NCT02386553] ">NURTURE 2015</a>). One trial in 34 children with SMA types II and III, aged two to 14 years that investigated the effects of three doses of nusinersen at four different doses has been completed, and results are pending (<a href="./references#CD006282-bbs2-0030" title="DarrasBT , ChiribogaC , SwobodaK , IannacconeS , MontesJ , RauschN , et al. Results of a first‐in‐human phase I study to assess the safety, tolerability, and dose range finding of a single intrathecal dose of ISIS‐SMNRx in patients with spinal muscular atrophy. Annals of Neurology2013;74 Suppl 17:S128. NCT01703988 . An open‐label safety, tolerability and dose‐range finding study of multiple doses of ISIS SMNRx in patients with spinal muscular atrophy (SMNRx ‐ CS2). clinicaltrials.gov/show/NCT01703988 (first received 8 October 2012). [IONIS SMNRx‐CS2 ; NCT01703988] ">NCT01703988</a>). One open‐label trial in 52 children with SMA types II and III testing one dose of nusinersen is completed, but results are pending (<a href="./references#CD006282-bbs2-0031" title="NCT02052791 . An open‐label safety and tolerability study of IONIS SMNRx in patients with spinal muscular atrophy who previously participated in IONIS SMNRx‐CS2 or IONIS SMNRx‐CS10. www.clinicaltrials.gov/show/NCT02052791 (first received 30 January 2014). [IONIS SMNRx‐CS12 ; ISIS 396443‐CS12 ; NCT02052791] ">NCT02052791</a>). One open‐label extension study (<a href="./references#CD006282-bbs2-0040" title="NCT02594124 . An open‐label study (SHINE) for patients with spinal muscular atrophy (SMA) who participated in studies with IONIS‐SMNRx. clinicaltrials.gov/show/NCT02594124 (first received 30 October 2015). [EUCTR2015‐001870‐16‐DE; IONIS SMNRx‐CS11; ISIS 396443‐CS11 ; NCT02594124] ">SHINE 2015</a>) evaluated the effects of continuous treatment in patients previously participating in <a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a> and <a href="./references#CD006282-bbs2-0121" title="FinkelRS , MercuriE , DarrasBT , ConnollyAM , KuntzNL , KirschnerJ . Nusinersen versus sham control in infantile‐onset spinal muscular atrophy. New England Journal of Medicine2017;377(18):1723‐32. [ENDEAR; IONIS SMNRx‐CS3B ; ISIS 396442‐CS3B ; NCT02193074] ">Finkel 2017 (ENDEAR)</a>. The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved the use of nusinersen for SMA types I to IV. </p> </section> <section id="CD006282-sec-0235"> <h5 class="title">Olesoxime</h5> <p>One open‐label extension study with olesoxime was started (see <a href="./references#CD006282-bbs2-0035" title="NCT02628743 . A study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02628743 (first received 1 December 2015). [2015‐001589‐25; BN29854 ; EUCTR2015‐001589‐25‐GB; NCT02628743] ">OLEOS</a>) to analyse long‐term effects in non‐ambulatory participants with SMA types II and III who participated in the previous study (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>), but the pharmaceutical company announced that the trial and further development of olesoxime would be cancelled due to unsatisfactory results (<a href="./references#CD006282-bbs2-0218" title="JethwaS , on behalf of the Roche SMA Team. www.treatsma.uk/wp‐content/uploads/2018/05/2018‐05‐30‐Olesoxime‐PG‐update‐May‐2018.pdf 30 May 2018. ">Roche 2018</a>). </p> </section> <section id="CD006282-sec-0236"> <h5 class="title">Phenylbutyrate</h5> <p>One pilot study with phenylbutyrate 500 mg/kg/day using an intermittent schedule (seven days on and seven days off) in participants with SMA type II suggested positive effects on motor function after nine weeks of treatment with oral phenylbutyrate (<a href="./references#CD006282-bbs2-0027" title="MercuriE , BertiniE , MessinaS , PelliccioniM , D'AmicoA , ColittoF , et al. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscular Disorders2004;14(2):130‐5. [PUBMED: 14733959] ">Mercuri 2004</a>). One multicentre phase I/II open‐label trial intentionally evaluating multiple dosage levels of sodium phenylbutyrate to determine the maximum tolerated dose or the highest dose that can be safely given to children with SMA types II or III was terminated after the inclusion of nine participants due to poor compliance to the study drug administration of 500 mg/kg/day (<a href="./references#CD006282-bbs2-0034" title="NCT00439569 . Clinical trial of sodium phenylbutyrate in children with spinal muscular atrophy types II or III. clinicaltrials.gov/show/NCT00439569 (first received 21 February 2007). [HHSN265200423611C; N01NS42361_NPTUNE01; NCT00439569; NPTUNE01] ">NPTUNE01 2007</a>). Analysis of data is pending but is probably underpowered. One phase I/II open‐label study on sodium phenylbutyrate 450 mg/kg/day to 600 mg/kg/day in 14 presymptomatic infants genetically confirmed to have SMA with suspected SMA type I or II according to family history and <i>SMN2</i> copy number, has been completed, but results are pending (see <a href="./references#CD006282-bbs2-0234" title="STOPSMA . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA). clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>). </p> </section> <section id="CD006282-sec-0237"> <h5 class="title">Riluzole</h5> <p>One study on pharmacokinetics of oral riluzole in 14 participants aged six to 20 years with SMA types II and III indicated that a dose of 50 mg/day of riluzole showed the same daily exposure of riluzole as in the indicated levels in previous trials with people with amyotrophic lateral sclerosis (<a href="./references#CD006282-bbs2-0011" title="AbbaraC , EstournetB , LacomblezL , LelièvreB , OuslimaniA , LehmannB , et al. Riluzole pharmacokinetics in young patients with spinal muscular atrophy. British Journal of Clinical Pharmacology2011;71(3):403‐10. [PUBMED: 21284699] ">Abbara 2011</a>). One RCT with riluzole in 141 participants with SMA types II and III is completed, but has not been published and data were not available (<a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>). </p> </section> <section id="CD006282-sec-0238"> <h5 class="title">Salbutamol</h5> <p>One case series of nine people with SMA type II treated with salbutamol showed positive effects on pulmonary function and patient perception of motor function (<a href="./references#CD006282-bbs2-0207" title="PasanisiMB , GiovannettiAM , BussolinoC , CampanellaA , LeonardiM , MorandiL . Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscular Disorders2014;24:9‐10. ">Pasanisi 2014</a>; <a href="./references#CD006282-bbs2-0044" title="TanC , WilliamsAN . Oral salbutamol in 2 wheelchair bound cases of SMA type II. Archives of Disease in Childhood2011;96 Suppl 1:G77(P). ">Tan 2011</a>). In one pilot trial with 13 participants with SMA types II and III, there was a significant increase in muscle strength and pulmonary function after six months of salbutamol treatment (<a href="./references#CD006282-bbs2-0024" title="KinaliM , MercuriE , MainM , DeBiasiaF , KaratzaA , HigginsR , et al. Pilot trial of albuterol in spinal muscular atrophy. Neurology2002;59(4):609‐10. [PUBMED: 12196659] ">Kinali 2002</a>). The next open‐label trial involving 23 participants with SMA type II presented a significant improvement in functional scores after six and 12 months of treatment with salbutamol without any major adverse effects (<a href="./references#CD006282-bbs2-0036" title="PaneM , StaccioliS , MessinaS , D'AmicoA , PelliccioniM , MazzoneES , et al. Daily salbutamol in young patients with SMA type II. Neuromuscular Disorders2008;18(7):536‐40. [PUBMED: 18579379] ">Pane 2008</a>). One open‐label trial with 28 participants with SMA types I to III, aged one to 20 years, showed an increase in motor function (HFMS) and pulmonary function in 25% of participants and stability of functional scores in the rest of participants. The results of this study have not been published and are only available through conference reports (<a href="./references#CD006282-bbs2-0038" title="Prufer de Queiroz Campos AraujoA . Long‐term open salbutamol trial in spinal muscular atrophy. Journal of Neurology2010;257 (Suppl 1):S101. [PUBMED: 20495927] ">Prufer de Queiroz Campos Araujo 2010</a>). One pilot study in 10 participants with SMA types II to IV reported an improvement on perceived motor function, disability and fatigue after salbutamol treatment (<a href="./references#CD006282-bbs2-0019" title="GiovannettiAM , PasanisiMB , ČerniauskaitėM , BussolinoC , LeonardiM , MorandiL . Perceived efficacy of salbutamol by persons with spinal muscular atrophy: a mixed methods study. Muscle &amp; Nerve2016;54(5):843‐9. PasanisiMB , GiovannettiAM , BussolinoC , CampanellaA , LeonardiM , MorandiL . Perception of efficacy in adult patients affected by spinal muscular atrophy (SMA) treated with salbutamol. Neuromuscular Disorders2014;24(9‐10):914. ">Giovannetti 2016</a>). Pulmonary function, including maximal static inspiratory pressure, sniff nasal inspiratory pressure and slow vital capacity, showed effects of one‐year treatment with daily oral salbutamol in seven children with SMA type II and III compared to a natural history cohort of children with SMA type II (<a href="./references#CD006282-bbs2-0023" title="KhiraniS , DabajI , AmaddeoA , Olmo ArroyoJ , RopersJ , TirolienS , et al. Effect of salbutamol on respiratory muscle strength in spinal muscular atrophy. Pediatric Neurology2017;73:78‐87. ">Khirani 2017</a>). Only one RCT with salbutamol is completed and suggested that salbutamol induced improvement of motor performance in the majority of the 45 adults with SMA type III. However, this trial has not been published and limited information is only available through conference abstracts (<a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>). </p> </section> <section id="CD006282-sec-0239"> <h5 class="title">Small molecules</h5> <section id="CD006282-sec-0240"> <h6 class="title">RO6885247/RG7800</h6> <p>One phase I randomised, double‐blind, placebo‐controlled, multiple‐dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6885247/RG7800 in people with SMA types I, II and III was started in November 2014, but later terminated due to potential safety reasons in December 2016 (for details see <a href="./references#CD006282-bbs1-0003" title="">Studies awaiting classification</a>; <a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>). </p> </section> <section id="CD006282-sec-0241"> <h6 class="title">RO7034067 or RG7916 (risdiplam)</h6> <p>One open‐label trial including children and adults aged 12 to 60 years with SMA types II and III, previously treated with an <i>SMN2</i> anti‐sense oligonucleotide, is recruiting participants (<a href="./references#CD006282-bbs2-0020" title="NCT03032172 . A study of RO7034067 in adult and pediatric participants with spinal muscular atrophy (Jewelfish). clinicaltrials.gov/show/NCT03032172 (first received 24 January 2017). ">JEWELFISH 2017</a>). One RCT with RO7034067/RG7916 has started recruiting children and adults with SMA types II and III (<a href="./references#CD006282-bbs2-0059" title="SUNFISH . A study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in type 2 and 3 spinal muscular atrophy participants (Sunfish). clinicaltrials.gov/show/NCT02908685 (first received 19 September 2016). ">SUNFISH 2016</a>). One trial will include genetically confirmed, presymptomatic infants with SMA (<a href="./references#CD006282-bbs2-0212" title="RAINBOWFISH . A study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophy (Rainbowfish). clinicaltrials.gov/ct2/show/NCT03779334 (first received 18 December 2018). [BN40703 ; NCT03779334] ">RAINBOWFISH</a>), but has not started at time of writing this review. </p> </section> </section> <section id="CD006282-sec-0242"> <h5 class="title">Somatropin</h5> <p>There are no known trials or studies on somatotropin in SMA, apart from the trial included in this review (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>). </p> </section> <section id="CD006282-sec-0243"> <h5 class="title">Thyrotropin‐releasing hormone</h5> <p>A positive effect of TRH in SMA was considered since one uncontrolled study found improvement in motor function and electromyographic findings in participants with SMA types II and III after TRH therapy (<a href="./references#CD006282-bbs2-0241" title="TakeuchiY , MiyanomaeY , KomatsuH , OomizonoY , NishimuraA , OkanoS , et al. Efficacy of thyrotropin‐releasing hormone in the treatment of spinal muscular atrophy. Journal of Child Neurology1994;9(3):287‐9. ">Takeuchi 1994</a>). </p> </section> <section id="CD006282-sec-0244"> <h5 class="title">Valproic acid</h5> <p>Two case series and four open‐label studies showed an increase of SMN transcripts levels in almost all participants with oral valproic acid, but only possibly a beneficial effect on pulmonary function and variable results on motor abilities and muscle strength (<a href="./references#CD006282-bbs2-0016" title="DarbarIA , PlaggertPG , ResendeMBD , ZanotelliE , ReedUC . Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. BMC Neurology2011;11:36. [PUBMED: 21435220] ">Darbar 2011</a>; <a href="./references#CD006282-bbs2-0025" title="KisselJT , ScottCB , ReynaSP , CrawfordTO , SimardLR , KrosschellKJ , et al. SMA CARNIVAL trial part II: a prospective, single‐armed trial of L‐carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PloS One2011;6(7):e21296. [PUBMED: 21754985] ">Kissel 2011</a>; <a href="./references#CD006282-bbs2-0039" title="SaitoT , NurputraDK , HarahapNI , HarahapIS , YamamotoH , MuneshigeE , et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience2014;3:49‐57. ">Saito 2014</a>; <a href="./references#CD006282-bbs2-0043" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PloS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>; <a href="./references#CD006282-bbs2-0045" title="TsaiLK , YangCC , HwuWL , LiH . Valproic acid treatment in six patients with spinal muscular atrophy. European Journal of Neurology2007;14(12):e8‐9. [PUBMED: 18028187] ">Tsai 2007</a>; <a href="./references#CD006282-bbs2-0046" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. [PUBMED: 16775228] ">Weihl 2006</a>). One retrospective uncontrolled case series reported improvement of motor function in seven adults with SMA types III and IV during treatment with valproic acid (<a href="./references#CD006282-bbs2-0046" title="WeihlCC , ConnollyAM , PestronkA . Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology2006;67(3):500‐1. [PUBMED: 16775228] ">Weihl 2006</a>). In another retrospective case series, global muscle strength improved in two children and one adolescent with SMA types II and III, but there was no effect in three other participants (<a href="./references#CD006282-bbs2-0045" title="TsaiLK , YangCC , HwuWL , LiH . Valproic acid treatment in six patients with spinal muscular atrophy. European Journal of Neurology2007;14(12):e8‐9. [PUBMED: 18028187] ">Tsai 2007</a>). One prospective case series of seven people with SMA types II and III showed increased SMN transcripts, overall improvement of pulmonary function and improved motor function (<a href="./references#CD006282-bbs2-0039" title="SaitoT , NurputraDK , HarahapNI , HarahapIS , YamamotoH , MuneshigeE , et al. A study of valproic acid for patients with spinal muscular atrophy. Neurology and Clinical Neuroscience2014;3:49‐57. ">Saito 2014</a>). One open‐label trial with 12‐month treatment of valproic acid and L‐carnitine in 33 children with SMA type III found no effects on motor function (<a href="./references#CD006282-bbs2-0025" title="KisselJT , ScottCB , ReynaSP , CrawfordTO , SimardLR , KrosschellKJ , et al. SMA CARNIVAL trial part II: a prospective, single‐armed trial of L‐carnitine and valproic acid in ambulatory children with spinal muscular atrophy. PloS One2011;6(7):e21296. [PUBMED: 21754985] ">Kissel 2011</a>). One open‐label trial with valproic acid in 42 children and adults with SMA types I, II and III showed only slight improvement in gross motor function in younger non‐ambulatory type II children, variable responses of SMN transcripts in blood and carnitine depletion during treatment (<a href="./references#CD006282-bbs2-0043" title="SwobodaKJ , ScottCB , ReynaSP , PriorTW , LaSalleB , SorensonSL , et al. Phase II open label study of valproic acid in spinal muscular atrophy. PloS One2009;4(5):e5268. [PUBMED: 19440247] ">Swoboda 2009</a>). Results from the open‐label study in 13 participants aged one to seven years with SMA types I to III are pending (<a href="./references#CD006282-bbs2-0041" title="SMART01 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=5544(first received August 2014). [JPRN‐SMA‐IIA00190] ">SMART01</a>). </p> <p>There are four ongoing studies with valproic acid in SMA, including one RCT investigating monotherapy with valproic acid in children with SMA types I and II aged one to seven years (<a href="./references#CD006282-bbs2-0058" title="SMART02 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: confirmatory trial. dbcentre3.jmacct.med.or.jp/JMACTR/App/JMACTRS06/JMACTRS06.aspx?seqno=5544 (first received 12 January 2016). [27‐3594; JPRN‐JMA‐IIA00231] ">SMART02</a>), one RCT investigating combined therapy of valproic acid plus L‐carnitine in children aged two to 15 years with SMA types II and III (<a href="./references#CD006282-bbs2-0057" title="NCT01671384 . Valproate and levocarnitine in children with spinal muscular atrophy. clinicaltrials.gov/show/NCT01671384 (first received 13 August 2012). [NCT01671384] ">NCT01671384</a>), and two open‐label trials including people with SMA types I, II and III (<a href="./references#CD006282-bbs2-0021" title="JPRN‐JapicCTI‐163450 . Phase 3 study of K‐828‐SP. apps.who.int/trialsearch/Trial2.aspx?TrialID=JPRN‐JapicCTI‐163450(first received November 2016). ">JPRN‐JapicCTI‐163450 2016</a>; <a href="./references#CD006282-bbs2-0042" title="SMART03 . Multicenter cooperative and investigator initiated clinical trial using valproic acid in childhood onset spinal muscular atrophy: continuous administration trial. dbcentre3.jmacct.med.or.jp/jmactr/App/JMACTRE02_04/JMACTRE02_04.aspx?kbn=3&amp;seqno=4602(first received August 2016). ">SMART03</a>). </p> </section> </section> </section> <section id="CD006282-sec-0245"> <h3 class="title" id="CD006282-sec-0245">Overall completeness and applicability of evidence</h3> <p>All trials included in this review investigated the effects of drug treatment in children or adults (or both) with SMA types II and III, in terms of disability, muscle strength, ability to stand or walk, quality of life, time to death or full‐time ventilation and adverse events. The trials investigated 10 different treatments, additionally the inclusion criteria and outcome measures varied between trials, which makes it impossible to perform meta‐analyses. </p> <p>A major issue in SMA, irrespective of the investigated therapy, is the timing of the treatment in relation to its potential effect. Previous experimental studies suggested that there is a limited window of opportunity to rescue or stabilise motor neuron function in the early or presymptomatic stages of the disease. None of the 10 trials identified for inclusion in this review primarily included people who had just been diagnosed. One phase I/II study with phenylbutyrate in presymptomatic infants genetically confirmed to have SMA, and suspected to have SMA type I or II according to family history and <i>SMN2</i> copy number, has been completed and results are pending (<a href="./references#CD006282-bbs2-0234" title="STOPSMA . Study to evaluate sodium phenylbutyrate in pre‐symptomatic infants with spinal muscular atrophy (STOPSMA). clinicaltrials.gov/show/NCT00528268 (first received 10 September 2007). [1R01HD054599‐01; 22183; NCT00528268] ">STOPSMA 2007</a>). One trial was started with nusinersen treatment in presymptomatic infants with genetically confirmed SMA (<a href="./references#CD006282-bbs2-0204" title="NCT02386553 . A study of multiple doses of IONIS SMNRx (ISIS 396443) delivered to infants with genetically diagnosed and presymptomatic spinal muscular atrophy (NURTURE). www.clinicaltrials.gov/show/NCT02386553 (first received 27 February 2015). [2014‐002098‐12; 232SM201; NCT02386553] ">NURTURE 2015</a>). </p> <p>The practice of supportive care, e.g. pulmonary, nutritional and orthopaedic supportive therapy, in children and adults with SMA types II and III probably differs between centres and countries (<a href="./references#CD006282-bbs2-0081" title="BladenCL , ThompsonR , JacksonJM , GarlandC , WegelC , AmbrosiniA , et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. Journal of Neurology2014;261(1):152‐63. [PUBMED: 24162038] ">Bladen 2014</a>). Practice guidelines for the clinical care of children and adults with SMA are given in the consensus statement for standard care in SMA (<a href="./references#CD006282-bbs2-0122" title="FinkelRS , MercuriE , MeyerOH , SimondsAK , SchrothMK , GrahamRJ , et al. Diagnosis and management of spinal muscular atrophy: part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscular Disorders2018;28(3):197‐207. ">Finkel 2018</a>; <a href="./references#CD006282-bbs2-0187" title="MercuriE , FinkelRS , MuntoniF , WirthB , MontesJ , MainM , et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders2018;28(2):103‐15. ">Mercuri 2018</a>). For future trials it is important that the level of supportive care is explicitly mentioned to avoid baseline differences in the treatment arms and between participating centres. </p> <section id="CD006282-sec-0246"> <h4 class="title">Certainty of the evidence</h4> <p>None of the included trials were completely free of bias according to the Cochrane 'Risk of bias' tool (<a href="./references#CD006282-bbs2-0143" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <p>The randomisation method was not clear in four trials (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). Allocation concealment was not clear in four trials (<a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>) and at high risk of bias in <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>. Blinding of parents, participants and observers were adequate in all trials except <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>, for which the risk of bias related to blinding of participants and personnel and outcome assessors was unclear. We graded the risk of attrition bias high in four trials (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0005" title="MercuriE , BertiniE , MessinaS , SolariA , D'AmicoA , AngelozziC , et al. Randomized, double‐blind, placebo‐controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology2007;68(1):51‐5. [PUBMED: 17082463] ">Mercuri 2007</a>; <a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), and unclear in three trials (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). Reporting bias was suspected in four trials (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0002" title="ChenTH , ChangJG , YangYH , MaiHH , LiangWC , WuYC , et al. Randomized, double‐blind, placebo‐controlled trial of hydroxyurea in spinal muscular atrophy. Neurology2010;75(24):2190‐7. [PUBMED: 21172842] NCT00485511 . A trial of hydroxyurea in spinal muscular atrophy. clinicaltrials.gov/ct2/show/NCT00485511 (first received 13 June 2007). ">Chen 2010</a>; <a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0009" title="TzengAC , ChengJ , FryczynskiH , NiranjanV , StitikT , SialA , et al. A study of thyrotropin‐releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. American Journal of Physical Medicine &amp; Rehabilitation2000;79(5):435‐40. [PUBMED: 10994885] ">Tzeng 2000</a>), and unclear in one trial (<a href="./references#CD006282-bbs2-0007" title="MillerRG , MooreDH , DronskyV , BradleyW , BarohnR , BryanW , et al. A placebo‐controlled trial of gabapentin in spinal muscular atrophy. Journal of the Neurological Sciences2001;191(1‐2):127‐31. [PUBMED: 11677003] ">Miller 2001</a>). </p> <p>The cross‐over design with potential carry‐over effects in three studies placed two studies at unclear risk of bias (<a href="./references#CD006282-bbs2-0003" title="KirschnerJ , SchorlingD , HauschkeD , Rensing‐ZimmermannC , WeinU , GriebenU , et al. Somatropin treatment of spinal muscular atrophy: a placebo‐controlled, double‐blind crossover pilot study. Neuromuscular Disorders2014;24(2):134‐42. [PUBMED: 24300782] NCT00533221 . Pilot study of growth hormone to treat SMA type II and III. clinicaltrials.gov/ct2/show/NCT00533221 (first received 21 September 2007). ">Kirschner 2014</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), and one study at high risk of bias (<a href="./references#CD006282-bbs2-0004" title="KisselJT , ElsheikhB , KingWM , FreimerM , ScottCB , KolbSJ , et al. SMA valiant trial: a prospective, double‐blind, placebo‐controlled trial of valproic acid in ambulatory adults with spinal muscular atrophy. Muscle &amp; Nerve2014;49(2):187‐92. [PUBMED: 23681940] NCT00481013 . Valproic acid in ambulant adults with spinal muscular atrophy (VALIANTSMA). clinicaltrials.gov/ct2/show/NCT00481013. ">Kissel 2014</a>). Baseline differences resulted in potential bias in four trials, which we graded at either an unclear risk of bias (<a href="./references#CD006282-bbs2-0006" title="MercuriE , DarrasBT , ChiribogaCA , DayJW , CampbellC , ConnollyAM , et al. Nusinersen versus sham control in later‐onset spinal muscular atrophy. New England Journal of Medicine2018;378(7):625‐35. [IONIS 396443‐CS4] NCT02292537 . A study to assess the efficacy and safety of nusinersen (ISIS 396443) in participants with later‐onset spinal muscular atrophy (SMA) (CHERISH). clinicaltrials.gov/ct2/show/NCT02292537 (first received 17 November 2014). ">Mercuri 2018 (CHERISH)</a>; <a href="./references#CD006282-bbs2-0008" title="NCT00227266 . Valproic acid and carnitine in patients with spinal muscular atrophy. clinicaltrials.gov/ct2/show/study/NCT00227266 (first received 27 September 2005). SwobodaKJ , ScottCB , CrawfordTO , SimardLR , ReynaSP , KrosschellKJ , et al. SMA CARNI‐VAL trial part I: double‐blind, randomized, placebo‐controlled trial of L‐carnitine and valproic acid in spinal muscular atrophy. PloS One2010;5(8):e12140. [PUBMED: 20808854] ">Swoboda 2010</a>), or a high risk of bias (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>; <a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>). </p> <p>Grading unexplained heterogeneity or inconsistency of results was not possible, since we could not pool data in a meta‐analysis for any drug treatment. We downgraded the evidence one level for imprecision when studies were small or included an insufficient number of participants according to the power analysis of the study. </p> <p>One issue that is noteworthy and unique for SMA is that the phenotype of patients varies significantly among and within SMA types II and III. Additionally, <i>SMN2</i> copy number correlates with disease severity. Therefore, studies should consider SMA type and <i>SMN2</i> copy number as a stratification criterion. None of the included studies incorporated <i>SMN2</i> copy number in the inclusion criteria or subgroup analyses, which might have influenced results. </p> <p>Motor assessments were all done with methods validated in SMA or other neuromuscular disorders. However, the disability scores and techniques to measure muscle strength currently used are possibly not sensitive enough to detect subtle changes in muscle strength and motor function, and may therefore underestimate or fail to detect a potential beneficial effect of treatment (type II error). </p> <p>We are confident that we have minimised the risk of publication bias by evaluating all trial registries and screening trials and studies awaiting publication. </p> </section> </section> <section id="CD006282-sec-0247"> <h3 class="title" id="CD006282-sec-0247">Potential biases in the review process</h3> <p>There may be some potential for bias in this review process as there were changes to the protocol. These included additions and deletions to the outcomes and alterations to the reporting of adverse events, as reported in <a href="#CD006282-sec-0271">Differences between protocol and review</a>. None of these changes were made as a result of the findings of the included studies but rather to improve the structure of the review. </p> <p>All the included trials were relatively small and had a short‐term follow‐up period. We did not extensively report on adverse events. We could not exclude the possibility of missing uncommon adverse events in our review. </p> <p>We are confident that we have identified all clinically relevant trials, as we conducted a comprehensive search of all published literature and clinical trial registries, and three of the review authors regularly attend international conferences on SMA. </p> <p>The results of our review might be biased since, at the time of writing, the results had not been published from nine completed trials, investigating 4‐AP (<a href="./references#CD006282-bbs2-0053" title="NCT01645787 . Short and long term treatment with 4‐AP in ambulatory SMA patients. clinicaltrials.gov/show/NCT01645787 (first received 5 July 2012). [AAAI7400 ; NCT01645787] ">NCT01645787</a>), ALC (<a href="./references#CD006282-bbs2-0049" title="MerliniL , BasogluB , Dohna‐SchwakeC , FebrerA , Hausmanova‐PetrusewiczI , JedrzejowskaM , et al. European spinal muscular atrophy RCT of acetyl‐L‐carnitine in SMA. Neuromuscular Disorders2007;17:780‐1. ">Merlini 2007</a>), CK‐2127107 (<a href="./references#CD006282-bbs2-0054" title="NCT02644668 . A study of CK‐2127107 in patients with spinal muscular atrophy. clinicaltrials.gov/show/NCT02644668 (first received 23 December 2015). [CY 5021; NCT02644668] RudnickiS , AndrewsJ , MalikF , WolffA , DayJ . CK‐2127107 a selective activator of the fast skeletal muscle troponin complex, for the potential treatment of spinal muscular atrophy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2016;17(Suppl 1):P261. ">NCT02644668</a>), hydroxyurea (<a href="./references#CD006282-bbs2-0052" title="NCT00568802 . A pilot therapeutic trial using hydroxyurea in type II and type III spinal muscular atrophy patients. clinicaltrials.gov/show/NCT00568802 (first received 4 December 2007). [NCT00084006; NCT00568802; SU‐11012007‐781 79233] ">NCT00568802</a>), pyridostigmine (<a href="./references#CD006282-bbs2-0055" title="SPACE . SPACE trial SMA and pyridostigmine in adults and children; experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4. apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2011‐004369‐34‐NL(first received October 2016). [EUCTR2011‐004369‐34‐NL] ">SPACE</a>), riluzole (<a href="./references#CD006282-bbs2-0047" title="NCT00774423 . Study to evaluate the efficacy of riluzole in children and young adults with spinal muscular atrophy (SMA) (ASIRI). clinicaltrials.gov/show/NCT00774423 (first received 16 October 2008). [NCT00774423; P040904] ">ASIRI 2008</a>), rat nerve growth factor (<a href="./references#CD006282-bbs2-0048" title="CHICTR‐TRC‐10001093 . Rat nerve growth factor injection in the treatment of children with spinal muscular atrophy: a randomized controlled trial. www.chictr.org.cn/showprojen.aspx?proj=8445 (first received 11 February 2010). [ChiCTR‐TRC‐10001093] ">CHICTR‐TRC‐10001093</a>), RO06885247/RG7800 (<a href="./references#CD006282-bbs2-0050" title="NCT02240355 . A study of RO6885247 in adult and pediatric patients with spinal muscular atrophy (MOONFISH). clinicaltrials.gov/show/NCT02240355 (first received 11 September 2014). [2014‐002246‐41; BP29420 ; NCT02240355] ">MOONFISH 2014</a>), and salbutamol (<a href="./references#CD006282-bbs2-0051" title="MorandiL , AbiusiE , PasanisiMB , LomastroR , FioriS , DiPietroL , et al. Salbutamol tolerability and efficacy in adult type III SMA patients: results of a multicentric, molecular and clinical, double‐blind, placebo‐controlled study. Neuromuscular Disorders2013;9(10):771. TizianoFD , LomastroR , DiPietroL , PasanisiMB , FioriS , AngelozziC , et al. Phase‐ll multicenter double‐blind, placebo‐controlled study of tolerability and efficacy of salbutamol in adult type III SMA patients. Acta Myologica2012;31:97. ">Morandi 2013</a>). </p> <p>The review authors are investigators in trials of different drug treatments in SMA. The search and selection of trials were not, however, biased by the review authors' involvement in these trials. Data analysis of the creatine trial (<a href="./references#CD006282-bbs2-0010" title="WongBL , HynanLS , IannacconeST , AmSMART Group. A randomized, placebo‐controlled trial of creatine in children with spinal muscular atrophy. Journal of Clinical Neuromuscular Disease2007;8(3):101‐10. [EMBASE: 46673514] ">Wong 2007</a>, with Dr Iannaccone as investigator and author) was performed by Drs Wadman and Vrancken. Data analysis for the olesoxime trial was checked by Dr Iannaccone, as Drs Wadman, van der Pol and Vrancken were site investigators (<a href="./references#CD006282-bbs2-0001" title="BertiniE , DessaudE , MercuriE , MuntoniF , KirschnerJ , ReidC , et al. Safety and efficacy of olesoxime in patients with type 2 or non‐ambulatory type 3 spinal muscular atrophy: a randomised, double‐blind, placebo‐controlled phase 2 trial. Lancet Neurology2017;16(7):513‐22. Corrections in Lancet Neurology 2017; 16(8):584. [DOI: 10.1016/S1474‐4422(17)30085‐6; 3134415] NCT01302600 . Safety and efficacy of olesoxime (TRO19622) in 3‐25 years SMA patients. clinicaltrials.gov/ct2/show/NCT01302600 (first received 24 February 2011). ">Bertini 2017</a>). </p> </section> <section id="CD006282-sec-0248"> <h3 class="title" id="CD006282-sec-0248">Agreements and disagreements with other studies or reviews</h3> <p>To the best of our knowledge, there are no other systematic reviews considering the whole spectrum of drug treatments in SMA. Several reviews have also identified and discussed various drug treatments in SMA (<a href="./references#CD006282-bbs2-0062" title="AndertonRS , MastagliaFL . Advances and challenges in developing a therapy for spinal muscular atrophy. Expert Review of Neurotherapeutics2015;15(8):895‐908. ">Anderton 2015</a>; <a href="./references#CD006282-bbs2-0071" title="ArnoldWD , BurghesAH . Spinal muscular atrophy: the development and implementation of potential treatments. Annals of Neurology2013;74(3):348‐62. ">Arnold 2013</a>; <a href="./references#CD006282-bbs2-0107" title="DarrasBT , KangPB . Clinical trials in spinal muscular atrophy. Current Opinion in Pediatrics2007;19(6):675‐9. ">Darras 2007</a>; <a href="./references#CD006282-bbs2-0167" title="LeweltA , NewcombTM , SwobodaKJ . New therapeutic approaches to spinal muscular atrophy. Current Neurology and Neuroscience Reports2012;12(1):42‐53. ">Lewelt 2012</a>; <a href="./references#CD006282-bbs2-0203" title="NurputraDK , LaiPS , HarahapNI , MorikawaS , YamamotoT , NishimuraN , et al. Spinal muscular atrophy: from gene discovery to clinical trials. Annals of Human Genetics2013;77(5):435‐63. ">Nurputra 2013</a>; <a href="./references#CD006282-bbs2-0233" title="StavarachiM , ApostolP , TomaM , CimponeriuD , GavrilaL . Spinal muscular atrophy disease: a literature review for therapeutic strategies. Journal of Medicine and Life2010;3(1):3‐9. ">Stavarachi 2010</a>; <a href="./references#CD006282-bbs2-0240" title="SwobodaKJ , KisselJT , CrawfordTO , BrombergMB , AcsadiG , D'AnjouG , et al. Perspectives on clinical trials in spinal muscular atrophy. Journal of Child Neurology2007;22(8):957‐66. ">Swoboda 2007</a>; <a href="./references#CD006282-bbs2-0248" title="TisdaleS , PellizzoniL . Disease mechanisms and therapeutic approaches in spinal muscular atrophy. Journal of Neuroscience2015;35(23):8691‐700. ">Tisdale 2015</a>), with some focusing specifically on preclinical studies (<a href="./references#CD006282-bbs2-0226" title="SeoJ , HowellMD , SinghNN , SinghRN . Spinal muscular atrophy: an update on therapeutic progress. Biochimica Biophysica Acta2013;1832(12):2180‐90. ">Seo 2013</a>), genetic therapies (<a href="./references#CD006282-bbs2-0110" title="DonnellyEM , BoulisNM . Update on gene and stem cell therapy approaches for spinal muscular atrophy. Expert Opinion on Biological Therapy2012;11:1463‐71. ">Donnelly 2012</a>; <a href="./references#CD006282-bbs2-0266" title="ZanettaC , NizzardoM , SimoneC , MonguzziE , BresolinN , ComiGP , et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clinical Therapeutics2014;36(1):128‐40. ">Zanetta 2014</a>), solely histone deacetylase inhibitor therapies (<a href="./references#CD006282-bbs2-0190" title="MohseniJ , Zabidi‐HussinZA , SasongkoTH . Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy. Genetics and Molecular Biology2013;36(3):299‐307. ">Mohseni 2013</a>), SMN‐inducing therapies (<a href="./references#CD006282-bbs2-0155" title="KaczmarekA , SchneiderS , WirthB , Markus RiesslandM . Investigational therapies for the treatment of spinal muscular atrophy. Expert Opinion on Investigational Drugs2015;24(7):967‐81. ">Kaczmarek 2015</a>), or small molecule and molecular therapies (<a href="./references#CD006282-bbs2-0266" title="ZanettaC , NizzardoM , SimoneC , MonguzziE , BresolinN , ComiGP , et al. Molecular therapeutic strategies for spinal muscular atrophies: current and future clinical trials. Clinical Therapeutics2014;36(1):128‐40. ">Zanetta 2014</a>). Our conclusions are in line with these reviews. </p> <p>Although we have tried to give an overview of the efficacy of drug treatment with gabapentin, creatine, nusinersen, valproic acid with and without acetylcarnitine, somatotropin, TRH, phenylbutyrate, olesoxime and hydroxyurea in preclinical studies, studies with animal models of SMA or studies in participants with SMA (<a href="#CD006282-sec-0223">Discussion</a>), the overview on non‐randomised and preclinical trials and studies was not based on a systematic review and potential studies might have been missed. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD006282-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/urn:x-wiley:14651858:media:CD006282:CD006282-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_t/tCD006282-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD006282-fig-0001" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006282-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/urn:x-wiley:14651858:media:CD006282:CD006282-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_t/tCD006282-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 10 included studies." data-id="CD006282-fig-0002" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all 10 included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD006282-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/urn:x-wiley:14651858:media:CD006282:CD006282-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_t/tCD006282-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD006282-fig-0003" src="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/media/CDSR/CD006282/image_n/nCD006282-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral creatine compared to placebo for children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral creatine compared to placebo for children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral creatine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral creatine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: GMFM<br/> Scale: 0–264<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in disability score was –1</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Median change 1 higher</b><br/> (1 lower to 2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in total muscle strength</b> (total muscle strength)<br/> assessed with: quantitative muscle testing (in pounds)<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in total muscle strength was 2.42 pounds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.25 pounds lower</b><br/> (10.1 lower to 7.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only participants aged ≥ 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: Parent Questionnaire for the PedsQL Neuromuscular Module<br/> Scale: 0–100<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in quality of life was 2</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Median change 7 lower</b><br/> (11 lower to 3 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate better quality of life.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 9 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.83 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.56 % predicted higher</b><br/> (10.8 lower to 11.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only participants aged ≥ 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1 death occurred in the placebo group in 28 participants (36 per 1000)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0 deaths occurred in the treatment group among 27 participants (0 per 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>571 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>480 per 1000 (291 to 800)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0.84</b> (0.51 to 1.4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 43 events in 16/28 participants in placebo group and 55 events in 13/27 participants treated with creatine. Adverse events were systematically, prospectively collected at every study visit. Adverse events included mainly respiratory infections. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>GMFM:</b> Gross Motor Function Measure; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>MMT:</b> Manual Muscle Testing; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>b</sup> Downgraded one level due to inconsistency. Unknown cohort representation (outcome reported for 22 of the randomised participants).<br/> <sup>c</sup> Downgraded one level because of imprecision. Small sample size, inadequately for optimal information size (OIS). Cut off for OIS was the calculated sample size of the trial.<br/> <sup>d</sup> Downgraded one level for risk of bias. No information on type of adverse events included.<br/> <sup>e</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Oral creatine compared to placebo for children with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral gabapentin compared to placebo for adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral gabapentin compared to placebo for adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral gabapentin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral gabapentin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: SMAFRS<br/> Scale: 0–50<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The median change in the SMAFRS score was 0 in the gabapentin group (37 participants) and –2 in the placebo group (34 participants) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the SMAFRS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed as: % change in total muscle strength from baseline<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –2.2%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 3.3% higher</b><br/> (6.9 lower to 14 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring ability to walk</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/35 participants in the placebo group developed the ability to walk at 9 or 12 months' follow‐up </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/38 participants treated with oral gabapentin developed the ability to walk at 9 or 12 months' follow‐up </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: change (%) from baseline in mini‐SIP<br/> Scale: 0–19<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was –0.26%</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.36% higher</b><br/> (0.29 lower to 1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the mini‐SIP indicate poorer health status.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –2.9 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.1 % predicted lower</b><br/> (4.1 lower to 1.9 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Data from analysis of participants who completed ≥ 2 visits.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment to death or full‐time ventilation</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0 reported deaths and 0 participants required full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: median 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Adverse events were reported to be infrequent and not statistically different between treatment groups. Numerical data on adverse events were not available. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were systematically, prospectively collected at every study visit.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>mini‐SIP:</b> mini‐Sickness Impact Profile; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy; <b>SMAFRS:</b> Spinal Muscular Atrophy Functional Rating Scale. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because the small sample size.<br/> <sup>b</sup> Downgraded one level for risk of bias. Incomplete data at 12‐month follow‐up and it was unclear why cases dropped out. Three cases (two treated, one placebo) were excluded from analysis because of extreme outcomes (greater than three standard deviations).<br/> <sup>c</sup> Downgraded one level because of imprecision; small sample size, inadequate for optimal information size (OIS).<br/> <sup>d</sup> Downgraded one level because no data on adverse events were available.<br/> <sup>e</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Oral gabapentin compared to placebo for adults with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral hydroxyurea<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral hydroxyurea</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: GMFM<br/> Scale: 0–264<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 2.02</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.88 lower</b><br/> (3.89 lower to 0.13 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the GMFM indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MHFMS<br/> Scale: 0–40<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.04</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.02 lower</b><br/> (0.12 lower to 0.07 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in non‐ambulatory participants.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MMT<br/> Scale: 16–80<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –0.03</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.55 lower</b><br/> (2.65 lower to 1.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in litres)<br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.22 L</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.01 L higher</b><br/> (0.25 lower to 0.26 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>1 participant died in the treatment group after 5 visits (after 8 months of treatment), due to respiratory complications. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Also reported as the 1 serious adverse event.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 18 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>All participants experienced adverse events. 129 events occurred in the 20 participants in the placebo group. 224 events occurred in the 37 participants in the hydroxyurea group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events were systematically, prospectively collected using a questionnaire at every study visit. Adverse events: laboratory disturbances (e.g. neutropenia, thrombocytopenia, high transaminases), respiratory complaint, gastrointestinal complaints, rash, neurological symptoms, unspecified. 1 participant died in the treatment group due to respiratory complications.<sup>d</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>GMFM:</b> Gross Motor Function Measure; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision. CIs were very wide.<br/> <sup>b</sup> Downgraded one level for imprecision because of small sample size (inadequate for optimal information size (OIS)). Cut‐off for OIS was the calculated sample size of the trial.<br/> <sup>c</sup> Downgraded one level for indirectness, because of discrepancy in results of respiratory failure (results in text and figures appeared different).<br/> <sup>d</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Oral hydroxyurea compared to placebo for children and adults with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>Patient or population:</b> children with SMA type II<br/> <b>Setting:</b> hospital visits (24 hours' observation at trial site after first procedure, 6 hours' observation after subsequent injections)<br/> <b>Intervention:</b> intrathecal injected nusinersen<br/> <b>Comparison:</b> sham procedure </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with sham procedure</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intrathecal injected nusinersen</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in disability score</b><br/> assessed with: HFMSE Score: 0–66<br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in HFMSE in the control group was –1.9 points</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean change in HFMSE in the nusinersen‐treated group was 5.9 points higher than in the sham procedure group (3.7 higher to 8.1 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 5.9</b> (3.7 to 8.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in disability score (3 point‐change)</b><br/> assessed with: HFMSE<br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>262 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471 per 1000 (259 to 812)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.8</b> </p> <p>(0.99 to 3.1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11/42 participants in the sham‐controlled group showed a 3‐point change on the HFMSE. 48/84 participants in the nusinersen group showed a 3‐point change on the HFMSE. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in muscle strength</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Acquiring the ability to stand or walk</b><br/> assessed with: WHO Motor Milestone criteria<br/> Follow‐up: 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1/42 children in the sham‐controlled group acquired the ability to stand alone.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/84 children treated with nusinersen acquired the ability to stand alone.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.5</b> (0.03 to 7.80) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to walk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>0/42 children in the sham‐controlled group acquired the ability to walk with assistance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/84 children treated with nusinersen acquired the ability to walk with assistance.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.5</b> (0.06 to 36.1) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Change in pulmonary function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Time from beginning of treatment until death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: mean 15 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>900 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.9</b> (0.9 to 1.0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78/84 (93%) participants treated with nusinersen experienced an adverse event, while 42/42 (100%) participants treated in the sham‐controlled group had any adverse event. </p> <p>Adverse events were systematically, prospectively collected at every study visit. Adverse events included proteinuria, hyponatraemia, transient low platelet counts, vasculitis, pyrexia, headache, vomiting, back pain and epistaxis. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>HFMSE:</b> Hammersmith Functional Motor Measure Expanded; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>MMT:</b> manual muscle testing; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy; <b>WHO:</b> World Health Organization. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>b</sup> Downgraded two levels for imprecision because of small sample size, low event rate and wide CI.<br/> <sup>c</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Intrathecal injected nusinersen compared to sham procedure for children with SMA type II</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐ambulatory children and adolescents with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral olesoxime<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral olesoxime</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM (D1+D2)<br/> Scale: 0–75<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.82</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2 higher</b><br/> (0.25 lower to 4.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MFM indicate better function. Combined analysis of participants assessed with MFM‐32 or MFM‐20. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM total score<br/> Scale: 0–96<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.04 higher</b><br/> (0.21 lower to 4.28 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MFM indicate better function. Combined analysis of participants assessed with MFM‐32 or MFM‐20. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MFM responder analysis<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.43</b><br/> (–0.98 to 2.08) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Higher scores on the MFM indicate better function. Participants were classified as 'responders' in case MFM‐32 or MFM‐20 showed no change or better scores compared to baseline, and 'non‐responders'. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>39 per 100</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 100<br/> (–38 to 80) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: HFMS<br/> Scale: 0–40<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –1.72</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.94 higher</b><br/> (0.28 lower to 2.17 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMS indicate better function.<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: PedsQL Neuromuscular Module<br/> Score: 0–100<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.25</b><br/> (4.58 lower to 5.08 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate a better quality of life.</p> <p>Scores on participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was +6.16 % predicted</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.88 % predicted lower</b><br/> (3.14 lower to 6.91 higher ) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>2 participants died; 1 with cardiac arrest (olesoxime group) and 1 with increased bronchial secretions (placebo group). Deaths were not deemed to be related to treatment. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 24 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1000 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>950 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.95</b> (0.91 to 0.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612 events occurred in 57 participants in the placebo group. 1104 events occurred in 108 participants in the olesoxime group. Adverse events were systematically, prospectively collected at every study visit. Adverse events: (upper) respiratory tract infection, gastroenteritis, influenza, vomiting, abdominal pain, diarrhoea, cough, pyrexia, pain in extremity, scoliosis, arthralgia, fall, headache. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMS:</b> Hammersmith Functional Motor Score; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>MMT:</b> manual muscle testing; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for indirectness because trial authors combined two different outcome measures (MFM‐32 and MFM20) to assess the primary outcome with no correction in analysis.<br/> <sup>b</sup> Downgraded one level for risk of bias because of differences between baseline groups.<br/> <sup>c</sup> Downgraded one level for imprecision because of the small sample size.<br/> <sup>d</sup> Downgraded one level for imprecision because the small sample size was unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Oral olesoxime compared to placebo for non‐ambulatory children and adolescents with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral phenylbutyrate compared to placebo for children with SMA type II</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral phenylbutyrate compared to placebo for children with SMA type II</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA type II<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral phenylbutyrate<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral phenylbutyrate</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: Hammersmith Functional Motor Scale (HFMS)<br/> Scale: 0–40<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.13 lower</b><br/> (0.84 lower to 0.58 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: handheld dynamometer (in Newtons)<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Leg megascore</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (leg megascore) was 3.22 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.04 N higher</b><br/> (2.46 lower to 4.54 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of muscle strength by myometry.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Arm megascore</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (arm megascore) was –0.42 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.98 N higher</b><br/> (1.67 lower to 5.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of muscle strength by myometry.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (% predicted)<br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.01 % predicted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.04 % predicted higher</b><br/> (0.07 lower to 0.15 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Children aged &gt; 5 years had additional assessment of FVC.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: mean 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths were reported. No data available on ventilation.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 13 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>994 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>292 per 1000 (118 to 740)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 3.1</b> (1.25 to 7.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/53 participants had ≥ 1 adverse events in the phenylbutyrate and placebo group. 19/54 participants had ≥ 1 adverse events in the phenylbutyrate group. </p> <p>Adverse events were systematically and prospectively collected at every study visit. Adverse events included rash, drowsiness with hallucinations, nausea and constipation. No full report on types of adverse events was available. 3 participants discontinued the trial because of severe drowsiness, rash or constipation.<sup>b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMS:</b> Hammersmith Functional Motor Score; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level because of risk of bias.<br/> <sup>b</sup> Downgraded one level for imprecision because the small sample size.<br/> <sup>c</sup> Downgraded one level because of imprecision on small sample size. Small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Oral phenylbutyrate compared to placebo for children with SMA type II</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> children and adults with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> subcutaneous somatotropin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with subcutaneous somatotropin</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: HFMSE<br/> Scale: 0–66<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median change in disability score was –1.05</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Median change 0.25 higher</b><br/> (1 lower to 2.5 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the HFMSE indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MMT with hand‐held myometry from Citec (in Newtons)<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Upper limbs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (upper limbs) was 0.30 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.08 N lower</b><br/> (3.79 lower to 3.95 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Lower limbs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength (lower limbs) was 0.95 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.23 N higher</b><br/> (2.19 lower to 6.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> <p>Follow‐up: 40 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>The trial report states that the trial found no significant differences in quality of life between the somatotropin‐treated group and the placebo group. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in litres)<br/> Follow‐up: 3 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was –0.11 L</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.22 L higher</b><br/> (0.02 lower to 0.4 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: mean 40 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No participant died or required full‐time ventilation in either group</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 40 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>368 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>578 per 1000 (278 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.57</b><br/> (0.78 to 3.17) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>c,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 adverse events occurred, 14 during somatotropin treatment and 9 during placebo treatment. Adverse events were systematically, prospectively collected at every study visit. Adverse events included headache, arthralgia, myalgia, oedema, elevated serum thyroid‐stimulating hormone and myalgia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>HFMSE:</b> Hammersmith Functional Motor Score Expanded; <b>MD:</b> mean difference; <b>MFM:</b> Motor Function Measure; <b>MMT:</b> Manual Muscle Testing; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to risk of bias. HFMSE ranges were not available and because of the potential carry‐over effect due to the cross‐over design.<br/> <sup>b</sup> Downgraded one level for imprecision because of very small study size.<br/> <sup>c</sup> Downgraded one level because of potential bias from carry‐over effects due to the cross‐over design.<br/> <sup>d</sup> Downgraded two levels due to risk of bias. The report provided no information about how quality of life was measured and did not provide numerical data. There was a potential carry‐over effect due to the cross‐over design.<br/> <sup>e</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Subcutaneous somatotropin compared to placebo for children and adults with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> children with SMA types II and III<br/> <b>Setting:</b> in hospital treatment<br/> <b>Intervention:</b> intravenous TRH<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with intravenous TRH</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: hand‐held dynamometry (CSD‐500, Amitec; in pounds)<br/> Scale: 0–6<br/> Follow‐up: 5 weeks </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was 0.48 pounds</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.34 pounds higher</b><br/> (0.54 lower to 1.22 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to death or full‐time ventilation</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Not measured but no deaths reported</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No events in 3 participants treated with placebo</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>12 events in 6 participants treated with TRH</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events included abdominal discomfort, flushing, nausea and vomiting.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy; <b>TRH:</b> thyrotropin‐releasing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level for sample size.<br/> <sup>b</sup> Downgraded two levels for baseline imbalance and lack of allocation concealment.<br/> <sup>c</sup> Downgraded one level for imprecision because the small sample size is unlikely to have captured uncommon adverse events.<br/> <sup>d</sup> Downgraded one level for indirectness, because data on adverse events was not collected systematically. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Intravenous thyrotropin releasing hormone compared to placebo for children with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral valproic acid plus acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Oral valproic acid + acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> non‐ambulatory children with SMA types II and III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral valproic acid + acetyl‐L‐carnitine<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral valproic acid + acetyl‐L‐carnitine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: MHFMS<br/> Scale: 0–40<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was 0.18</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.64 higher</b><br/> (1.1 lower to 2.38 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the MHFMS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: myometry with myometer (in kg)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength was –0.25 kg</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.43 kg higher</b><br/> (0.69 lower to 3.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: PedsQL<br/> Scale: 0–100<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was 0.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>MD 2.2 lower</b><br/> (9.27 lower to 4.87 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the PedsQL indicate better quality of life. Only 54 participants completed PedsQL at follow‐up. Characteristics of this subset are unknown. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No numerical data available for analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Only performed in participants aged &gt; 5 years.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>0 deaths or no need for full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>581 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>755 per 1000 (534 to 1000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.32</b> (0.92 to 1.89) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/31 participants in the placebo group had ≥ 1 adverse events. 23/30 participants in the valproic acid + acetyl‐L‐carnitine group had ≥ 1 adverse events. </p> <p>Adverse events were systematically, prospectively collected at every study visit.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>MHFMS:</b> Modified Hammersmith Functional Motor Scale; <b>PedsQL:</b> Pediatric Quality of Life Inventory; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded for imprecision because the small sample size.<br/> <sup>b</sup> Downgraded two levels because of very small sample size, inadequately for optimal information size (OIS). Cut off for OIS was the calculated sample size of the trial.<br/> <sup>c</sup> Downgraded one level due to risk of bias. Only a subset of participants completed PedsQL at follow‐up.<br/> <sup>d</sup> Downgraded one level due to inconsistency. Only a subset of participants completed follow‐up.<br/> <sup>e</sup> Downgraded one level due to risk of bias. Data on pulmonary function was not available.<br/> <sup>f</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Oral valproic acid plus acetyl‐L‐carnitine compared to placebo for non‐ambulatory children with SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD006282-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Oral valproic acid compared to placebo for ambulatory adults with SMA type III</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Oral valproic acid compared to placebo for ambulatory adults with SMA type III</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>Patient or population:</b> ambulatory adults with SMA type III<br/> <b>Setting:</b> outpatient clinic<br/> <b>Intervention:</b> oral valproic acid<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="2" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Risk with oral valproic acid</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in disability score</b><br/> assessed with: SMAFRS<br/> Scale: 0–50<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in disability score was –0.35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.06 higher</b><br/> (1.32 lower to 1.44 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher scores on the SMAFRS indicate better function.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Change in muscle strength</b><br/> assessed with: MVICT (in Newtons)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Arms</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength of arms was –0.01 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.23 N lower</b><br/> (1.03 lower to 0.57 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Legs</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in muscle strength of legs was 0.35 N</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 0.37 N lower</b><br/> (1.09 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Acquiring the ability to stand or walk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>Not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in quality of life</b><br/> assessed with: mini‐SIP<br/> Scale: 0–19<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in quality of life was 0.91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.1 lower</b><br/> (3.8 lower to 1.6 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Higher score on the mini‐SIP indicates a poorer health status.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Change in pulmonary function</b><br/> assessed with: FVC (in % predicted)<br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in pulmonary function was 0.53% predicted</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.24% predicted lower</b><br/> (4.71 lower to 2.23 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time from beginning of treatment until death or full‐time ventilation</b><br/> Follow‐up: 6 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>No deaths or full‐time ventilation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Adverse events related to treatment</b><br/> Follow‐up: 12 months </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>364 per 1000 (200 to 655)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.80</b> (0.44 to 1.44) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 cross‐over RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96 adverse events occurred, 66 in the placebo group and 30 in the valproic acid group. Adverse events were systematically, prospectively collected at every study visit and included upper airway tract infection or symptoms, dizziness, headache, peripheral neuropathy, tremor, fatigue, pain, abdominal pain, nausea, vomiting, decreased platelet count, weight gain and alopecia.<sup>a,b</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>FVC:</b> forced vital capacity; <b>MD:</b> mean difference; <b>mini‐SIP:</b> mini‐Sickness Impact Profile; <b>MVICT:</b> maximum voluntary isometric contraction testing; <b>RCT:</b> randomised controlled trial; <b>SMA:</b> spinal muscular atrophy; <b>SMAFRS:</b> Spinal Muscular Atrophy Rating Scale; <b>TRH:</b> thyrotropin‐releasing hormone. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="8" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level because of potential carry‐over effect due to the cross‐over design.<br/> <sup>b</sup> Downgraded one level for imprecision because of very small study size.<br/> <sup>c</sup> Downgraded for imprecision because the small sample size is unlikely to have captured uncommon adverse events. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Oral valproic acid compared to placebo for ambulatory adults with SMA type III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0011"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic criteria for SMA types II and III</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Primary criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMA type II: age of onset between 6 and 18 months and have been able to sit independently, but never been able to walk without assistance. </p> <p>SMA type III: age of onset after 18 months and has/had the ability to walk without assistance. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Genetic analysis to confirm the diagnosis, with deletion or mutation of the SMN1 gene (5q11.2‐13.3) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Supporting criteria</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Symmetrical muscle weakness of limb and trunk.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Proximal muscles more affected than distal muscles and lower limbs more than upper limbs. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No abnormality of sensory function.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serum creatine kinase activity ≤ 5 times the upper limit of normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Denervation on electrophysiological examination, and no nerve conduction velocities &lt; 70% of the lower limit of normal. No abnormal sensory nerve action potentials. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Muscle biopsy showing atrophic fibres of both types, hypertrophic fibres of one type (usually type I), and in chronic cases type grouping. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No involvement of the central neurological systems, such as hearing or vision.</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="1"> <div class="table-footnote"> <p><a href="./references#CD006282-bbs2-0269" title="ZerresK , DaviesKE . 59th ENMC International Workshop: Spinal Muscular Atrophies: recent progress and revised diagnostic criteria 17‐19 April 1998, Soestduinen, The Netherlands. Neuromuscular Disorders1999;9(4):272‐8. ">Zerres 1999</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Diagnostic criteria for SMA types II and III</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0012"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral creatine versus placebo outcomes (Wong 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (79%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (‐1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in quality of life (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐7 (‐11 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age 2 to 5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (‐4 to 9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in QoL (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (‐8 to 13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age 5 to 18 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability and QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (‐2 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in quality of life (PedsQL, neuromuscular module)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6 (‐15 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (69%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in arms muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.34 (6.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.49 (8.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.83 (‐8.75 to 5.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in legs muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.51 (4.21)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93 (3.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58 (‐2.70 to 3.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total muscle strength (QMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.17 (9.67)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.42 (10.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.25 (‐10.1 to 7.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.77</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC % of predicted value in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.27 (14.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.83 (11.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.56 (‐10.75 to 11.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Creatine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.51 to 1.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (death by respiratory failure)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; GMFM: Gross Motor Function Measure; NA: not available; PedsQL: Pediatric Quality of Life Inventory; QMT: quantitative muscle test; QoL: quality of life; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Oral creatine versus placebo outcomes (Wong 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0013"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Oral gabapentin versus placebo outcomes (Miller 2001a)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Follow‐up at 12 months</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median change in disability score (SMAFRS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (‐1 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in quality of life (mini‐SIP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36 (‐0.29 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.28</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis grip muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (75%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in grip muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.6 (‐2.5 to 11.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis arms muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in arms muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.9 (‐2.5 to 6.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis feet muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (70%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in feet muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.29 (‐8.3 to 8.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis total muscle strength</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (57%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in total muscle strength (MVC) in percentage from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.3 (‐6.9 to 14)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis development of walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with development of walking</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (78%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in pulmonary function (FVC % of predicted value)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐4.1 to 1.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Gabapentin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; mini‐SIP: mini Sickness Impact Profile; MVC: maximum voluntary contraction; NA: not available; SMAFRS: Spinal Muscular Atrophy‐Functional Rating Scale. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Oral gabapentin versus placebo outcomes (Miller 2001a)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0014"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Oral hydroxyurea versus placebo outcomes (Chen 2010)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (GMFM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in disability score (GMFM) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14 (0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.02 (0.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.88 (‐3.89 to 0.13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis muscle strength (MMT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in muscle strength (MMT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.58 (0.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.03 (0.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.55 (‐2.65 to 1.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for pulmonary function (FVC in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SE) change in pulmonary function (FVC in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.21 (0.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.22 (0.12)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (‐0.25 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SE) in disability score (MHFMS) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.03)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (‐0.12 to 0.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hydroxyurea</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse event episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.65</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number (SD) of adverse event episodes per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.05 (3.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.45 (2.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.4 (‐2.21 to 1.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.66</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse event episodes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean number (SD) of severe adverse event episodes per participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.51 (1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01 (‐0.77 to 0.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (5%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FVC: forced vital capacity; GMFM: Gross Motor Function Measure; MHFMS: Modified Hammersmith Functional Motor Scale; MMT: manual muscle testing; SD: standard deviation; SE: standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Oral hydroxyurea versus placebo outcomes (Chen 2010)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0015"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Intrathecal injected nusinersen versus placebo outcomes (Mercuri 2018)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Interim analysis<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in HFMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.9 (3.7 to 8.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Final analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change in HFMSE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.9 (3.1 to 6.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of participants with 3‐point‐change on HFMSE (%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.5 (12.7 to 48.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>&lt; 0.001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage (number) of children who achieved ≥ 1 new WHO motor milestone (% (number))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20 (13)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (‐7 to 34)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Nusinersen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Percentage (number) of children who achieved ability to stand alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.5 (0.03 to 7.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage (number) of children who achieved ability to walk with assistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.5 (0.06 to 36.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9 (0.9 to 1.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; HFMSE: Hammersmith Functional Motor Scale Expanded; WHO: World Health Organization. </p> <p><sup>a</sup> Conducted in children who completed at least six months of the trial. Data of children who had not yet completed the 15‐month period were imputed.<br/> <sup>b</sup> Included 35 participants in the nusinersen group and 19 participants in the control group who completed the 15‐month assessment. Data for 49 participants in the nusinersen group and 23 participants in the control group were imputed.<br/> <sup>c</sup> The number of children with observed data for the 15‐month assessment was 66 in the nusinersen group and 34 in the control group, and the number of children with imputed data was 18 in the nusinersen group and eight in the control group. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Intrathecal injected nusinersen versus placebo outcomes (Mercuri 2018)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0016"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Oral olesoxime versus placebo outcomes (Bertini 2017)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Estimated difference (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis MFM‐32 D1+D2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>ab</sup> change (95% CI) in disability score (MFM D1+D2) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.18 (‐1.30 to 1.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.82 (‐3.68 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.00 (‐0.25 to 4.25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis MFM total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>ab</sup> change (95% CI) in disability score (MFM total score) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (‐0.9 to 2.070</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.45 (‐3.31 to 0.41)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.04 (‐0.21 to 4.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> change (95% CI) in disability score (HFMS) at 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.78 (‐1.60 to 0.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.72 (‐2.74 to ‐0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.94 (‐0.28 to 2.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of nerve innervation value (CMAP) (in mV) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70 (65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (60%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in total amplitude CMAP from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.07 (‐0.49 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.16 (‐0.74 to 0.43)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of MUNE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58 (54%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (53%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in total MUNE from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐4.51 (‐12.21 to 3.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐6.69 (‐16.86 to 3.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.71</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for FVC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64 (59%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (67%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean<sup>b</sup> (95% CI) change in FVC from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.28 (‐0.32 to 8.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.16 (1.00 to 11.33)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.88 (‐3.14 to 6.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of quality of life (PedsQL) from baseline to 24 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71 (66%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (65%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in quality of life (PedsQL) from baseline to 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (‐4.58 to 5.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.92</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Olesoxime</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for responder analysis MFM‐32 score D1+D2 (24 months) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of participants with good response according to MFM‐32 score D1+D2<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22 (39)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (‐0.98 to 2.08)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1104 (64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>612 (36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.91 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (17%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (25%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.67 (0.37 to 1.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of deaths</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 (9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (12%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; CMAP: compound muscle action potential; FVC: forced vital capacity; HFMS: Hammersmith Functional Motor Scale; MFM: Motor Function Measure; MFM D1+D2: functional domains 1 and 2 of the Motor Function Measure; MUNE: motor unit number estimation; NA: not available; PedsQL: Pediatric Quality of Life Inventory; SD: standard deviation. </p> <p><sup>a</sup> Least squared mean of MFM, including MFM‐32 and MFM‐20 assessments.<br/> <sup>b</sup> Calculated with available data.<br/> <sup>c</sup> Participants with no change or improvement of scores were considered 'responders', participants with a decline in score were considered 'non‐responders'. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Oral olesoxime versus placebo outcomes (Bertini 2017)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0017"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oral phenylbutyrate versus placebo outcomes (Mercuri 2007)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenylbutyrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (83%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (85%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (9.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.8 (9.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.7 (‐4.78 to 3.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in HFMS<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.60 (0.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.13 (‐0.84 to 0.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age &gt; 5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength arm megascore (dynamometry)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.56 (6.94)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.42 (8.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.98 (‐1.67 to 5.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.74</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change muscle strength leg megascore (dynamometry)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.26 (8.64)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.22 (6.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.04 (‐2.46 to 4.54)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.78</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of HFMS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (43%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC % of predicted value in litres)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.03 (0.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (0.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04 (‐0.07 to 0.15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Phenylbutyrate</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (1.25 to 7.84)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.01</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of withdrawals because of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.86 (0.49 to 7.11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.96 (0.18 to 21.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; HFMS: Hammersmith Functional Motor Scale; SD: standard deviation; </p> <p><sup>a</sup>Mean change from baseline. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Oral phenylbutyrate versus placebo outcomes (Mercuri 2007)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0018"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Subcutaneous somatotropin versus placebo outcomes (Kirschner 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Total number of participants randomised (cross‐over setting)</p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Somatropin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants completing phase 1 of study protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants completing phase 2 of study protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for intention‐to‐treat analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (80%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength of upper limb (hand‐held myometry in megascore of biceps and handgrip) (Newton) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (6.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (10.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.35 (‐7.12 to 4.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability score (HFMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Median (SD) change in disability score (HFMSE)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.05 (3.19)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (5.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25 (‐1 to 2.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.58</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis arm megascore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in arm megascore (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.05 (6.42;<br/> ‐11 to 19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (10.60;<br/> ‐18 to 34.3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08 (‐3.79 to 3.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.97</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis leg megascore</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in leg megascore (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.96 (7.64; ‐10 to 24.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (9.93; ‐18 to 22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.23 (‐2.19 to 6.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis muscle strength (MRC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change MRC (% of maximum score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.31 (5.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.43 (7.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.74 (‐6.7 to 1.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function (FVC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in pulmonary function (FVC improvement in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (0.25; ‐0.4 to 0.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.11 (0.40; ‐1.4 to 0.36)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23 (‐0.01 to 0.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.08</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Somatropin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk Ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.57 (0.78 to 3.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (15%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 (0%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; HFMSE: Hammersmith Functional Motor Scale Expanded; MRC: Medical Research Council; SD: standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Subcutaneous somatotropin versus placebo outcomes (Kirschner 2014)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0019"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intravenous TRH versus placebo outcomes (Tzeng 2000)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRH</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in muscle strength (dynamometry in pounds)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (0.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.48 (0.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.34 (‐0.54 to 1.22)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>TRH</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval; NA: not available; SD: standard deviation; TRH: thyrotropin‐releasing hormone. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Intravenous TRH versus placebo outcomes (Tzeng 2000)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0020"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Oral valproic acid plus acetylcarnitine versus placebo outcomes (Swoboda 2010)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid + acetyl‐L‐carnitine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants randomised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (93%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.82 (2.88)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.18 (3.98)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (‐1.1 to 2.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of nerve innervation value (CMAP)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (61%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19 (63%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total amplitude CMAP from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02 (0.70)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.10 (0.66)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.12 (‐0.33 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis of quality of life (PedsQL) from baseline to 12 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (87%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in quality of life (PedsQL) from baseline to 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.9 (13.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3 (12.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐2.2 (‐9.27 to 4.87)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Age &lt; 3 years old</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFMS)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (52%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (2.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.09 (5.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.24 (‐3.28 to 3.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.89</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aged 3–8 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis disability (MHFSM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (47%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (45%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean change (SD) in disability score (MHFSM) from baseline to 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.44 (3.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.41 (2.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85 (‐1.25 to 2.95)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Aged</b> ≥ <b>5 years</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in arms (myometry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in arm muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.64 (0.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.07 (1.04)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.57 (‐0.45 to 1.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.23<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in legs (myometry)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in leg muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.55 (0.83)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.85 (2.22)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.40 (‐1.98 to 4.79)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.19<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis muscle strength in both arms and legs (myometry) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in total muscle strength (myometry) from baseline to 6 months (kg)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (0.91)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.25 (2.47)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.43 (0.69 to 3.56)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.21</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for analysis pulmonary function (FVC in % of predicted)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in pulmonary function (FVC in % of predicted) from baseline to 6 months </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid + acetyl‐L‐carnitine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>All ages</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with adverse events (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (77%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18 (58%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.32 (0.92 to 1.89)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants with severe adverse events (6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (6%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.1 (0.60 to 12.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; CMAP: compound maximum action potential; FVC: forced vital capacity; MHFMS: Modified Hammersmith Functional Motor Scale; PedsQL: Pediatric Quality of Life Inventory; SD: standard deviation. </p> <p><sup>a</sup> Underpowered. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Oral valproic acid plus acetylcarnitine versus placebo outcomes (Swoboda 2010)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD006282-tbl-0021"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oral valproic acid versus placebo outcomes (Kissel 2014)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Difference (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants randomised first 6 months (cross‐over setting)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis after 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (91%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Analysis after 6 months before cross‐over</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis SMAFRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in SMAFRS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.29 (1.59)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.35 (2.32)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.06 (‐1.32 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis upper extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in MVICT upper extremity (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.24 (1.17)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.01 (1.05)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.23 (‐1.03 to 0.57)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.54</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis lower extremity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in lower extremity MVICT (Newton)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.02 (0.65)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.35 (1.30)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.37 (‐1.09 to 0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.36</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants evaluable for analysis pulmonary function (FVC)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (88%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (100%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD; range) change in pulmonary function (FVC improvement in litres)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.04 (0.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.30 (1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.34 (‐0.94 to 0.26)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.31</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants evaluable for QoL analysis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean (SD) change in mini‐SIP for QoL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐0.19 (2.80)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.91 (4.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐1.1 (‐3.8 to 1.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Valproic acid</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Risk ratio (95% CI)<sup>a</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8 (0.44 to 1.44)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number of participants with severe adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.0 (0.15 to 6.69)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Number (%) of participants discontinued intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; FVC: forced vital capacity; mini‐SIP: mini‐Sickness Illness Profile; MVICT: maximum voluntary isometric contraction; NA: not available; QoL: quality of life; SD: standard deviation; SMAFRS: Spinal Muscular Atrophy Functional Rating Scale. </p> <p><sup>a</sup>Calculated with available data. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Oral valproic acid versus placebo outcomes (Kissel 2014)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD006282.pub5/full#CD006282-tbl-0021">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD006282.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD006282-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD006282-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD006282-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD006282-note-0032">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD006282-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD006282-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD006282-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006282\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006282\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006282\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD006282\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD006282\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=WbpyPs9C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006282.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD006282.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD006282.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD006282.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD006282.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725023455"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006282.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725023459"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD006282.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e711b897c1bdf',t:'MTc0MDcyNTAyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 